Pathology In Depth

Library › Ovary, fallopian tube and peritoneum pathology: non-neoplastic lesions, epithelial, sex cord-stromal and germ cell tumors, staging and peritoneal lesions

Ovary, fallopian tube and peritoneum pathology: non-neoplastic lesions, epithelial, sex cord-stromal and germ cell tumors, staging and peritoneal lesions

Last reviewed 2026-11-10 by a board-certified pathologist. 277 references.

Non-Neoplastic Ovary and Fallopian Tube: Cysts, Endometriosis, Torsion, Salpingitis, Ectopic Pregnancy and Tubal Precursor Lesions

Definition. Non-neoplastic adnexal lesions are cysts, stromal proliferations, pregnancy-related changes, inflammatory and infectious processes, ectopic pregnancy and endometriosis of the ovary, fallopian tube and broad ligament. Several of them simulate neoplasms on clinical, gross or microscopic examination (Clement 1993; Medeiros and Bell 2010). The distal fallopian tube also contains the precursor lesions of tubo-ovarian high-grade serous carcinoma: the p53 signature, the serous tubal intraepithelial lesion (STIL) and serous tubal intraepithelial carcinoma (STIC) (Lee et al. 2007; Visvanathan et al. 2011). The WHO Classification of Female Genital Tumours, 5th edition (2020), is the current classification (Köbel and Kang 2022; CAP Ovary 1.5.0.0).

Related page: Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response (high-grade serous carcinoma, primary site assignment, BRCA and HRD testing) Related page: Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary (endometriosis-associated endometrioid and clear cell carcinoma, Brenner tumors) Related page: Pelvic washing cytology and ovarian cyst FNA (washings in risk-reducing salpingo-oophorectomy, endosalpingiosis and psammoma bodies in washings) Related page: Ovarian cyst fluid and FNA cytology (ovarian cyst fluid cytology) Related page: Benign Endometrium, Endometrial Polyps and Endometrial Hyperplasia (adenomyosis and endometrial hyperplasia) Related page: Paget Disease of the Nipple, Inflammatory Carcinoma, Male Breast Carcinoma and Hereditary Breast Cancer (BRCA1 and BRCA2 genetics and breast cancer risk) Related page: Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors (granulosa cell, Sertoli-Leydig cell and steroid cell tumors)

Normal ovary and fallopian tube: structures that mimic lesions

  • Tubal epithelium. The fallopian tube mucosa is lined mainly by a single layer of secretory, ciliated and intercalated cells over a stromal core (Bogaerts et al. 2022). Early serous neoplasia arises in the secretory cells (Lee et al. 2007).
  • Walthard cell nests. Walthard nests are nests of transitional-type epithelium on the tubal serosa and paratubal tissue. All Walthard nests in one series expressed GATA3, 3 of 13 showed occasional PAX8 expression, and all lacked PAX2 and SALL4 (Roma and Masand 2014). In a second series, 89.5% of Walthard nests expressed GATA3 and all expressed p63 (Esheba et al. 2009).
  • Walthard nests and Brenner tumor. Brenner tumors share the GATA3-positive, PAX8-negative profile of Walthard nests, and 43% of patients with a Brenner tumor had Walthard nests in the tube or periovarian tissue (Roma and Masand 2014). Walthard nests were found in 28% of controls, 50% of patients with Brenner tumors and 59% of patients with mucinous tumors (Seidman and Khedmati 2008). A Walthard nest is an incidental microscopic finding; a Brenner tumor forms an ovarian mass (Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary).
  • Hilus cells. Hilus cell nests occur in the ovarian hilum. They were four times as frequent in Stein-Leventhal ovaries as in control ovaries (Hughesdon 1982). Hilus cell hyperplasia is one of the pregnancy-associated lesions that mimic a neoplasm (Clement 1993). Hilus cells are ultrastructurally similar to testicular Leydig cells. Reinke crystals, acidophilic rod-like cytoplasmic inclusions, occur in hilus cells; they are pathognomonic of hilus cell tumor but are found in only about half of these tumors (Malakzai et al. 2021).
  • Cortical inclusion cysts. Two types of cortical inclusion cyst occur. Ciliated tubal-type cysts were PAX8 positive in 20 of 21 cases and were found only after menarche. Flat cysts of ovarian surface type were PAX8 negative and calretinin positive in 4 of 5 cases (Banet and Kurman 2015). Progesterone receptor was expressed in 66% of ciliated cysts and in no flat cysts (Banet and Kurman 2015). No p53 signatures were found in cortical inclusion cysts of BRCA carriers (Folkins et al. 2008).

Ovarian cysts and stromal lesions

  • Follicle cyst. The wall of a follicle cyst is lined by an inner granulosa cell layer and an outer theca interna layer, with surrounding ovarian stroma (Chae and Rheu 2013).
  • Autonomous follicle cyst in childhood. Autonomous functional follicle cysts are the most common cause of gonadotropin-independent precocious puberty in girls. Unilocular cysts <1 cm in prepubertal girls are clinically insignificant, whereas cysts with precocious pseudopuberty generally measure >2 cm. The differential diagnosis includes granulosa cell tumor and McCune-Albright syndrome (Chae and Rheu 2013).

Corpus luteum and hemorrhagic corpus luteum cyst

  • Formation. After ovulation the follicle collapses and the granulosa layer luteinizes while it is still avascular. Vessels then penetrate the granulosa layer and fill the central cavity with blood. Excessive bleeding enlarges the corpus luteum into a hemorrhagic corpus luteum cyst, which may rupture (Medvediev et al. 2020).
  • Evolution. The clot first forms a fine fibrin network in the central cavity and then organizes. After luteolysis the corpus luteum becomes a corpus albicans (Medvediev et al. 2020).
  • Rupture. Rupture causes hemoperitoneum, especially with anticoagulant therapy or congenital bleeding disorders. Right-sided rupture predominated in reported series (65.9% and 81.25%) (Medvediev et al. 2020).

Polycystic ovary syndrome and stromal hyperthecosis

  • Diagnostic criteria. The 2023 international guideline diagnoses polycystic ovary syndrome (PCOS) with two of three features: clinical or biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovaries on ultrasound. Anti-Müllerian hormone may replace ultrasound in adults. Other causes must be excluded (Teede et al. 2023). These criteria extend the 2003 Rotterdam consensus, which states that no single criterion is sufficient for diagnosis (Rotterdam ESHRE/ASRM 2004).
  • Ultrasound threshold. A follicle number per ovary of ≥20 in at least one ovary is the threshold for polycystic ovarian morphology in adults. An ovarian volume of ≥10 mL or ≥10 follicles per section is used with older equipment (Teede et al. 2023). PCOS prevalence is 10–13% worldwide under the Rotterdam criteria (Teede et al. 2023).
  • Morphology. Compared with control ovaries, Stein-Leventhal ovaries had twice the cross-sectional area, the same number of primordial follicles, twice the number of ripening and atretic follicles, a tunica thickened by 50% and more collagenized, and five times as much subcortical stroma. Lutein cell nests were present in four-fifths of cases (Hughesdon 1982).
  • Stromal hyperthecosis. Hyperthecosis combines nests of luteinized stromal cells with marked stromal increase. Hughesdon regarded it as a late stage of Stein-Leventhal morphology (Hughesdon 1982). In postmenopausal women it presents with virilization and high serum testosterone, almost always involves both ovaries, and requires exclusion of androgen-producing neoplasms (Boudaouara et al. 2025).
  • Stromal hyperplasia. Ovarian stromal hyperplasia is a nodular or diffuse proliferation of the ovarian stroma without the luteinized stromal cells of hyperthecosis. Stromal hyperplasia and hyperthecosis are uncommon non-neoplastic causes of ovarian hyperandrogenism, with an incidence of 1 in 300 to 1 in 1,000 cases of hirsutism. In postmenopausal women, laparoscopic bilateral salpingo-oophorectomy is both diagnostic and therapeutic (Lozoya Araque et al. 2020).

Pregnancy-associated ovarian lesions

Six non-neoplastic ovarian lesions of pregnancy can simulate a neoplasm: pregnancy luteoma, hyperreactio luteinalis, large solitary luteinized follicle cyst of pregnancy and puerperium, intrafollicular granulosa cell proliferations, hilus cell hyperplasia and ectopic decidua. Each regresses after pregnancy or is treated conservatively (Clement 1993).

Lesion Gross Microscopic Clinical features Main mimic Source
Pregnancy luteoma Solid, brown, friable mass; bilateral in 25–50% Large epithelioid luteinized cells with eosinophilic cytoplasm; inhibin A and melan-A positive; AE1/AE3 negative Found at cesarean section; maternal virilization in 25–65%; regresses after delivery Sertoli-Leydig cell tumor, Krukenberg tumor Stewart and Twidale 2024
Hyperreactio luteinalis Bilateral multicystic ovaries, 8.5–29 cm Multiple follicle cysts lined by granulosa cells and theca cells with abundant eosinophilic cytoplasm; stromal edema; no solid granulosa growth Pregnancy and gestational trophoblastic disease; regresses spontaneously Cystic granulosa cell tumor, especially juvenile type Watkins et al. 2021
Large solitary luteinized follicle cyst of pregnancy and puerperium Unilocular thin-walled cyst; 15 cm and 14 cm in two cases One to several layers of luteinized cells with focal bizarre nuclei; nests of luteinized cells in an edematous wall; reticulin around cell groups Pregnancy or puerperium; benign Unilocular cystic granulosa cell tumor Lomme et al. 2011
  • Hyperreactio luteinalis. In 10 cases, patients were 22 to 30 years old, most cases were found incidentally at cesarean section, and ovaries were bilateral and multicystic in 8 (Watkins et al. 2021). Mitoses were more frequent in the granulosa layer (mean 2.6) than in the theca layer (mean 1 per 10 high-power fields). The absence of pale or vacuolated cytoplasm and of solid granulosa growth separates hyperreactio luteinalis from juvenile granulosa cell tumor (Watkins et al. 2021).
  • Large solitary luteinized follicle cyst. Occasional mitoses do not exclude the diagnosis. Adult granulosa cell tumor lacks bizarre luteinized cells and shows nuclear grooves and Call-Exner bodies. Juvenile granulosa cell tumor is mitotically active (Lomme et al. 2011).
  • Pregnancy luteoma and the fetus. When the mother is virilized, about 80% of female fetuses are also virilized. Without maternal virilization the fetus is not affected (Stewart and Twidale 2024).

Adnexal torsion, massive ovarian edema and ovarian fibromatosis

  • Torsion. Adnexal torsion is the fifth most common gynecologic emergency. In adolescents the most common associated lesions are benign functional cysts and benign teratomas, and up to 46% of torsed ovaries in children and adolescents have no associated mass (ACOG 2019). No clinical or imaging finding confirms torsion before surgery. ACOG recommends detorsion with preservation of the adnexa regardless of its appearance (ACOG 2019).
  • Massive ovarian edema. In 11 cases, patients were 13 to 39 years old, most presented with abdominal pain, torsion was present in 5, and the ovary measured up to 15 cm with a watery cut surface. Edematous stroma surrounded residual normal ovarian structures; lutein cells were present in the stroma in 4 (Young and Scully 1984).
  • Ovarian fibromatosis. In 14 cases the ovary measured up to 12 cm and was firm and white. Spindle cells with dense collagen surrounded normal follicular structures (Young and Scully 1984). The overlap of age, symptoms and histology with massive edema suggests that the two lesions are related (Young and Scully 1984).

Paratubal and broad ligament cysts

  • Origin. Paratubal cysts are remnants of the paramesonephric or mesonephric ducts and make up an estimated 5–20% of adnexal masses (Atileh et al. 2020).
  • Parovarian cysts. Of 8 large intraligamentous parovarian cysts, 7 were classified as paramesonephric in origin on surgical and histologic grounds. Earlier reports had proposed a mesothelial origin for most of these cysts (Stock 1987).
  • Papillary cystadenoma of the broad ligament. Clear cell papillary cystadenoma of the broad ligament is a manifestation of von Hippel-Lindau syndrome. Its recognition prompts referral for genetic risk assessment (Garg et al. 2018).

Endometriosis

  • Definition and frequency. Endometriosis is ectopic endometrial stroma and epithelium. It affects about 10% of women of reproductive age (Anglesio et al. 2017).
  • CD10 for the stroma. CD10 stained ectopic endometrial stroma in 22 of 25 cases of endometriosis, with little staining of other tissues. It confirms endometriosis when morphology is doubtful (Sumathi and McCluggage 2002).
  • Variant appearances. Glands may be sparse or absent (stromal endometriosis). Foamy and pigmented histiocytes, fibrosis, elastosis, smooth muscle metaplasia, myxoid change and decidual change can obscure the stroma. Necrotic pseudoxanthomatous nodules, polypoid growth, bulky disease and vascular, lymphatic or perineural invasion can suggest a neoplasm (Clement 2007).
  • Polypoid endometriosis. In 24 cases, polypoid masses up to 14 cm involved the colon, ovary, uterine serosa, cervix, vagina and other sites. Seven patients were on unopposed estrogen. Periglandular stromal hypercellularity, stromal atypia and intraglandular stromal papillae were absent in all but two cases, which separates polypoid endometriosis from adenosarcoma (Parker et al. 2004).
  • Atypical endometriosis. Cytologic atypia and hyperplasia are separate findings and should be reported separately because their premalignant potential likely differs (Clement 2007). Atypical endometriosis was present in 1.7% of ovarian endometriosis. It was in contiguity with carcinoma in 13 cases, most often clear cell and endometrioid carcinoma (Fukunaga et al. 1997).
  • Somatic mutations. Deep infiltrating endometriosis without cancer carried cancer driver mutations in ARID1A, PIK3CA, KRAS or PPP2R1A in 10 of 39 patients (26%). The mutations were confined to the epithelium (Anglesio et al. 2017).
  • Cancer risk. Self-reported endometriosis was associated with clear cell carcinoma (odds ratio 3.05), low-grade serous carcinoma (2.11) and endometrioid carcinoma (2.04). It was not associated with mucinous carcinoma, high-grade serous carcinoma or borderline tumors (Pearce et al. 2012).

Inflammatory and infectious lesions of the fallopian tube

Pelvic inflammatory disease and tubo-ovarian abscess

  • Definition. Pelvic inflammatory disease (PID) is a spectrum of upper genital tract inflammation that includes endometritis, salpingitis, tubo-ovarian abscess and pelvic peritonitis (Workowski et al. 2021).
  • Organisms. Neisseria gonorrhoeae and Chlamydia trachomatis are often implicated, but only about 50% of women with acute PID test positive for either. Vaginal flora such as anaerobes, Gardnerella vaginalis, Haemophilus influenzae, enteric gram-negative rods and Streptococcus agalactiae have also been associated with PID (Workowski et al. 2021).
  • Histologic criteria. Endometrial biopsy with histopathologic evidence of endometritis is one of the more specific criteria for PID. Endometritis may be the only sign of PID in some women, so endometrial biopsy is warranted at laparoscopy without visible salpingitis (Workowski et al. 2021).
  • Intrauterine devices. The PID risk associated with an intrauterine device (IUD) is confined mainly to the first 3 weeks after insertion (Workowski et al. 2021).
  • Actinomyces. Pelvic and ovarian actinomycosis is associated with long-term IUD use. It forms solid or cystic adnexal masses that invade adjacent tissue, can raise CA125 and is often mistaken for ovarian carcinoma. Sulfur granules within suppurative inflammation establish the diagnosis (Cao et al. 2023).

Tuberculous salpingitis and hydrosalpinx

  • Tuberculous salpingitis. Female genital tuberculosis usually spreads from a focus elsewhere in the body. The tubes are affected, typically bilaterally, in 90–100% of cases, the endometrium in 50–80% and the ovaries in 20–30% (Tzelios et al. 2022). Hysterosalpingography can show a rigid pipe-stem tube. Mycobacterial culture is the reference standard, and endometrial biopsies are most useful in the late secretory phase (Tzelios et al. 2022).
  • Hydrosalpinx. Hydrosalpinx follows tubal occlusion, mainly of the distal fimbriated end, and is caused mostly by PID; endometriosis, pelvic adhesions and previous surgery also contribute. It is present in about 30% of cases of tubal disease. It lowers implantation success in in vitro fertilization, and salpingectomy is offered before IVF (Aljassim et al. 2026).

Xanthomatous lesions and salpingitis isthmica nodosa

  • Pseudoxanthomatous salpingiosis. Lipofuscin-laden macrophages accumulate in the tubal lamina propria. It is associated with longstanding endometriosis and is thought to follow leakage of blood from ovarian endometriosis into the tube (Seidman et al. 1993). Xanthogranulomatous salpingitis is a separate form of chronic inflammation (Kostopoulou et al. 2008).
  • Salpingitis isthmica nodosa. Salpingitis isthmica nodosa (SIN) is nodular thickening of the proximal tube (Skibsted et al. 1991). It is diagnosed by the presence of isthmic diverticula (Jenkins et al. 1993). Its incidence in fertile women is 0.6–11%, and it is more common with ectopic pregnancy and infertility (Jenkins et al. 1993). Re-examination of salpingectomy specimens doubled the number of cases detected (24 compared with 12). Women with SIN had more histologic salpingitis and a higher risk of two or more tubal pregnancies (Skibsted et al. 1991).

Tubal ectopic pregnancy

  • Definition. Ectopic pregnancy is a pregnancy outside the uterine cavity. The fallopian tube is the most common site. Early tubal pregnancy is treated with minimally invasive surgery or with methotrexate; tubal pregnancy in an unstable patient requires prompt surgery (ACOG 2018).
  • Tubal disease and recurrence. In 15 tubes with a recurrent ipsilateral tubal pregnancy after conservative surgery, residual histologic evidence of the earlier implantation site was present in only 5 of 16 sites. Chronic salpingitis, follicular salpingitis and SIN were the main findings associated with recurrence (Stock 1990).
  • Persistent ectopic pregnancy. Of 2498 patients treated by salpingostomy, 52 (2.08%) had persistent ectopic pregnancy. It was defined as a postoperative day 7 serum β-hCG that fell less than 15% from the day 4 level, or rose or failed to fall for at least a week. Persistent trophoblast was more frequent after salpingostomy than after salpingectomy (Zhang et al. 2017).

Risk-reducing salpingo-oophorectomy and tubal precursor lesions

Origin of high-grade serous carcinoma in the distal tube

  • Fimbrial origin. In BRCA-positive women undergoing salpingo-oophorectomy, all 5 carcinomas were tubal, 3 were in the fimbria, and no ovarian carcinoma was found. One carcinoma was found only after further sectioning of the fimbria (Medeiros et al. 2006). In 122 BRCA-positive women, 7 (5.7%) had an early malignancy, all in the fimbrial or ampullary tube and all in women aged 44 years or older (Callahan et al. 2007).
  • Association with pelvic carcinoma. With complete adnexal examination, tubal intraepithelial carcinoma was present in 5 of 5 tubal, 4 of 6 peritoneal and 20 of 30 ovarian serous carcinomas. Of these lesions, 93% involved the fimbria (Kindelberger et al. 2007).
  • Clonality. Identical TP53 mutations were present in 27 of 29 pairs of STIC and concurrent high-grade serous carcinoma (Kuhn et al. 2012). Evolutionary analysis of exome sequencing placed p53 signatures and STIC upstream of ovarian carcinoma, with a window of about 7 years between STIC and ovarian carcinoma (Labidi-Galy et al. 2017).

Gross handling: the SEE-FIM protocol

  • Method. In the SEE-FIM protocol (Sectioning and Extensively Examining the FIMbriated end), the tube is dissected from the ovary. The fimbrial end, about the distal 2 cm, is amputated and sliced longitudinally into 4 or more slices. The rest of the tube is sliced transversely. All tissue is processed (Singh et al. 2016).
  • CAP requirements. The ovaries and tubes are submitted entirely in patients with known BRCA1/BRCA2 or other predisposing variants, or at suspected increased risk, even when grossly normal. This detailed examination increases detection of precursor lesions or early carcinoma about 4-fold. The isthmus and ampulla are cut transversely at 2- to 3-mm intervals. Fixation for 1 to 2 hours before sectioning may prevent epithelial sloughing. In high-grade serous carcinoma without a gross fimbrial lesion, complete microscopic examination of each tube by SEE-FIM is recommended (CAP Ovary 1.5.0.0).
  • Effect of a protocol. A surgical-pathologic protocol of complete removal and serial sectioning of tubes and ovaries detected 7 occult malignancies in 67 BRCA carriers. All 7 were in specimens processed by complete or partial protocol (Powell et al. 2005).
  • Meta-analysis. Across 39 studies of 6833 BRCA1/2 carriers, pooled STIC incidence at risk-reducing salpingo-oophorectomy was 2.8%. Incidence was 2.8% with SEE-FIM and 2.7% without it (P = .92), and 3.2% with total embedding compared with 1.7% without (P = .24) (Bogaerts et al. 2022).
  • Benign salpingectomy. Systematic examination of 522 tubes removed for benign indications in women at low risk found 4 STICs. Three would have been missed by a single random section, and the fimbriae of most specimens fit in 1 or 2 cassettes per tube (Rabban et al. 2014). STIC is found in <0.01% of salpingectomies for benign indications (Bogaerts et al. 2022).

Spectrum of tubal lesions: p53 signature, STIL and STIC

  • p53 signature. A p53 signature is a stretch of morphologically normal secretory cells, at least 12 consecutive cells long, with strong nuclear p53 expression (Folkins et al. 2008; Visvanathan et al. 2011). p53 signatures predominate in the fimbria (80–100%) and show DNA damage by γ-H2AX staining. TP53 mutations were found in 8 of 14 fully analyzed signatures (Lee et al. 2007). p53 signatures occurred in 38% of tubes from BRCA-positive women and in 33% from women of unknown BRCA status (Folkins et al. 2008).
  • Proliferation index. p53 signatures had a MIB-1 index of 0–30%. STICs had an index above 45%, usually above 70%. Intermediate lesions had an index of 40–75% with preserved polarity (Jarboe et al. 2008).
  • STIC morphology. The most frequently reported features of STIC are loss of cell polarity, nuclear pleomorphism, high nuclear to cytoplasmic ratio, mitotic activity, pseudostratification and prominent nucleoli (Bogaerts et al. 2022). In the reproducibility study, at least 1 mitotic figure and epithelial stratification were the criteria with the best agreement (Visvanathan et al. 2011).
  • Reproducibility. Interobserver agreement for STIC compared with not STIC was fair on morphology alone (κ = 0.39). It rose to substantial (κ = 0.73) with an algorithm that combines morphology with p53 and Ki-67 (Visvanathan et al. 2011). Six pathologists who completed web-based training on the algorithm reached κ = 0.67 (Vang et al. 2012).
Category Morphology p53 immunostain Ki-67 index Source
STIC Unequivocal or suspicious for STIC Abnormal (moderate to strong nuclear expression in >75% of lesional cells, ≥12 cells when no atypia, or complete absence) ≥10% Visvanathan et al. 2011; Vang et al. 2012
STIL Atypia (unequivocal or suspicious) without the full STIC combination of abnormal p53 and Ki-67 ≥10% Abnormal or wild-type <10% or ≥10% Visvanathan et al. 2011; Vang et al. 2012
p53 signature Not suspicious; normal-appearing secretory cells Abnormal, ≥12 consecutive cells Low Visvanathan et al. 2011; Folkins et al. 2008
Normal or reactive Suspicious or not suspicious Wild-type <10% Visvanathan et al. 2011

STIL is the algorithm's atypical intermediate category. Agreement among 6 trained pathologists was 76% for the 4 categories and 93% for STIC compared with non-STIC (Vang et al. 2012).

  • Algorithm rule. Abnormal p53 combined with a high Ki-67 index is required for a final diagnosis of STIC when morphology is unequivocal or suspicious (Visvanathan et al. 2011). Abnormal p53 includes complete absence of staining as well as overexpression. Strong diffuse staining correlates with TP53 missense mutations and complete absence with null mutations (Kuhn et al. 2012).
  • Frequency of lesions at RRSO. Pooled incidence in risk-reducing specimens was 16.2% for p53 signatures and 1.6% for STIL (Bogaerts et al. 2022). TP53 is mutated in about 92% of STICs by sequencing (Bogaerts et al. 2022).
  • 2023 Delphi consensus. An international panel of 34 gynecologic pathologists from 11 countries rated 64 statements on STIC diagnosis. Twenty-seven statements (42%) reached consensus, covering processing and macroscopy, microscopy, immunohistochemistry, interpretation and reporting, and the final set was approved by 85% of the panel (Bogaerts et al. 2023). The 2022 systematic review recommends SEE-FIM grossing, review by a subspecialized gynecologic pathologist, selective p53 and Ki-67 staining and a second opinion (Bogaerts et al. 2022).

Clinical significance of isolated STIC

  • CAP reporting and staging. STIC found incidentally or in a risk-reducing salpingo-oophorectomy or opportunistic salpingectomy does not need synoptic reporting. When a staging procedure was done, STIC without invasion or extratubal spread may be staged pT1a if it involves one tube, pT1b if it involves both tubes and pT1c3 if peritoneal washings or ascites contain malignant cells, with an annotation that no invasive carcinoma is present. Ascites without malignant cells does not affect stage (CAP Ovary 1.5.0.0).
  • Peritoneal carcinoma risk. In an individual patient data meta-analysis of 3121 BRCA carriers, 115 had STIC at risk-reducing salpingo-oophorectomy. The hazard ratio for later peritoneal carcinomatosis was 33.9 with STIC. Risks at 5 and 10 years were 10.5% and 27.5% with STIC and 0.3% and 0.9% without STIC (Steenbeek et al. 2022).
  • Earlier review. Of 78 patients with isolated STIC, 3 BRCA carriers (4.5%) developed primary peritoneal carcinoma at 43 to 72 months (Patrono et al. 2015).
  • Management. No evidence supports adjuvant therapy for isolated STIC, and it is not recommended (Renz et al. 2025). STIC found at risk-reducing surgery is reported as originating in the fallopian tube (Renz et al. 2025).
  • Timing of surgery. Guidelines advise risk-reducing salpingo-oophorectomy at 35–40 years for BRCA1 carriers and 40–45 years for BRCA2 carriers (Renz et al. 2025). ACOG supports complete bilateral salpingectomy at obstetric, gynecologic and some non-gynecologic abdominopelvic surgery for primary prevention of epithelial ovarian cancer (ACOG 2026).

Differential diagnosis of non-neoplastic adnexal masses

Finding Favors Alternative diagnosis (distinguishing features) Source
Bilateral multicystic ovaries in pregnancy, luteinized theca cells, edema Hyperreactio luteinalis Juvenile granulosa cell tumor (solid growth, vacuolated cytoplasm) Watkins et al. 2021
Unilocular cyst of pregnancy lined by luteinized cells with bizarre nuclei, few mitoses Large solitary luteinized follicle cyst Adult granulosa cell tumor (grooves, Call-Exner bodies) Lomme et al. 2011
Solid brown mass at cesarean section, inhibin and melan-A positive, regresses after delivery Pregnancy luteoma Sertoli-Leydig cell tumor (usually unilateral; virilization in 40–80%) Stewart and Twidale 2024
Polypoid endometriotic mass without stromal hypercellularity or atypia Polypoid endometriosis Adenosarcoma Parker et al. 2004
Adnexal mass with sulfur granules in a long-term IUD user Actinomycosis Ovarian carcinoma Cao et al. 2023
GATA3-positive, PAX8-negative transitional nest on tubal serosa Walthard nest Brenner tumor (mass) Roma and Masand 2014
Endometriosis in the wall of the fallopian tube: a focus of endometrial-type glands, some cystically dilated, surrounded by a cuff of dense, cellular endometrial-type stroma (left), within the smooth muscle of the tubal wall; the normal plicae of the tubal lumen are at right. Glands plus stroma make the diagnosis. H&E, low power (magnification not stated).
Endometriosis in the wall of the fallopian tube: a focus of endometrial-type glands, some cystically dilated, surrounded by a cuff of dense, cellular endometrial-type stroma (left), within the smooth muscle of the tubal wall; the normal plicae of the tubal lumen are at right. Glands plus stroma make the diagnosis. H&E, low power (magnification not stated).Image: Ed Uthman, Wikimedia Commons, CC BY 2.0.

Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response

Definition. Serous tumors of the ovary, fallopian tube and peritoneum range from benign serous cystadenoma and adenofibroma through serous borderline tumor to low-grade serous carcinoma (LGSC) and high-grade serous carcinoma (HGSC). LGSC and HGSC have been separate histotypes since the WHO 4th edition (2014). They arise by different pathways: LGSC carries MAPK pathway mutations (KRAS, BRAF, NRAS), and HGSC carries TP53 mutations in almost every case (Köbel and Kang 2022). The WHO 5th edition (2020) uses the combined term tubo-ovarian high-grade serous carcinoma, reflecting the evidence that most HGSCs arise from serous tubal intraepithelial carcinoma (STIC) in the fallopian tube (Köbel and Kang 2022; CAP Ovary 1.5.0.0).

Related page: Non-Neoplastic Ovary and Fallopian Tube: Cysts, Endometriosis, Torsion, Salpingitis, Ectopic Pregnancy and Tubal Precursor Lesions (STIC, STIL, p53 signature, SEE-FIM and risk-reducing salpingo-oophorectomy) Related page: Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary (endometrioid, clear cell and mucinous carcinoma and the histotype immunohistochemistry panel) Related page: Endometrial Carcinoma: Histologic Types and Molecular Classification (p53 immunohistochemistry patterns in endometrial carcinoma) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (Lynch syndrome and mismatch repair testing) Related page: Paget Disease of the Nipple, Inflammatory Carcinoma, Male Breast Carcinoma and Hereditary Breast Cancer (BRCA1 and BRCA2 genetics and breast cancer risk) Related page: Pelvic washing cytology and ovarian cyst FNA (washings, psammoma bodies and serous lesions in washings) Related page: Metastatic Müllerian Carcinoma in Serous Effusions (Müllerian carcinoma in effusions) Related page: Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary (FIGO 2014 staging, lymph node inclusions and endosalpingiosis, peritoneal mesothelioma versus serous carcinoma) Related page: Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors (Peutz-Jeghers, DICER1, rhabdoid tumor predisposition and Gorlin syndromes and their ovarian tumors)

Pathogenesis of serous carcinoma: the dualistic model

  • Type I and type II tumors. The dualistic model divides ovarian carcinomas into type I tumors, which develop from benign extraovarian lesions that implant on the ovary, and type II tumors. Type II tumors are mainly HGSCs, many of which develop from intraepithelial carcinoma of the fallopian tube and disseminate early (Kurman and Shih 2016).
  • Low-grade pathway. LGSC evolves slowly from serous adenofibroma or serous borderline tumor. It has frequent KRAS, BRAF or ERBB2 mutations, lacks TP53 mutation and is genetically stable (Vang et al. 2009; Singer et al. 2003).
  • High-grade pathway. HGSC shows TP53 mutation in 96% of tumors, low-frequency recurrent mutations in NF1, BRCA1, BRCA2, RB1 and CDK12, and extensive copy-number change. Homologous recombination is defective in about half of HGSCs (Cancer Genome Atlas Research Network 2011).

Serous cystadenoma, adenofibroma and serous borderline tumor

  • Serous cystadenoma and KRAS or BRAF mutation. Identical KRAS or BRAF mutations were found in serous cystadenoma epithelium adjacent to serous borderline tumor. Serous cystadenomas without a borderline component lacked these mutations, which places the mutation early in the transition from cystadenoma to borderline tumor (Vang et al. 2009).
  • Serous papillary adenofibroma. In 13 serous papillary adenofibromas (median age 47 years), the tumors were cystic or cystic and solid with small papillae. Ultrasound showed papillae in 2 of 13 cases. ER was positive in 12 and PR in all 13, and Ki-67 was ≤1% or negative in 9 (Zhao et al. 2025).
  • LGSC with macropapillary invasion. Some LGSCs invade as inverted macropapillae, a pattern that can be misdiagnosed as serous adenofibroma (Vang et al. 2009).

Morphology of serous borderline tumor

  • Definition and terminology. Serous borderline tumor shows epithelial proliferation with hierarchical papillary branching and low-grade cytology in at least 10% of the tumor volume, without stromal invasion (CAP Ovary 1.5.0.0). Serous borderline tumor is the term used in the CAP protocol and the WHO 5th edition; older papers use atypical proliferative serous tumor (Zeppernick et al. 2014; CAP Ovary 1.5.0.0). It is the precursor of LGSC (Zeppernick et al. 2014). Serous borderline tumors can arise in serous cystadenomas (Vang et al. 2009).
  • Typical pattern. Typical serous borderline tumors show hierarchical branching papillae that end in small papillae or tufts. The lining cells are columnar and often ciliated (Burks et al. 1996).
  • Eosinophilic cells. Cells with abundant eosinophilic cytoplasm and bland nuclei were present in all 25 BRAF-mutated borderline tumors. They express p16, have a low Ki-67 index and show features of oncogene-induced senescence (Zeppernick et al. 2014).

Micropapillary pattern of serous borderline tumor

  • Definition. The micropapillary pattern shows a filigree of highly complex micropapillae arising directly from large bulbous papillae. The micropapillae are covered by round to cuboidal cells with a high nuclear to cytoplasmic ratio (Burks et al. 1996). Of 26 such tumors, 24 (92%) contained areas of typical serous borderline tumor (Burks et al. 1996).
  • Size criterion. The micropapillary/cribriform variant has micropapillae without fibrovascular cores, at least 5 times longer than wide, arising directly from broad papillae ("Medusa head"), and/or small cribriform spaces, in an area measuring at least 5 mm (CAP Ovary 1.5.0.0). Borderline tumors with micropapillary foci or microinvasion are sampled extensively (CAP Ovary 1.5.0.0).

Microinvasion in serous borderline tumor

  • Current definition. Serous borderline tumor with microinvasion has invasive foci <5 mm in greatest dimension in any single focus, seen as single cells or small clusters of plump eosinophilic cells, or small papillary clusters in lacunar spaces without a stromal reaction. Microinvasive LGSC resembles LGSC but has only foci <5 mm; these tumors usually behave like serous borderline tumors at stages I–II (CAP Ovary 1.5.0.0).

  • Prognosis. In a series of 276 patients, stromal microinvasion correlated with adverse outcome independent of stage, micropapillary architecture and implant type (Longacre et al. 2005). Micropapillary stromal invasion may carry a risk closer to LGSC and is reported specifically; size limits of 3 mm or 5 mm were used historically (McKenney et al. 2006).

Peritoneal implants and lymph node involvement in serous borderline tumor

  • Implant prognosis. In 4129 patients from 97 reports, survival was 95.3% with non-invasive implants and 66% with invasive implants (Seidman and Kurman 2000).
  • Classification of invasive implants. Some centers consider invasive implants to be LGSC, and WHO nomenclature changed accordingly in 2014. ESGO considers it premature to define serous borderline tumors with invasive implants as LGSC (Renz et al. 2025).
  • Current CAP terminology. Implants are non-invasive by definition, and former "invasive implants" are reported as extraovarian LGSC. When an ovarian tumor that appears to be a serous borderline tumor has such deposits, it is sampled further and categorized as LGSC (CAP Ovary 1.5.0.0).
  • Peritoneal fluid. Borderline tumor cells in peritoneal fluid are reported as atypia of undetermined significance under the International System for Reporting Serous Fluid Cytopathology. In a T1 tumor they stage it pT1c3 (CAP Ovary 1.5.0.0). Washings are covered in Pelvic washing cytology and ovarian cyst FNA.
  • Lymph nodes. Lymph node involvement was associated with 98% survival at 6.5 years (Seidman and Kurman 2000).
  • Progression. Progression to LGSC occurred in 6.8% of 276 patients, at 7 to 288 months, and was associated with lower survival (Longacre et al. 2005).
  • Treatment. Borderline tumors at all stages are treated with surgery. Chemotherapy has not been shown to be beneficial. Spontaneous regression of peritoneal implants has been observed (Renz et al. 2025).
  • Primary peritoneal serous borderline tumor. This rare tumor is often asymptomatic and is frequently associated with endosalpingiosis. Recurrence is low and no cancer-related deaths have been reported (Iannone et al. 2025). A serous tumor is designated primary peritoneal only when entirely submitted ovaries and tubes show no involvement and no STIC (CAP Ovary 1.5.0.0).

Low-grade serous carcinoma

  • Morphology. The invasive component consists of micropapillae and small round nests that infiltrate the stroma haphazardly and are often surrounded by a clear space or cleft. The nuclei are small, uniform and round to oval with even chromatin. Psammoma bodies are common and may be numerous. An inverted macropapillary pattern shows medium-sized round papillae surrounded by clear spaces (Vang et al. 2009).
  • Nuclear criterion. Low-grade nuclei show mild to moderate atypia. Variation of ≥3:1 in nuclear size and shape indicates HGSC (Malpica et al. 2004; Vang et al. 2009).
  • Molecular features. About 50% of LGSCs carry MAPK pathway mutations, including BRAF and KRAS, and they are TP53 wild type (Renz et al. 2025).
  • Clinical behavior. LGSC is less sensitive to chemotherapy than HGSC (Gershenson et al. 2022).
  • Targeted therapy. In the GOG 281/LOGS trial of 260 patients with recurrent LGSC, trametinib prolonged median progression-free survival to 13.0 months, compared with 7.2 months for standard of care (hazard ratio 0.48) (Gershenson et al. 2022). Avutometinib (a RAF/MEK clamp) with defactinib (a FAK inhibitor) received FDA accelerated approval for KRAS-mutated recurrent LGSC (Grisham et al. 2026b). In the RAMP 201 study of 115 patients, median progression-free survival was 19.6 months with a KRAS mutation and 12.7 months without (Grisham et al. 2026a).

High-grade serous carcinoma

  • Architecture. HGSC shows papillary, glandular, nested and solid growth. Papillae are large and complex, lined by stratified epithelium with irregular slit-like spaces. Occasional HGSCs have a micropapillary pattern (Vang et al. 2009).
  • Cytology. Nuclei are enlarged and pleomorphic with prominent nucleoli and abundant mitoses, including atypical forms. Bizarre tumor giant cells are common.
  • SET features. Solid, pseudoendometrioid and transitional cell carcinoma-like (SET) patterns occur in HGSC. BRCA1-associated HGSCs more often showed SET features, higher mitotic indexes, more tumor-infiltrating lymphocytes and geographic or comedo necrosis (Soslow et al. 2012).
  • Intermediate nuclei. About 4% of serous carcinomas have intermediate ("grade 2") nuclei, and 10 of 11 such tumors carried TP53 mutations (Vang et al. 2009). The term "moderately differentiated" serous carcinoma is no longer used; these tumors are high grade (Renz et al. 2025).
  • TP53 as a defining feature. On review of 14 TCGA HGSCs without TP53 mutation, 13 were either not pure HGSC or another diagnosis. Absence of TP53 alteration is essentially inconsistent with de novo HGSC (Vang et al. 2016).

Comparison of serous borderline tumor, LGSC and HGSC

Feature Serous borderline tumor Low-grade serous carcinoma High-grade serous carcinoma Source
Invasion None, or microinvasion (<5 mm) Destructive stromal invasion by micropapillae and nests with clefts Destructive invasion; papillary, glandular, solid CAP Ovary 1.5.0.0; Vang et al. 2009
Lining cells and nuclei Columnar, often ciliated cells in hierarchical papillae Uniform, small nuclei; <3:1 variation Pleomorphic; ≥3:1 variation Malpica et al. 2004; Vang et al. 2009
Mitoses per 10 HPF Not used for classification Mean 4 (range 1–12) Median 38 (range 14–137) Vang et al. 2009
Psammoma bodies Not graded Common, often numerous Less frequent Vang et al. 2009
KRAS/BRAF 61% 68% (micropapillary carcinoma) 0 of 72 Singer et al. 2003
TP53 mutation 2 of 25 (8%) 1 of 12 (8.3%); rare 96% Singer et al. 2005; Vang et al. 2009; Cancer Genome Atlas Research Network 2011
p53 immunostain Not tested in the cited series Wild type Abnormal (overexpression, complete absence or cytoplasmic) Köbel et al. 2016; Köbel and Kang 2022
WT1 Not tested in the cited series Diffusely positive Diffusely positive Köbel and Kang 2022
p16 Positive in senescent eosinophilic cells Patchy pattern favors LGSC (84%) Block-diffuse pattern favors HGSC (88%) Zeppernick et al. 2014; Köbel and Kang 2022

Immunohistochemistry of serous carcinoma

WT1 and lineage markers in serous carcinoma

p53 immunohistochemistry patterns in ovarian carcinoma

Optimized p53 immunohistochemistry predicts TP53 mutation in ovarian carcinoma. The shared pattern scheme is also used in endometrial carcinoma (Endometrial Carcinoma: Histologic Types and Molecular Classification).

p53 pattern Appearance Predicted TP53 status Source
Overexpression Diffuse, strong nuclear staining in ≥80% of tumor cells Missense (gain-of-function or nonsynonymous) mutation Köbel et al. 2016; CAP Gynecologic Biomarker 1.3.0.0
Complete absence No nuclear or cytoplasmic staining in tumor cells, with a satisfactory internal positive control Loss-of-function mutation (stop-gain, frameshift, splice) Köbel et al. 2016; CAP Gynecologic Biomarker 1.3.0.0
Cytoplasmic Cytoplasmic staining Loss-of-function mutation; 2.3% of HGSCs Köbel et al. 2016
Wild type Variable nuclear staining of differing intensity No detectable mutation, or a nonexpressed loss-of-function mutation in 4.1% of HGSCs Köbel et al. 2016
  • Accuracy. Deleterious TP53 mutations were found in 169 of 171 HGSCs (99%). Optimized p53 staining reached a specificity of 1.00 for TP53 mutation (Köbel et al. 2016).
  • Use in serous typing. Abnormal p53 excludes LGSC with 100% specificity (Köbel and Kang 2022).
  • Sources of p53 misinterpretation. In a proficiency test, the p53 error rate was 8.8%, and 84% of errors resulted from weak staining (Lee et al. 2016). Local optimization with low-expressing control tissue such as tonsil is required for accurate reading of the complete-absence and cytoplasmic patterns (Köbel et al. 2021).

Low-grade versus high-grade serous carcinoma

  • Two tumor types. Serous carcinomas are not graded. Low-grade and high-grade serous carcinoma are distinct tumor types that differ in risk factors, precursors, chemotherapy response and genetic events. They are separated mainly by nuclear variability, with at least 3-fold variation in nuclear size in HGSC. In difficult cases block-type p16, abnormal p53 and mitotic activity help (CAP Ovary 1.5.0.0).
  • Origin of the division. The MD Anderson system that introduced this division uses nuclear atypia as the primary criterion and mitotic rate as a secondary feature: low-grade tumors have mild to moderate atypia and up to 12 mitoses per 10 HPF, and high-grade tumors have marked atypia and more than 12 mitoses per 10 HPF (Malpica et al. 2004).
  • Reproducibility. Among 9 pathologists classifying 80 serous carcinomas, the overall κ was 0.909 (Malpica et al. 2007).

Primary site assignment of high-grade serous carcinoma

FIGO 2014 requires a primary site (Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary) but gives no guidance on how to assign it (Singh et al. 2014). The consensus criteria assign most HGSCs to the fallopian tube (Singh et al. 2016).

Finding Primary site Comment Source
STIC present Fallopian tube Regardless of size of ovarian and peritoneal disease Singh et al. 2016; CAP Ovary 1.5.0.0
Mucosal HGSC in the tube, with or without STIC Fallopian tube Regardless of size of ovarian and peritoneal disease Singh et al. 2016; CAP Ovary 1.5.0.0
Part or all of the tube inseparable from the tubo-ovarian mass Fallopian tube Regardless of size of ovarian and peritoneal disease Singh et al. 2016; CAP Ovary 1.5.0.0
Both tubes separate from the mass, with no STIC or mucosal HGSC in either tube Ovary Both tubes fully examined by SEE-FIM Singh et al. 2016; CAP Ovary 1.5.0.0
Both tubes and both ovaries fully examined, with no gross or microscopic STIC or HGSC Peritoneal Only in specimens removed at primary surgery before chemotherapy Singh et al. 2016; CAP Ovary 1.5.0.0
Tubes and ovaries not available for complete examination: small biopsy or cytology, prior salpingo-oophorectomy with incomplete tubal examination, some treated specimens Tubo-ovarian Uterine serous carcinoma is the main mimic on small biopsies Singh et al. 2016; CAP Ovary 1.5.0.0
After chemotherapy with no residual disease Tubo-ovarian Residual disease after chemotherapy is assigned by the criteria above Singh et al. 2016

The CAP protocol adopts the WHO 5th edition criteria, and site assignment as "undesignated" should be avoided (CAP Ovary 1.5.0.0).

  • Validation. With the new criteria, 79% of chemotherapy-naive and 68% of post-neoadjuvant HGSCs were assigned to the tube. Traditional criteria had classified 73% and 63% as ovarian primaries. Four pathologists agreed on the primary site in 48 of 50 cases (96%) (Singh et al. 2015).
  • Effect on terminology. With current site assignment, primary peritoneal HGSC is exceedingly rare (Köbel and Kang 2022). The term tubo-ovarian HGSC separates this disease from uterine serous carcinoma and ovarian LGSC (Singh et al. 2016).

Hereditary syndromes and germline testing

  • Prevalence of germline variants. Of 1915 unselected women with ovarian carcinoma, 15% carried BRCA1 or BRCA2 mutations, 3.3% carried mutations in BRIP1, RAD51C, RAD51D, PALB2 or BARD1, and 0.4% carried mismatch repair gene mutations (Norquist et al. 2016).
  • Family history. Of women with high-grade non-mucinous ovarian cancer and germline BRCA1/2 mutations, 44% have no family history of breast or ovarian cancer (Renz et al. 2025). BRCA1-associated cancers present at a median age in the mid-40s (Renz et al. 2025).
Gene or syndrome Ovarian or tubo-ovarian cancer risk Associated tumors Source
BRCA1 44% to age 80 Breast cancer Kuchenbaecker et al. 2017
BRCA2 17% to age 80 Breast cancer Kuchenbaecker et al. 2017
RAD51C 11% to age 80 (relative risk 7.55) Tubo-ovarian carcinoma; breast cancer Yang et al. 2020a
RAD51D 13% to age 80 (relative risk 7.60) Tubo-ovarian carcinoma; breast cancer Yang et al. 2020a
BRIP1 Odds ratio 8.13 (Icelandic frameshift variant) Ovarian cancer Rafnar et al. 2011
PALB2 5% to age 80 (relative risk 2.91) Breast cancer; pancreatic cancer Yang et al. 2020b
Lynch syndrome 20% (MLH1), 24% (MSH2), 1% (MSH6) to age 70 Endometrial cancer 54% (MLH1); colorectal cancer 41–48% (MLH1, MSH2) Bonadona et al. 2011

BRCA and homologous recombination deficiency testing

Guideline recommendations for BRCA and HRD testing

  • ASCO 2020. All women with epithelial ovarian cancer should be offered germline testing for BRCA1, BRCA2 and other ovarian cancer susceptibility genes, irrespective of clinical features or family history. Women without a germline BRCA1/2 pathogenic or likely pathogenic variant should have somatic tumor testing for BRCA1/2 (Konstantinopoulos et al. 2020).
  • Germline and somatic yield. Germline BRCA1/2 mutations are found in 13–15% of women with ovarian cancer, and somatic tumor testing finds about another 5–7% (Konstantinopoulos et al. 2020). Tumor testing is less sensitive than germline testing: up to 5% of germline mutations are missed if tumor results decide whether germline sequencing is done (Konstantinopoulos et al. 2020).
  • Mismatch repair. Women with clear cell, endometrioid or mucinous ovarian cancer should be offered somatic tumor testing for mismatch repair deficiency (Konstantinopoulos et al. 2020).
  • HRD assays in ASCO. ASCO made no recommendation supporting routine tumor testing with homologous recombination deficiency (HRD) assays (Konstantinopoulos et al. 2020).
  • ESMO 2020. Trial evidence supports BRCA mutation testing and two commercial assays that also measure genomic instability for identifying HGSCs with different magnitudes of PARP inhibitor benefit. Existing tests lack negative predictive value (Miller et al. 2020).
  • European consensus 2022. Germline non-BRCA homologous recombination repair and mismatch repair gene mutations predict familial risk. They do not predict PARP inhibitor sensitivity in the first-line setting (Vergote et al. 2022).
  • Tissue before neoadjuvant chemotherapy. Histologic confirmation before neoadjuvant chemotherapy ensures enough tissue for HRD and somatic BRCA testing (Renz et al. 2025).
  • CAP biomarker template. The CAP gynecologic biomarker template (version 1.3.0.0) has no reporting element for BRCA1/2, HRD or homologous recombination status. Its elements include ER, PR, HER2, mismatch repair, p53, PD-L1, folate receptor alpha and MSI (CAP Gynecologic Biomarker 1.3.0.0).

Tissue selection for HRD testing

  • Recommended tissue. For HGSC tested with the Myriad myChoice assay, samples with tumor cell content ≥30% and tumor area ≥0.5 cm² on the H&E section are recommended. With appropriate selection, success rates reach 98% (Romey et al. 2024).
Test Specimen What it detects Clinical use Source
Germline multigene panel Blood or saliva Inherited BRCA1/2, RAD51C, RAD51D, BRIP1, PALB2 and mismatch repair variants All epithelial ovarian cancers; cascade testing of relatives Konstantinopoulos et al. 2020
Tumor BRCA1/2 sequencing Tumor tissue Germline plus somatic BRCA1/2 variants Women without a germline BRCA1/2 variant Konstantinopoulos et al. 2020
Genomic instability (HRD) assay Tumor tissue, ≥30% tumor cells and ≥0.5 cm² tumor area BRCA status plus a genomic instability score Magnitude of PARP inhibitor benefit in first-line HGSC Miller et al. 2020; Romey et al. 2024
Mismatch repair immunohistochemistry Tumor tissue Loss of MLH1, PMS2, MSH2 or MSH6 Clear cell, endometrioid and mucinous carcinoma; Lynch screening Konstantinopoulos et al. 2020

PARP inhibitor and antibody-drug conjugate trials in ovarian carcinoma

Trial Population Biomarker result Source
SOLO1 (olaparib maintenance) Newly diagnosed stage III–IV high-grade serous or endometrioid carcinoma with BRCA1/2 mutation Progression-free at 3 years 60% vs 27%; hazard ratio 0.30 Moore et al. 2018
PAOLA-1 (olaparib plus bevacizumab) Newly diagnosed advanced high-grade carcinoma regardless of BRCA status Hazard ratio 0.33 in HRD-positive tumors and 0.43 in HRD-positive tumors without BRCA mutation Ray-Coquard et al. 2019
PRIMA (niraparib maintenance) Newly diagnosed advanced carcinoma after response to platinum Median progression-free survival, HRD-positive: 21.9 vs 10.4 months; overall: 13.8 vs 8.2 months González-Martín et al. 2019
MIRASOL (mirvetuximab soravtansine) Platinum-resistant high-grade serous carcinoma with high folate receptor alpha Overall survival 16.46 vs 12.75 months; hazard ratio 0.67 Moore et al. 2023
  • CAP scoring of folate receptor alpha. With the FDA-approved VENTANA FOLR1 (FOLR-2.1) RxDx companion assay, positivity is ≥75% of viable tumor cells with moderate to strong membrane staining. Moderate to strong staining in <75% of cells, weak staining in any proportion or no staining is negative. Mirvetuximab soravtansine received FDA accelerated approval on November 14, 2022, for FRα-positive platinum-resistant epithelial ovarian, tubal or primary peritoneal cancer after 1–3 prior regimens (CAP Gynecologic Biomarker 1.3.0.0; FDA 2022). Regular approval for the same indication followed on March 22, 2024 (FDA 2024).

Chemotherapy response score after neoadjuvant chemotherapy

  • CAP requirement. The CRS is required only for HGSC after neoadjuvant chemotherapy. It is assessed on the omental section showing the least response, and 4 to 6 omental sections from the most abnormal areas are recommended. The categories are CRS1, no definite or minimal response; CRS2, moderate response; and CRS3, marked response with no or minimal residual cancer (CAP Ovary 1.5.0.0).
  • Development. The chemotherapy response score (CRS) was developed in interval debulking specimens of stage IIIC–IV tubo-ovarian HGSC. Applied to the omentum, it was reproducible (κ = 0.67 in validation) and predicted progression-free survival. Applied to the adnexa, it did not stratify prognosis (Böhm et al. 2015).
  • Platinum sensitivity. CRS 3 had a 94.3% negative predictive value for progression within 6 months (Böhm et al. 2015).
CRS Response Histologic definition Source
1 No or minimal response Mainly viable tumor with no or minimal regression-associated fibroinflammatory change limited to a few foci; cases in which regression and tumor-associated desmoplasia or inflammation cannot be separated Böhm et al. 2015; Lawson et al. 2020
2 Appreciable response amid viable tumor Viable tumor readily identifiable; multifocal or diffuse regression-associated change with tumor in sheets, streaks or nodules, up to extensive regression with multifocal residual tumor Böhm et al. 2015; Lawson et al. 2020
3 Complete or near-complete response No residual tumor, or minimal irregularly scattered tumor foci as individual cells, cell groups or nodules up to 2 mm; recording "no residual tumor" or "microscopic residual tumor present" is advisable Böhm et al. 2015; Lawson et al. 2020; CAP Ovary 1.5.0.0

Regression-associated fibroinflammatory change is fibrosis with macrophages, including foam cells, mixed inflammatory cells and psammoma bodies, as distinct from tumor-related inflammation or desmoplasia (CAP Ovary 1.5.0.0).

  • Validation. In an individual patient data meta-analysis of 877 patients from 16 sites, CRS 3 occurred in 28%. CRS 3 compared with CRS 1–2 had hazard ratios of 0.55 for progression-free survival and 0.65 for overall survival. Patients with germline BRCA1/2 mutations were more likely to achieve CRS 3 (Cohen et al. 2019; corrigendum Cohen et al. 2021).
  • Adnexal score. Adnexal CRS 1–2 carried almost four times the risk of platinum-resistant disease compared with adnexal CRS 3 (Lawson et al. 2020).

Differential diagnosis of serous tumors

Diagnostic question Discriminating features Source
Serous borderline tumor with micropapillary pattern versus LGSC Destructive stromal invasion by micropapillae and nests with clefts defines LGSC; foci of invasion <5 mm define microinvasion CAP Ovary 1.5.0.0; Vang et al. 2009
LGSC versus HGSC Nuclear variation ≥3:1, high mitotic rate and abnormal p53 indicate HGSC; abnormal p53 excludes LGSC Malpica et al. 2004; Köbel and Kang 2022
HGSC versus high-grade endometrioid carcinoma WT1 and p53 panel in Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary Köbel and Kang 2022
Serous borderline tumor of the ovary: hierarchically branching papillae lined by stratified cuboidal to columnar cells with mild to moderate atypia and tufting (left and top), with small rounded gland-like invaginations of the same epithelium into the fibrous wall (center right). The invaginations are smooth-contoured and lack the irregular small nests, single cells and desmoplasia of stromal invasion, and a psammoma body lies at center right. H&E, medium power (magnification not stated).
Serous borderline tumor of the ovary: hierarchically branching papillae lined by stratified cuboidal to columnar cells with mild to moderate atypia and tufting (left and top), with small rounded gland-like invaginations of the same epithelium into the fibrous wall (center right). The invaginations are smooth-contoured and lack the irregular small nests, single cells and desmoplasia of stromal invasion, and a psammoma body lies at center right. H&E, medium power (magnification not stated).Image: Mikael Häggström, M.D., Wikimedia Commons, CC0.

Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary

Definition. The non-serous epithelial tumors of the ovary are mucinous, endometrioid, clear cell, seromucinous and Brenner tumors, each with benign, borderline and malignant forms, together with mesonephric-like adenocarcinoma, carcinosarcoma, undifferentiated and dedifferentiated carcinoma and mixed carcinoma. The WHO 5th edition (2020) lists five principal ovarian carcinoma histotypes: high-grade serous, low-grade serous, mucinous, endometrioid and clear cell carcinoma. In descending order of frequency they are high-grade serous, endometrioid, clear cell, low-grade serous and mucinous carcinoma (Köbel and Kang 2022). Endometrioid and clear cell carcinomas arise from endometriosis (Köbel and Kang 2022).

Related page: Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response (serous borderline tumor, low-grade and high-grade serous carcinoma, BRCA and HRD testing) Related page: Non-Neoplastic Ovary and Fallopian Tube: Cysts, Endometriosis, Torsion, Salpingitis, Ectopic Pregnancy and Tubal Precursor Lesions (endometriosis, atypical endometriosis and Walthard nests) Related page: Appendiceal Neoplasms: Mucinous Neoplasms, Pseudomyxoma Peritonei, Goblet Cell Adenocarcinoma and Neuroendocrine Tumors (low-grade appendiceal mucinous neoplasm, pseudomyxoma peritonei and PSOGI categories) Related page: Endometrial Carcinoma Staging, CAP Reporting and Biomarker Testing (synchronous endometrial and ovarian carcinoma and the FIGO 2023 rule) Related page: Endometrial Carcinoma: Histologic Types and Molecular Classification (FIGO grading thresholds, endometrial molecular classification and mesonephric-like carcinoma) Related page: Cervical Glandular Lesions: Benign Mimics, Adenocarcinoma In Situ and Endocervical Adenocarcinoma (gastric-type and HPV-associated endocervical adenocarcinoma metastatic to the ovary) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (Lynch syndrome and mismatch repair testing)

Changes in the WHO 5th edition for non-serous epithelial tumors

Category WHO 4th edition (2014) WHO 5th edition (2020) Source
Seromucinous carcinoma Separate histotype Classified as endometrioid carcinoma with mucinous differentiation; low-grade serous carcinoma with mucinous differentiation is separated from it Köbel and Kang 2022; CAP Ovary 1.5.0.0
Seromucinous cystadenoma and borderline tumor Separate category Retained as distinct categories Köbel and Kang 2022; CAP Ovary 1.5.0.0
Mesonephric-like adenocarcinoma Not listed New entity Köbel and Kang 2022
Mixed carcinoma Not listed Reintroduced, noted as rare Köbel and Kang 2022
Carcinosarcoma Mixed epithelial and mesenchymal tumor Malignant epithelial tumor (metaplastic carcinoma) Köbel and Kang 2022

Pathologists agreed with a reference diagnosis of seromucinous carcinoma in only 39–56% of cases, and integrated morphology, immunophenotype and genotype reclassified 72% as endometrioid, 25% as low-grade serous and 3% as mucinous carcinoma (Rambau et al. 2017).

Mucinous tumors of the ovary

Mucinous borderline tumor and intraepithelial carcinoma

  • Definition. Mucinous borderline tumor shows proliferation of gastrointestinal-type mucinous epithelium with low-grade nuclear atypia in at least 10% of the tumor, with stratification, tufting and villous or filiform papillae. Lesser proliferation is classified as mucinous cystadenoma with focal epithelial proliferation (CAP Ovary 1.5.0.0).
  • Intraepithelial carcinoma and microinvasion. Intraepithelial carcinoma shows excessively stratified epithelium with high nuclear grade and frequent mitoses confined to the epithelium, and it prompts further sampling for invasion. Microinvasion consists of foci <5 mm, usually small nests or single cells with a desmoplastic stromal response (CAP Ovary 1.5.0.0).
  • Frequency of true primaries. Of 52 consecutive mucinous carcinomas involving the ovaries, 40 (77%) were metastatic and 12 (23%) were primary. Pure primary mucinous carcinoma made up 2.4% of primary ovarian carcinomas (Seidman et al. 2003).
  • Outcome of intraepithelial carcinoma. Intestinal-type borderline tumors with epithelial atypia only were clinically benign at stage I. Of 69 patients with borderline tumors containing intraepithelial carcinoma, 2 had fatal recurrences; both tumors were incompletely staged and one had ruptured (Lee and Scully 2000).
  • Molecular progression. Mucinous carcinoma arises from benign and borderline precursors in the ovary. TP53 mutation and copy-number change, including a 9p13 amplicon, accompany progression (Cheasley et al. 2019).

Mucinous carcinoma: expansile and infiltrative invasion

  • Two patterns. Mucinous carcinomas are classified as expansile (confluent, non-destructive) or infiltrative (destructive stromal invasion), as proposed by Lee and Scully (Renz et al. 2025). Expansile growth is at least 5 mm of back-to-back glands with minimal intervening stroma, without desmoplasia or stromal invasion. Infiltrative growth consists of individual glands and cell clusters that provoke a stromal, often desmoplastic, response (CAP Ovary 1.5.0.0).
  • Outcome by pattern. All 12 carcinomas with expansile invasion were stage I, and none of the 10 with follow-up recurred. Five of 6 infiltrative carcinomas above stage I with follow-up were fatal (Lee and Scully 2000).
  • Lymph nodes. No patient with apparent stage I expansile carcinoma had lymph node metastases; 3 of 10 with infiltrative carcinoma did (Muyldermans et al. 2013).
  • Small infiltrative foci. Microfoci (<5 mm) of infiltrative pattern or nuclear grade 3 within an otherwise expansile carcinoma did not change prognosis. Infiltrative carcinoma had lower overall and progression-free survival than borderline tumor and expansile carcinoma (Genestie et al. 2021).
  • Treatment relevance. Guidelines suggest avoiding chemotherapy in stage I mucinous carcinoma of expansile type (Renz et al. 2025). Homologous recombination deficiency and mismatch repair deficiency do not occur in mucinous carcinoma (Köbel and Kang 2022).

Mural nodules and tumors associated with ovarian mucinous neoplasms

  • Sarcoma-like mural nodules. These nodules are multiple, small, sharply demarcated from the mucinous tumor and composed of a heterogeneous cell population. They coexpress vimentin and cytokeratin and behave favorably. True sarcomatous nodules and anaplastic carcinoma carry a worse prognosis (Bagué et al. 2002).
  • Anaplastic carcinoma. Foci of anaplastic carcinoma were present in 13 of 19 infiltrative mucinous carcinomas (Rodríguez and Prat 2002).
  • Teratoma-associated mucinous tumors. Of 44 mucinous tumors associated with mature cystic teratoma, all were unilateral and had gastrointestinal-type differentiation. Those with pseudomyxoma ovarii were usually CK7-negative and CK20-positive (86%) and CDX2-positive (79%) (Vang et al. 2007).
  • Pseudomyxoma peritonei. Most intestinal-type mucinous borderline tumors recorded as stage III with pseudomyxoma peritonei were probably metastases to the ovary (Lee and Scully 2000). Pseudomyxoma peritonei is most often associated with appendiceal mucinous tumors (CAP Ovary 1.5.0.0; Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary; Appendiceal Neoplasms: Mucinous Neoplasms, Pseudomyxoma Peritonei, Goblet Cell Adenocarcinoma and Neuroendocrine Tumors).

Primary versus metastatic mucinous tumors in the ovary

Size and laterality of primary and metastatic mucinous tumors

  • Seidman rule. All bilateral mucinous carcinomas and unilateral carcinomas <10 cm are classified as metastatic, and unilateral carcinomas ≥10 cm as primary. The rule correctly classified 90% of tumors in routine practice (Seidman et al. 2003).
  • Exceptions. Metastatic colorectal and endocervical carcinomas produced the most large unilateral exceptions (Yemelyanova et al. 2008).
Primary site of metastasis Correctly classified by the 10-cm rule Correctly classified with a 13-cm cutoff Source
Primary ovarian tumors 100% 98% Yemelyanova et al. 2008
Colorectum 74% 80% Yemelyanova et al. 2008
Appendix, low-grade tumors 79% 79% Yemelyanova et al. 2008
Appendix, carcinomas 100% 100% Yemelyanova et al. 2008
Pancreaticobiliary tract 95% 100% Yemelyanova et al. 2008
Stomach 80% 100% Yemelyanova et al. 2008
Endocervix 55% 70% Yemelyanova et al. 2008

CK7 and SATB2 in primary and metastatic mucinous tumors

  • Panel performance. CK7 was the most accurate single marker (91.7% with a diffuse/non-diffuse cutoff), followed by SATB2 (88.8% with a present/absent cutoff). CK7 combined with SATB2, scored as absent, focal or diffuse, reached 95.3% accuracy and outperformed CK7, CK20 and CDX2 (87.5%) (Meagher et al. 2019).
  • Marker frequencies. CK20, CDX2 and SATB2 were expressed in 87%, 98% and 90% of lower gastrointestinal primaries. CK7 was expressed in 97% and PAX8 in 45% of ovarian mucinous neoplasms (Meagher et al. 2019).
  • Exceptions to the expected profile. SATB2 was expressed in 13% of ovarian mucinous carcinomas and 15% of ovarian endometrioid carcinomas, often in squamous morules. Diffuse PAX8 was seen in 6% of appendiceal neoplasms (Meagher et al. 2019).
  • CAP statement. CAP regards an immunohistochemical panel as of limited value because patterns vary. Primary mucinous adenocarcinoma may be PAX8 and/or PAX2 and CK7 positive and SATB2 and CDX2 negative. DPC4 (SMAD4) is intact in most primary ovarian mucinous carcinomas and lost in mucin-producing pancreaticobiliary tumors (CAP Ovary 1.5.0.0).
Feature Favors primary ovarian mucinous tumor Favors metastasis Source
Laterality Unilateral; bilateral rare Bilateral in more than 75% Seidman et al. 2003; CAP Ovary 1.5.0.0
Size ≥10 cm (≥13 cm optimized); size >10–12 cm frequent <10 cm Seidman et al. 2003; Yemelyanova et al. 2008; CAP Ovary 1.5.0.0
Surface involvement Rare Possible CAP Ovary 1.5.0.0
Nodular growth Rare Frequent CAP Ovary 1.5.0.0
Hilar involvement Rare Frequent CAP Ovary 1.5.0.0
Lymphovascular invasion Rare Possible CAP Ovary 1.5.0.0
Growth pattern Expansile frequent; infiltrative possible Infiltrative frequent; single-cell infiltration possible CAP Ovary 1.5.0.0
Precursor components Benign and borderline components in the same tumor Absent Cheasley et al. 2019
CK7 Diffuse Absent or focal (lower gastrointestinal) Meagher et al. 2019
SATB2 Absent Present (lower gastrointestinal) Meagher et al. 2019
PAX8 Present in 45% Usually absent; diffuse in 6% of appendiceal neoplasms Meagher et al. 2019
DPC4 (SMAD4) Intact Lost in pancreaticobiliary tumors CAP Ovary 1.5.0.0
Pseudomyxoma peritonei Rare; occurs with teratoma-associated tumors Appendiceal mucinous neoplasm Lee and Scully 2000; Vang et al. 2007

Grading of mucinous and endometrioid carcinoma

  • Which tumors are graded. Histologic grade is required for endometrioid and mucinous carcinomas, immature teratomas and Sertoli-Leydig cell tumors. Clear cell carcinoma, malignant Brenner tumor, undifferentiated and dedifferentiated carcinoma, mesonephric-like carcinoma and carcinosarcoma are not graded. Serous carcinoma is classified as low-grade or high-grade serous carcinoma, two tumor types. For mixed tumors, the highest grade is reported with a comment on the others (CAP Ovary 1.5.0.0).
  • FIGO grading of endometrioid carcinoma. Endometrioid carcinoma is graded with the FIGO system used in the endometrium (Endometrial Carcinoma: Histologic Types and Molecular Classification). Grade 1 has 5% or less non-squamous solid growth, grade 2 has 6% to 50% and grade 3 has more than 50%. Notable nuclear atypia in most tumor cells of a grade 1 or 2 tumor, evident at low power and discordant with the architecture, raises the grade by one. Before upgrading, high-grade serous carcinoma is considered (CAP Ovary 1.5.0.0).
  • Mucinous carcinoma. CAP recommends the Silverberg system for mucinous carcinoma and allows FIGO or growth pattern-based grading. Silverberg grade is prognostic and FIGO grade is not (CAP Ovary 1.5.0.0).
  • Shimizu-Silverberg system. The system scores architecture (glandular 1, papillary 2, solid 3), nuclear pleomorphism (slight 1, moderate 2, marked 3) and mitoses per 10 high-power fields of 0.345 mm² (0–9 = 1, 10–24 = 2, ≥25 = 3). A total of 3–5 is grade 1, 6–7 grade 2 and 8–9 grade 3 (Shimizu et al. 1998; CAP Ovary 1.5.0.0).
System Applies to Criteria Grades Source
FIGO Endometrioid carcinoma (recommended); mucinous carcinoma (may be used) ≤5%, 6–50%, >50% non-squamous solid growth; one-step upgrade for notable nuclear atypia in most cells 1, 2, 3 CAP Ovary 1.5.0.0
Shimizu-Silverberg Mucinous carcinoma (recommended); endometrioid carcinoma (may be used) Architecture, pleomorphism and mitoses in 10 HPF of 0.345 mm², each scored 1–3 1 (3–5), 2 (6–7), 3 (8–9) Shimizu et al. 1998; Silverberg 2000; CAP Ovary 1.5.0.0
Growth pattern-based Mucinous carcinoma only Infiltrative growth ≤10% or >10% Low, high Busca et al. 2020; CAP Ovary 1.5.0.0
Two-tier (MD Anderson) Serous carcinoma; separates two tumor types (LGSC, HGSC) without a grade Nuclear atypia; mitoses >12 per 10 HPF as a secondary feature Low, high Malpica et al. 2004; CAP Ovary 1.5.0.0
Immature teratoma Immature teratoma (Ovarian Germ Cell Tumors: Teratomas, Dysgerminoma, Yolk Sac Tumor and Other Malignant Germ Cell Tumors) Quantity of immature neuroepithelium 2-tier or 3-tier CAP Ovary 1.5.0.0

Endometrioid tumors of the ovary

Endometrioid borderline tumor and carcinoma

  • Borderline and invasive criteria. In 56 stage I proliferative endometrioid tumors, confluent glandular growth was the most common form of stromal invasion and the best criterion for carcinoma. Invasion of <5 mm was classified as microinvasion and ≥5 mm as carcinoma (Bell and Kurman 2000).
  • Associated findings. Squamous differentiation was present in 24 and mucinous differentiation in 20 of the 56 tumors. Areas of borderline tumor were present in 13 of 15 carcinomas (Bell and Kurman 2000).
  • High-grade endometrioid carcinoma and HGSC. Agreement between 5 pathologists on grade 3 endometrioid carcinoma compared with HGSC was 69% on morphology alone and 96% with WT1 and p53 status (Assem et al. 2018).

Molecular classification of ovarian endometrioid carcinoma

  • Mutations. In 112 endometrioid carcinomas, mutations occurred in CTNNB1 (43%), PIK3CA (43%), ARID1A (36%), PTEN (29%), KRAS (26%) and TP53 (26%). CTNNB1 and TP53 mutations were mutually exclusive. CTNNB1-mutated tumors were 89% stage I–II with excellent outcome, and TP53-mutated tumors were often advanced with inferior survival (Hollis et al. 2020).
  • Endometrial-type molecular groups. In 511 endometrioid carcinomas, 3.5% were POLE-mutated, 13.7% mismatch repair-deficient, 9.6% p53-abnormal and 73.2% no specific molecular profile. Median overall survival was shortest for p53-abnormal tumors (4.7 years) (Krämer et al. 2020).
  • Mismatch repair and Lynch syndrome. Unmethylated MMR-deficient tumors made up 7% of 104 endometrioid carcinomas, and no clinicopathologic feature predicted MMR loss. The authors support universal MMR screening (Bennett et al. 2019). Somatic MMR testing of clear cell, endometrioid and mucinous carcinoma follows the ASCO guideline (Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response).
  • β-catenin. Nuclear β-catenin expression is specific for endometrioid carcinoma and is present in about 50%, mostly low-grade tumors with squamous differentiation (Köbel and Kang 2022).

Clear cell tumors of the ovary

  • Morphology. Clear cell carcinoma shows tubulocystic and papillary patterns. Clear cytoplasm in an HGSC without these patterns does not indicate clear cell carcinoma (Vang et al. 2009).
  • Endometriosis. Endometriosis was associated with 54% of clear cell carcinomas (Fukunaga et al. 1997).
  • Napsin A. Napsin A was positive in 71 of 86 clear cell carcinomas (83%) and all 13 clear cell adenofibromas. It was negative in 30 serous carcinomas, 19 endometrioid carcinomas, 10 mucinous carcinomas and 3 yolk sac tumors (Yamashita et al. 2015).
  • HNF1B. Nuclear HNF1B was expressed in all 30 clear cell tumors, including benign and borderline tumors, and rarely in other epithelial tumors (Kato et al. 2006).
  • ARID1A. ARID1A mutations were present in 46% of clear cell and 30% of endometrioid carcinomas and in no HGSC. Mutation and BAF250a loss were present in contiguous atypical endometriosis (Wiegand et al. 2010).
  • PIK3CA and other genes. PIK3CA mutations were present in 33% of clear cell carcinomas (46% of affinity-purified tumors), TP53 in 15% and KRAS in 7% (Kuo et al. 2009).
  • Mismatch repair. Mismatch repair deficiency was reported in 11.5% of clear cell ovarian cancers (Konstantinopoulos et al. 2020). It does not occur in prototypical clear cell carcinoma, and MMR-deficient tumors with diffuse stromal inflammation are more consistent with endometrioid carcinoma (Köbel and Kang 2022).

Seromucinous tumors

  • Composition. Seromucinous tumors contain serous and endocervical-type mucinous epithelium together with endometrioid, indifferent and squamous epithelium (Kurman and Shih 2016).
  • Immunophenotype. They frequently express ER and PR, infrequently express WT1 and lack CK20 and CDX2. They are often associated with endometriosis and frequently lose ARID1A expression (Kurman and Shih 2016).
  • Seromucinous carcinoma. Seromucinous carcinomas carried KRAS (70%), PIK3CA (37%), PTEN (19%) and ARID1A (16%) alterations and no CTNNB1 mutation (Rambau et al. 2017). In the WHO 5th edition they are classified as endometrioid carcinoma with mucinous differentiation (Köbel and Kang 2022).

Brenner tumors

  • Immunophenotype. All 32 Brenner tumors in one series were diffusely GATA3-positive and PAX8-, PAX2- and SALL4-negative (Roma and Masand 2014). In another series, all benign Brenner tumors were p63-positive, and the single malignant Brenner tumor was GATA3-negative (Esheba et al. 2009).
  • Histogenesis. Brenner tumor epithelium shares AKR1C3 and androgen receptor expression with tubal transitional metaplasia and Walthard nests, which supports a tubal origin (Kuhn et al. 2013).
  • Malignant Brenner tumor and transitional cell carcinoma. Borderline Brenner tumors are cystic, highly papillary tumors of transitional epithelium without stromal invasion; metastatic urothelial carcinoma is excluded. Malignant Brenner tumor shows stromal invasion with a benign or borderline Brenner component. Most tumors formerly called ovarian transitional cell carcinoma are a variant of HGSC with TP53 mutation, occasionally endometrioid carcinoma (CAP Ovary 1.5.0.0).

Mesonephric-like adenocarcinoma, carcinosarcoma, undifferentiated and mixed carcinoma

  • Mesonephric-like adenocarcinoma. This WHO 5th edition entity resembles cervical mesonephric carcinoma and is thought to arise by transdifferentiation of other Müllerian tumors. It is p53 normal and MMR proficient and frequently carries KRAS mutation (Köbel and Kang 2022). The tumor cells express GATA3, TTF-1, luminal CD10 and PAX8 and lack ER, PR and WT1 (CAP Ovary 1.5.0.0).
  • Carcinosarcoma. Carcinosarcoma is considered a metaplastic carcinoma, most frequently of HGSC, and is classified as a malignant epithelial tumor (Köbel and Kang 2022). Localized or regional carcinosarcoma had a higher early mortality than HGSC (hazard ratio 3.81) (Peres et al. 2019).
  • Undifferentiated and dedifferentiated carcinoma. These tumors arise from endometrioid carcinoma, most often in an MMR-deficient background, and acquire mutually exclusive SWI/SNF alterations in the undifferentiated component: ARID1A with ARID1B, SMARCA4 (BRG1) or SMARCB1 (INI1). They are extremely aggressive (Köbel and Kang 2022). Concurrent ARID1A and ARID1B inactivation was found in 12 of 24 BRG1- and INI1-intact dedifferentiated carcinomas (Coatham et al. 2016).
  • Mixed carcinoma. True mixed carcinoma is rare; mixed endometrioid and clear cell carcinoma in endometriosis is the most common combination, and most mixed tumors share a clonal origin (Köbel and Kang 2022).

Immunohistochemical panel for ovarian carcinoma histotypes

A four-marker panel of WT1, p53, napsin A and PR distinguishes the five principal histotypes with almost 90% precision. PAX8 can be added as a Müllerian marker (Köbel and Kang 2022).

Marker High-grade serous Low-grade serous Endometrioid Clear cell Mucinous Source
WT1 Diffuse Diffuse Positive in 10–15% Absent Absent Köbel and Kang 2022
p53 Abnormal in 99% Wild type Usually wild type; abnormal in 9.6–11% Usually wild type; TP53 mutation in 15% TP53 mutation in 58–71% of carcinomas Köbel et al. 2016; Krämer et al. 2020; Leskela et al. 2020; Kuo et al. 2009; Genestie et al. 2021
Napsin A Negative Negative Negative Positive in 83% Negative Yamashita et al. 2015
PR Positive in about 40% Lost in an aggressive subtype Positive in about 85% Negative Usually negative Köbel and Kang 2022
HNF1B Rare Rare Rare, non-diffuse Positive Rare Kato et al. 2006; Köbel and Kang 2022
PAX8 High frequency High frequency High frequency High frequency Positive in 45% Meagher et al. 2019
SATB2 4% <5% 15% 4% 13% Meagher et al. 2019
Nuclear β-catenin Not expected Not expected About 50% Not expected Not expected Köbel and Kang 2022
Differential diagnosis First-line markers Interpretation Source
HGSC and endometrioid carcinoma WT1, p53 WT1-positive with abnormal p53 is 99% specific for HGSC; WT1-negative with wild-type p53 is highly specific for endometrioid carcinoma Köbel and Kang 2022
HGSC and clear cell carcinoma WT1, napsin A, ER WT1 and ER positive confirm HGSC; WT1 negative and napsin A positive confirm clear cell carcinoma Köbel and Kang 2022
Endometrioid and clear cell carcinoma Napsin A, HNF1B, PR Napsin A positive, diffuse HNF1B and PR negative support clear cell carcinoma; the reverse confirms endometrioid carcinoma Köbel and Kang 2022
Endometrioid and mucinous carcinoma PR, vimentin PR positive and any vimentin support endometrioid carcinoma; 15% of endometrioid carcinomas are PR negative Köbel and Kang 2022
Endometrioid and low-grade serous carcinoma WT1 WT1 is positive in all LGSCs and in 10–15% of endometrioid carcinomas Köbel and Kang 2022
Endometrioid and mesonephric-like adenocarcinoma GATA3, TTF-1, ER, PR GATA3 or TTF-1 positive with ER and PR negative confirms mesonephric-like adenocarcinoma Köbel and Kang 2022
Endometrioid and dedifferentiated carcinoma ARID1B, BRG1, INI1 Loss of any of these confirms dedifferentiated carcinoma Köbel and Kang 2022
  • Endometrioid carcinoma with cytoplasmic clearing. Endometrioid carcinoma with cytoplasmic clearing can show the napsin A-positive, HNF1B-positive, PR-negative profile. ELAPOR1 and CDX2 positivity with AMACR negativity support endometrioid carcinoma (Köbel and Kang 2022).
  • Assay clones. WT1 errors in proficiency testing were limited to the 6F-H2 clone, and polyclonal napsin A produced more errors than monoclonal antibody (Lee et al. 2016).
Benign Brenner tumor of the ovary: rounded nests of urothelial-type (transitional) cells with pale cytoplasm and oval, grooved ('coffee bean') nuclei in a dense fibromatous stroma; several nests have central microcysts filled with eosinophilic secretion, resembling cystitis cystica. H&E, low power (magnification not stated).
Benign Brenner tumor of the ovary: rounded nests of urothelial-type (transitional) cells with pale cytoplasm and oval, grooved ('coffee bean') nuclei in a dense fibromatous stroma; several nests have central microcysts filled with eosinophilic secretion, resembling cystitis cystica. H&E, low power (magnification not stated).Image: Mikael Häggström, M.D., Wikimedia Commons, CC0.

Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors

Definition. Ovarian sex cord-stromal tumors comprise pure stromal tumors (fibroma and thecoma), pure sex cord tumors (adult and juvenile granulosa cell tumors) and mixed sex cord-stromal tumors (Sertoli-Leydig cell tumors) (Renz et al. 2025). Adult granulosa cell tumors account for 90% of malignant ovarian sex cord-stromal tumors and 2–5% of all ovarian cancers (Pilsworth et al. 2021). Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is classified among the miscellaneous ovarian tumors in the WHO 5th edition (McCluggage 2025). Its main differential diagnosis is juvenile granulosa cell tumor. The female adnexal tumor of probable Wolffian origin (FATWO) and the STK11 adnexal tumor arise mostly in para-adnexal soft tissue and share the sex cord-stromal differential (Bennett et al. 2020; Bennett et al. 2021).

Related page: Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response (hereditary breast and ovarian cancer and the adnexal hereditary syndrome table) Related page: Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary (endometrioid carcinoma with sertoliform pattern and the epithelial immunohistochemical panel) Related page: Ovarian Germ Cell Tumors: Teratomas, Dysgerminoma, Yolk Sac Tumor and Other Malignant Germ Cell Tumors (gonadoblastoma and germ cell immunohistochemistry) Related page: Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary (FIGO 2014 staging and sclerosing peritonitis) Related page: Ovarian cyst fluid and FNA cytology (granulosa cell tumor in cyst fluid) Related page: Hereditary Colorectal Cancer, Polyposis Syndromes and Mismatch Repair Testing (Peutz–Jeghers syndrome genetics) Related page: Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas (uterine tumor resembling ovarian sex cord tumor)

Recurrent molecular events now define several tumor types. Immunohistochemistry confirms sex cord-stromal lineage but has minimal value in separating the individual tumor types, and the molecular abnormality assists classification in problematic cases (McCluggage 2025).

Tumor Recurrent alteration Frequency in the defining study Associated syndrome Source
Adult granulosa cell tumor FOXL2 c.402C>G (p.C134W) 86 of 89 (97%) None Shah et al. 2009; McCluggage 2025
Adult granulosa cell tumor, progression TERT promoter C228T 22% of primary and 41% of recurrent tumors None Pilsworth et al. 2018
Juvenile granulosa cell tumor AKT1 in-frame duplications; GNAS AKT1 in >60% of tumors in girls under 15 years; GNAS in 30% Ollier disease, Maffucci syndrome Bessière et al. 2015; McCluggage 2025
Sertoli-Leydig cell tumor, moderately or poorly differentiated DICER1 RNase IIIb hotspot 30 of 30 DICER1 syndrome de Kock et al. 2017
Sertoli-Leydig cell tumor, well differentiated None (DICER1 wild type) 0 of 18 DICER1 mutated None McCluggage et al. 2023
Sclerosing stromal tumor FHL2::GLI2 fusion 17 of 26 (65%); other GLI2 rearrangements in 15% None Kim et al. 2020
Microcystic stromal tumor CTNNB1 exon 3; less often APC 8 of 14 (57%) CTNNB1 Familial adenomatous polyposis Irving et al. 2015; McCluggage et al. 2018
Sex cord tumor with annular tubules STK11 in syndromic cases Not applicable Peutz–Jeghers syndrome McCluggage 2025
Small cell carcinoma, hypercalcemic type SMARCA4 inactivation 30 of 32 sequenced cases Familial SCCOHT Witkowski et al. 2014
STK11 adnexal tumor STK11 alteration 21 of 21 sequenced Peutz–Jeghers syndrome Bennett et al. 2021

Immunohistochemistry of ovarian sex cord-stromal tumors

  • Inhibin and calretinin. In 215 ovarian tumors, calretinin stained 90% of fibrous tumors and inhibin stained 2% of epithelial tumors. Calretinin had 97% sensitivity and 85% specificity for sex cord-stromal and fibrous tumors (Movahedi-Lankarani and Kurman 2002).
  • SF-1. In 127 sex cord-stromal tumors of five types, inhibin and calretinin stained 56–100% and 36–100% of cases depending on type (Zhao et al. 2009). SF-1 stained all 27 Sertoli cell tumors and none of 60 endometrioid tumors, including sertoliform carcinomas, or 24 carcinoids (Zhao et al. 2008).
  • FOXL2. FOXL2 stained >95% of adult and juvenile granulosa cell tumors, fibromas and sclerosing stromal tumors, 1 of 11 steroid cell tumors and none of 368 non-sex cord-stromal tumors (Al-Agha et al. 2011).
Marker Sex cord-stromal tumors positive Main pitfall Source
Inhibin 92% Negative in many fibromas (22% positive) Movahedi-Lankarani and Kurman 2002
Calretinin 100% Stains 22% of epithelial tumors and mesothelium Movahedi-Lankarani and Kurman 2002
SF-1 100% across five tumor types Negative in endometrioid tumors and carcinoids Zhao et al. 2009; Zhao et al. 2008
WT1 All types except steroid cell tumor Stains 17% of endometrioid tumors Zhao et al. 2009; Zhao et al. 2008
FOXL2 80% Only 50% of Sertoli-Leydig cell tumors; positive in FATWO Al-Agha et al. 2011

Fibroma, cellular fibroma and thecoma of the ovary

  • Cellular and mitotically active cellular fibroma. Cellular fibroma has bland nuclei and ≤3 mitotic figures per 10 high-power fields. In 75 cellular fibromatous tumors, 40 had ≥4 mitoses per 10 high-power fields with bland cytology (mean 6.7, range 4–19). All were unilateral, and follow-up of 18 of these 40 patients was uneventful. Such tumors are classified as mitotically active cellular fibroma. Fibrosarcoma usually shows moderate to severe atypia with an elevated mitotic rate (Irving et al. 2006).
  • Meigs syndrome. Meigs syndrome is the triad of a benign ovarian tumor (fibroma, Brenner tumor or occasionally granulosa cell tumor), ascites and hydrothorax that resolves after removal of the tumor. Serum CA125 was elevated in 66 of 580 fibroma or fibrothecoma patients (11.3%), associated with tumor diameter ≥10 cm and ascites (Shen et al. 2018).

Luteinized thecoma associated with sclerosing peritonitis

  • Clinical features. In 27 cases, sclerosing peritonitis was documented in 25. Patients presented with abdominal distension, pain and ascites, sometimes with bowel obstruction (Staats et al. 2008).
  • Pathology. The ovarian lesions were clinically bilateral in 24 cases, measured 2–31 cm and often had a cerebriform cut surface. Mitotically active spindle cells, weakly luteinized cells, edema and entrapped follicles were typical. Spindle cells were inhibin negative. Luteinized cells stained for inhibin, calretinin or CD56 (Staats et al. 2008).
  • Outcome. No ovarian lesion spread during a mean follow-up of 5.9 years in 20 cases, but 3 patients died of sclerosing peritonitis (Staats et al. 2008).

Sclerosing stromal tumor and microcystic stromal tumor of the ovary

  • Sclerosing stromal tumor. FHL2::GLI2 fusions and other GLI2 rearrangements were absent from 48 other sex cord-stromal tumors. The fusion activates the Sonic Hedgehog pathway (Kim et al. 2020).

  • Microcystic stromal tumor, morphology. In the original 16 cases, all tumors were unilateral, with a mean size of 8.7 cm, and none had spread. The tumors combined microcysts, solid cellular regions and fibrous stroma with hyaline plaques. Bizarre nuclei were present in 10 cases, and mitoses numbered 0–2 per 10 high-power fields (Irving and Young 2009).

  • Microcystic stromal tumor, immunophenotype. CD10 and vimentin stained all 16 tumors, whereas inhibin and calretinin were each positive in only 1 of 16 (Irving and Young 2009). Diffuse nuclear FOXL2, WT1, cyclin D1 and β-catenin staining was present in all tumors tested, and SF-1 stained 12 of 15 (Irving et al. 2015).

  • Microcystic stromal tumor, molecular findings. All 14 tumors tested had wild-type FOXL2 (Irving et al. 2015). Microcystic stromal tumors carry alterations in the β-catenin–APC pathway and may be an extracolonic manifestation of familial adenomatous polyposis (McCluggage et al. 2018).

  • Signet-ring stromal tumor. This rare benign stromal tumor contains bland signet-ring cells, each with a single large empty vacuole devoid of mucin or lipid, in a cellular fibromatous stroma (Ramzy 1976; Tchrakian et al. 2022). Of 10 tumors diagnosed as signet-ring stromal tumor, 3 were reclassified as microcystic stromal tumor with signet-ring cells because of microcysts, hyalinized stroma, nuclear β-catenin and cyclin D1, or a CTNNB1 mutation, and a CTNNB1 deletion has been reported in a typical example (Kopczynski et al. 2016). The remaining tumors may be related to fibroma (Tchrakian et al. 2022). The tumor cells resemble those of Krukenberg tumor (Ramzy 1976), which is described in Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary.

Adult granulosa cell tumor

  • Clinical features. Adult granulosa cell tumors occur in perimenopausal women, with a median age at diagnosis of 50–54 years, and secrete estrogen and inhibins (Pilsworth et al. 2021). In a Dutch population cohort of 1031 granulosa cell tumors, concurrent endometrial carcinoma was present in 5.9% and endometrial hyperplasia in 25.5% (van Meurs et al. 2013).
  • Morphology. In 60 granulosa cell tumors, diffuse sheets were the most frequent pattern (47%). Call-Exner bodies were absent in 22.2%, and the authors concluded that they are not required for the diagnosis. Nuclear grooves were present in 72.9% and may indicate granulosa cell origin (Guleria et al. 2020). Grooves were also a consistent feature of metastatic tumor in aspirates (Saini et al. 2023). Juvenile granulosa cell tumor nuclei lack grooves (Young et al. 1984).
  • Molecular definition. The FOXL2 c.402C>G (p.C134W) mutation was present in 97% of adult granulosa cell tumors, 21% of thecomas and 10% of juvenile granulosa cell tumors. It was absent from 49 other sex cord-stromal tumors and 329 unrelated ovarian and breast tumors (Shah et al. 2009).
  • Misdiagnosis. FOXL2 testing of 336 tumors diagnosed as adult granulosa cell tumor reclassified 63 as other tumor types. The misdiagnosed cases accounted for 71.9% of disease-specific deaths within 5 years (McConechy et al. 2016).
  • Recurrence. Among 164 molecularly defined tumors (92% stage I), 32% recurred. The median time to first relapse was 7.4 years, 75% of relapses occurred within 10 years, and tumor rupture was the only independent predictor of recurrence. Active follow-up for 10–15 years is advised (Bryk et al. 2016). In 176 patients from Taiwan, recurrence was 21%, and residual tumor and tumor size >13.5 cm predicted recurrence (Sun et al. 2012).
  • TERT promoter. TERT promoter mutations were associated with shorter overall survival (Pilsworth et al. 2018).
  • High-grade transformation. A p53 immunostain is performed on granulosa cell tumors with high-grade transformation, and TP53 mutations accompany that transformation (CAP 2024).

Juvenile granulosa cell tumor

  • Clinical features. In 125 cases, the average age was 13 years, and 44% of patients were 10 years or younger. Isosexual pseudoprecocity was the presentation in 82% of prepubertal patients. Two patients had Ollier disease and two had Maffucci syndrome (Young et al. 1984).
  • Pathology. Diffuse and follicular patterns were present. The follicles varied in size and shape and contained basophilic or eosinophilic secretion, often mucin positive. Granulosa cells were luteinized to varying degrees and had dark round nuclei without grooves. Mitoses ranged from <1 to 32 per 10 high-power fields (average 7) (Young et al. 1984).
  • Outcome. Of 95 patients with follow-up, 92% were alive and free of disease.
  • Ollier disease and Maffucci syndrome. In a 4-year-old with Ollier disease, the same IDH1 p.R132C mutation was present in the juvenile granulosa cell tumor and an enchondroma (Zhang et al. 2023). The syndromes are caused by somatic mosaic IDH1 or IDH2 mutations (Amary et al. 2011; Pansuriya et al. 2011).

Sertoli-Leydig cell tumor

  • Clinical features. In 207 cases, patients averaged 25 years, and 75% were 30 years or younger. One-third presented with androgen excess. At operation, 97.5% were stage I and 1.5% were bilateral. Tumors averaged 13.5 cm, and 15% were ruptured (Young and Scully 1985).
  • Differentiation and outcome. Eleven percent were well differentiated, 54% moderately differentiated and 13% poorly differentiated, and 22% contained heterologous elements. A retiform pattern was prominent in 15%. All well-differentiated tumors were benign, whereas 11% of moderately differentiated, 59% of poorly differentiated and 19% of heterologous tumors were clinically malignant (Young and Scully 1985).
  • CAP grading. Grade is required for Sertoli-Leydig cell tumors in the CAP ovary protocol. They are graded with the 3-tier system of the WHO 5th edition (CAP 2024).
CAP grade (WHO 5th edition) Sertoli cell component Leydig cells Stroma Source
G1, well differentiated Hollow or solid tubules; no significant atypia or mitotic activity Readily identified clusters, cords and single cells Not specified CAP 2024
G2, moderately differentiated Nests, tubules or cords; mild, moderate or rarely bizarre atypia; modest mitoses Minimal, at the periphery Lobular pattern CAP 2024
G3, poorly differentiated Minor component of moderately differentiated tumor Sparse Sarcomatous stroma resembling primitive gonadal stroma CAP 2024
  • DICER1 mutation. DICER1 RNase IIIb mutations were present in 26 of 43 Sertoli-Leydig cell tumors (60%) in the first series, 4 with additional germline mutations (Heravi-Moussavi et al. 2012). After expert review, all 30 moderately and poorly differentiated tumors carried DICER1 mutations and none of 4 well-differentiated tumors did (de Kock et al. 2017). All 18 well-differentiated tumors in a later series were DICER1 wild type and lacked FOXL2 C134W, and the authors proposed that well-differentiated Sertoli-Leydig cell tumor is a distinct tumor type (McCluggage et al. 2023).
Molecular subtype Patient age (median) Differentiation Retiform or heterologous elements Source
DICER1 mutant 24.5 years Moderate or poor All 10 tumors with retiform or heterologous elements were DICER1 mutant (10 of 18 mutant tumors) Karnezis et al. 2019
FOXL2 c.402C>G mutant 79.5 years Moderate or poor Absent Karnezis et al. 2019
DICER1 and FOXL2 wild type 51 years Includes well differentiated Absent Karnezis et al. 2019
  • Molecular subtypes. In 42 tumors, DICER1 mutations (44%) and FOXL2 mutations (19%) were mutually exclusive. All tumors were FOXL2 positive by immunohistochemistry (Karnezis et al. 2019). FOXL2-mutant tumors may represent true Sertoli-Leydig cell tumors or adult granulosa cell tumors with Leydig-like luteinized stromal cells (CAP 2024).
  • DICER1 syndrome. Among 713 carriers of a germline DICER1 pathogenic or likely pathogenic variant, 103 developed an ovarian Sertoli-Leydig cell tumor at a median age of 14 years. Thirteen percent were diagnosed before 8 years of age, and the registry now recommends pelvic ultrasound from the time the germline variant is detected (Schultz et al. 2024). When a moderately or poorly differentiated Sertoli-Leydig cell tumor is diagnosed, the pathologist raises the possibility of a germline DICER1 variant and recommends genetic referral (McCluggage 2025).

Sertoli cell tumor, gynandroblastoma and sex cord tumor with annular tubules

  • Sertoli cell tumor. In 54 cases, patients were 2–76 years old (mean 30), and 6 had Peutz–Jeghers syndrome. All tumors were unilateral. A tubular pattern was present in every tumor, at least focally.
  • Gynandroblastoma. Gynandroblastoma contains both male (Sertoli or Leydig cell) and female (granulosa cell) components. In 16 cases, 3 carried DICER1 hotspot mutations in both components, all with moderately or poorly differentiated Sertoli-Leydig and juvenile granulosa cell components. None had FOXL2 C134W or AKT1 mutations, and all expressed FOXL2 in both components (Wang et al. 2018).
  • Sex cord tumor with annular tubules. Of 74 cases, 27 were associated with Peutz–Jeghers syndrome. These were benign, multifocal, bilateral, small or microscopic and calcified, and 4 of the 27 patients had a cervical adenocarcinoma, which caused death in 2. The 47 tumors without the syndrome were unilateral and usually large, and 7 were malignant (Young et al. 1982).

Steroid cell tumors of the ovary

  • Leydig cell (hilus cell) tumor. In 21 hilus cell tumors (12 with Reinke crystals), 62% presented with androgenic manifestations. Testosterone was high (200–2,400 ng/dL) despite a mean diameter of 2.1 cm. All tumors were centered in the hilus. None of the 10 patients with follow-up died of tumor (Paraskevas and Scully 1989).
  • Steroid cell tumor, not otherwise specified. In 63 cases, virilization was the most common presentation (41%). Four patients had Cushing syndrome. Six percent of tumors were bilateral. Of 50 patients with follow-up, 18 tumors were clinically malignant (Hayes and Scully 1987).
Feature in steroid cell tumor, NOS Proportion of cases with the feature that were malignant Source
≥2 mitotic figures per 10 high-power fields 92% Hayes and Scully 1987
Necrosis 86% Hayes and Scully 1987
Diameter ≥7 cm 78% Hayes and Scully 1987
Hemorrhage 77% Hayes and Scully 1987
Grade 2 or 3 nuclear atypia 64% Hayes and Scully 1987

Small cell carcinoma of the ovary, hypercalcemic type

  • Clinical features. In 150 cases, patients were 9–43 years old (average 23.9). Serum calcium was elevated in 62% of the patients in whom it was measured. Tumors were unilateral in 99% and averaged 15.3 cm, and about half had extraovarian spread (Young et al. 1994). SCCOHT is the most common undifferentiated ovarian malignancy in women under 40 years (Witkowski et al. 2014). Long-term survival is about 30% in early-stage cases (Tischkowitz et al. 2020).
  • Morphology. Diffuse sheets of small cells with follicle-like spaces were the most common pattern. Follicle-like spaces were present in 80% of cases and usually contained eosinophilic fluid (Young et al. 1994).
  • Genetics. SMARCA4 protein was lost in 82% of SCCOHT and in only 0.4% of other primary ovarian tumors (Ramos et al. 2014). All patients with SCCOHT are referred for germline SMARCA4 testing (McCluggage 2025).
  • BRG1 immunohistochemistry. Fifty-four of 56 SCCOHT showed complete loss of SMARCA4 expression, and the 2 with retained expression had SMARCA4 alterations. All 217 interpretable mimics retained expression, although 13% showed heterogeneous weak staining. Loss had 96.55% sensitivity and 100% specificity, and only complete loss is interpreted as loss. SMARCB1 (INI1) was retained in all 37 SCCOHT tested (Clarke et al. 2016).
  • Dual loss of BRG1 and BRM. All SMARCA4-negative SCCOHT also lacked SMARCA2 (BRM). Among ovarian tumors, SMARCA4 loss otherwise occurred only in 4% of clear cell carcinomas, and the dual-loss phenotype was specific for SCCOHT (Karnezis et al. 2016).

Female adnexal tumor of probable Wolffian origin and STK11 adnexal tumor

  • FATWO. In 15 tumors, patients were 32–69 years old and tumors measured 1.8–30 cm. All but one arose in para-adnexal soft tissue. A tubular pattern was present in all, with solid (73%) and sieve-like (47%) patterns. Tumors were keratin positive and TTF-1 negative. Pathogenic mutations were rare (STK11 in 3, APC in 1, MBD4 in 1) (Bennett et al. 2020).
  • STK11 adnexal tumor, definition. The STK11 adnexal tumor was first reported in 2021 (Bennett et al. 2021) and is not listed in the WHO 5th edition of 2020 (McCluggage et al. 2022). Its diagnosis currently requires molecular confirmation of STK11 inactivation or alteration (McCluggage 2025).
  • STK11 adnexal tumor, clinical features. In 22 cases, patients were 17–66 years old (median 39), and nearly half had Peutz–Jeghers syndrome. Eighteen tumors were paratubal. Metastases were present in 11 of 22 patients (50%), and recurrences occurred in 12 of 15 with follow-up (80%) (Bennett et al. 2021).
  • STK11 adnexal tumor, morphology and immunophenotype. The tumors consist of interanastomosing cords and trabeculae of atypical epithelioid cells in myxoid to edematous stroma, with transitions to tubular, cystic, cribriform and microacinar formations. Tumors express epithelial, sex cord (calretinin, inhibin, WT1) and mesothelial markers and hormone receptors. Claudin-4, FOXL2 and TTF-1 are consistently negative (Bennett et al. 2021).
  • STK11 immunohistochemistry. All 17 STK11 adnexal tumors showed complete loss of cytoplasmic STK11 staining. Of 105 mimics, all retained staining except one endometrioid carcinoma with mucinous differentiation, which showed complete loss, and one high-grade serous carcinoma with subclonal loss (Dehghani et al. 2024).
  • Reporting. Many tumors previously reported as malignant FATWO likely represent STK11 adnexal tumors. The report raises the possibility of Peutz–Jeghers syndrome if the patient is not known to have it (McCluggage 2025).
Feature FATWO STK11 adnexal tumor Source
Cytology Mostly low-grade atypia; mitoses 0–17 per 10 high-power fields Uniformly atypical; prominent nucleoli; median 9 mitoses per 10 high-power fields Bennett et al. 2020; Bennett et al. 2021
FOXL2 Positive in 3 of 3 Negative Al-Agha et al. 2011; Bennett et al. 2021
STK11 immunostain Retained (10 of 10) Complete cytoplasmic loss (17 of 17) Dehghani et al. 2024
Behavior 5 of 6 with follow-up alive and well Metastases in 11 of 22; recurrence in 12 of 15 with follow-up Bennett et al. 2020; Bennett et al. 2021
Syndrome Gene Ovarian or adnexal tumor Source
DICER1 syndrome DICER1 Moderately or poorly differentiated Sertoli-Leydig cell tumor; gynandroblastoma Schultz et al. 2024; Wang et al. 2018
Peutz–Jeghers syndrome STK11 Sex cord tumor with annular tubules; STK11 adnexal tumor; Sertoli cell tumor Young et al. 1982; Bennett et al. 2021; Oliva et al. 2005
Familial SCCOHT SMARCA4 Small cell carcinoma, hypercalcemic type Witkowski et al. 2014
Familial adenomatous polyposis APC Microcystic stromal tumor McCluggage et al. 2018
Ollier disease and Maffucci syndrome IDH1 or IDH2 (somatic mosaic; tumor-level mutations) Juvenile granulosa cell tumor Young et al. 1984; Pansuriya et al. 2011; Amary et al. 2011; Zhang et al. 2023
Nevoid basal cell carcinoma (Gorlin) syndrome PTCH1 (germline) Ovarian fibroma or calcification (24%) Evans et al. 1993; Hahn et al. 1996; Johnson et al. 1996

Differential diagnosis of ovarian sex cord-stromal tumors and their mimics

Tumor Main mimic Distinguishing finding Source
Juvenile granulosa cell tumor SCCOHT Inhibin positivity; SCCOHT shows complete BRG1 loss Movahedi-Lankarani and Kurman 2002; Clarke et al. 2016
Sertoli cell tumor Sertoliform endometrioid carcinoma; carcinoid SF-1 positive in Sertoli cell tumor and negative in both mimics Zhao et al. 2008
STK11 adnexal tumor FATWO; sex cord-stromal tumor Loss of STK11 staining; FOXL2 negative Dehghani et al. 2024; Bennett et al. 2021

Staging and CAP reporting of malignant sex cord-stromal tumors

  • Protocol scope. The CAP ovary protocol version 1.5.0.0 applies to malignant sex cord-stromal tumors. Its histologic type list includes adult and juvenile granulosa cell tumor, steroid cell tumor (NOS and malignant) and Sertoli-Leydig cell tumor (CAP 2024).
  • Staging. The CAP protocol applies the same pTNM and FIGO 2014 categories to malignant sex cord-stromal tumors as to carcinomas (CAP 2024). Stage at diagnosis is the most important prognostic factor for granulosa cell tumors, and guidelines support fertility-sparing surgery for them (Renz et al. 2025).

Ovarian Germ Cell Tumors: Teratomas, Dysgerminoma, Yolk Sac Tumor and Other Malignant Germ Cell Tumors

Definition. Ovarian germ cell tumors derive from the primitive germ cells of the embryonic gonad (Renz et al. 2025). They range from the benign mature cystic teratoma to malignant tumors: immature teratoma, dysgerminoma, yolk sac tumor, embryonal carcinoma, non-gestational choriocarcinoma and mixed malignant germ cell tumor. The CAP ovary protocol, version 1.5.0.0, applies to the malignant types, to teratoma with malignant transformation and to malignant struma ovarii (CAP 2024).

Epidemiology. Germ cell tumors predominate among ovarian malignancies in women under 20 years and are the most common ovarian tumors in the second and third decades (Renz et al. 2025). In 1,262 malignant germ cell tumors of the female genital tract in the SEER registries (1973–2002), 35.6% were immature teratomas, 32.8% dysgerminomas, 28.7% mixed germ cell tumors and 2.9% mature teratomas with malignant degeneration. The age-adjusted incidence was 0.338 per 100,000 women-years, the highest rate was at 15–19 years, and 5-year relative survival was 83.9% (Smith et al. 2006).

Related page: Mediastinal Germ Cell Tumors on FNA (germ cell immunohistochemistry and isochromosome 12p in cytology) Related page: Uncommon Nonlymphoid Malignancies in Serous Effusions (germ cell tumors in effusions) Related page: Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors (small cell carcinoma of hypercalcemic type and juvenile granulosa cell tumor) Related page: Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary (clear cell carcinoma and mucinous tumors associated with teratoma) Related page: Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary (FIGO 2014 staging and peritoneal implants) Related page: Pelvic washing cytology and ovarian cyst FNA (benign and neoplastic findings in pelvic washings)

Origin of ovarian teratomas and malignant germ cell tumors

  • Parthenogenetic origin. Benign ovarian teratomas were homozygous at centromeric chromosome polymorphisms for which the patients' normal tissues were heterozygous. They arise from a single germ cell after the first meiotic division (Linder et al. 1975).
  • Teratoma in the ovary and testis. Ovarian and prepubertal testicular teratomas derive from benign germ cells. Immaturity is an important finding in ovarian teratomas at any age, although its significance in children has been challenged (Ulbright 2005).
  • Isochromosome 12p. Five pure mature and three pure immature ovarian teratomas showed no i(12p) or other 12p amplification. In 6 mixed germ cell tumors, i(12p) was present in the non-teratomatous components in 5 and in the teratomatous component in 4. Teratoma in mixed ovarian germ cell tumors therefore has a different pathogenesis from pure ovarian teratoma (Poulos et al. 2006). Dysgerminoma, yolk sac tumor and embryonal carcinoma are associated with chromosome 12 abnormalities (CAP 2024).
  • Immature teratoma genomics. Ten immature teratomas had 2N near-diploid genomes with extensive loss of heterozygosity and no recurrent somatic mutations. All components within one tumor shared a clonal loss-of-heterozygosity pattern, whereas bilateral tumors had independent clonal origins (Heskett et al. 2020).
  • Two pathways in dysgerminoma. KIT exon 17 mutations were present in 5 of 13 unilateral dysgerminomas and in none of 4 bilateral dysgerminomas or 22 other germ cell tumors. Five phenotypic females with combined dysgerminoma and gonadoblastoma had Y-chromosome material (Hoei-Hansen et al. 2007).

Mature cystic teratoma and its complications

  • Clinical and gross features. In 517 patients with 573 mature cystic teratomas, the median age was 30 years and 60% were asymptomatic. Mean tumor size was 6.4 cm. The tumors were bilateral in 10.8%, torsion occurred in 3.5%, and malignant transformation in 0.17% (Comerci et al. 1994).
  • Anti-NMDA receptor encephalitis. Of 98 patients with anti-NMDA receptor encephalitis and oncologic assessment, 58 (59%) had a tumor, most commonly ovarian teratoma. Early tumor treatment was associated with better outcome and fewer relapses (Dalmau et al. 2008).
  • Squamous cell carcinoma. Squamous cell carcinoma accounts for 80% of malignant transformations of ovarian teratomas. In a systematic review of 277 patients, it occurred mainly in women older than 50 years with tumors larger than 100 mm and elevated squamous cell carcinoma antigen and CA125. Stage IA tumors had better survival (Hackethal et al. 2008).
  • Other transformations. In a single institution, 11 of 753 mature cystic teratomas (1.46%) underwent malignant transformation: 4 squamous cell carcinomas and 4 mucinous carcinomas (Oranratanaphan and Khemapech 2013). Somatic malignancy in an ovarian mature cystic teratoma is a de novo transformation (Ulbright 2005).
  • Reporting. The CAP histologic type list includes "teratoma with malignant transformation", with the type specified (CAP 2024).

Monodermal teratomas: struma ovarii, strumal carcinoid and carcinoid

  • Definition. Struma ovarii is an ovarian teratoma composed predominantly of thyroid tissue (Cao et al. 2026). Malignant struma ovarii has been defined as a teratoma containing at least 50% thyroid tissue that can metastasize (Lager et al. 2018). Thyroid tissue formed more than 50% of all but 2 of 27 biologically malignant struma ovarii (Shaco-Levy et al. 2010).
  • Malignant struma ovarii, predictors. Among 88 patients with histologically malignant or proliferative struma ovarii, adhesions, peritoneal fluid ≥1 L or an ovarian serosal rent occurred in 74% of the 27 biologically malignant tumors and in 10% of the 61 clinically benign tumors. A strumal component ≤6 cm recurred in 7%. Except for a papillary pattern or poorly differentiated carcinoma, no microscopic feature reliably predicted outcome. Survival was 89% at 10 years and 84% at 25 years (Robboy et al. 2009).
  • Biologically malignant struma ovarii. In 27 tumors with extraovarian spread, the thyroid tissue was follicular adenoma in 63% and papillary carcinoma in 26%. Recurrence occurred up to 29 years after surgery, and 37% of patients died of disease 1.5–32 years after diagnosis (Shaco-Levy et al. 2010).
  • Strumosis and reporting. Peritoneal implants of benign-appearing thyroid follicles, formerly called "strumosis", are regarded as metastases from well-differentiated carcinoma. Thyroid carcinoma arising in struma ovarii is staged with the AJCC or FIGO system, and its subtype follows the WHO 5th edition of thyroid tumors (CAP 2024).
  • Strumal carcinoid. In 50 cases, strumal carcinoid was an intimate mixture of thyroid tissue and carcinoid. All tumors were unilateral, and three-fifths arose in dermoid cysts or mature solid teratomas. No patient had the carcinoid syndrome, and only one died of tumor (Robboy and Scully 1980).
  • Primary insular carcinoid. In 48 cases, 33% had the carcinoid syndrome. Pure carcinoids or components 4–7 cm in diameter were associated with the syndrome in half of cases, and no patient had it when the carcinoid formed a small portion of a teratoma. Carcinoid metastatic to the ovary is nearly always bilateral, usually accompanied by peritoneal metastases and has a poor prognosis (Robboy et al. 1975).

Immature teratoma: diagnosis and grading

  • Diagnosis. Immaturity is usually recognized by embryonic-appearing neuroepithelium with mitotic activity and apoptosis. It is rarely based on cellular, mitotically active glial tissue. Fetal-type tissues alone are not sufficient for the diagnosis (Ulbright 2005).
  • Grading principle. Immature teratomas are the only malignant germ cell tumors that are graded. The grade is based on the number of low-power (40×) fields containing aggregates of immature neuroepithelium in any one slide. Immature elements other than neuroepithelium are not counted. Grade is a required CAP element, and either the 3-tier or the 2-tier system may be used (CAP 2024).
  • Origin of the grading system. Norris and colleagues graded 58 pure immature teratomas from 0 to 3. Grade of the primary tumor best determined extraovarian spread, and survival was 81%, 60% and 30% for grades 1, 2 and 3. All seven patients with grade 3 metastases died of tumor (Norris et al. 1976).
  • Reproducibility and the 2-tier system. In 244 immature teratomas, 16 of 91 patients (18%) with high-grade stage I tumors died with metastases, compared with 3 of 52 (6%) with grade 1 tumors that progressed, all 3 of which were inadequately sampled. Interobserver agreement was moderate with the 3-tier scale (κ=0.54) and better with a 2-tier scale (κ=0.66). Small foci (≤2 mm) of other germ cell elements did not adversely affect prognosis (O'Connor and Norris 1994).
3-tier grade (O'Connor and Norris; CAP) Immature neuroepithelium in any one slide 2-tier grade Source
Grade 1 Less than 1 low-power (40×) field Low grade CAP 2024; O'Connor and Norris 1994
Grade 2 1 to 3 low-power (40×) fields High grade CAP 2024; O'Connor and Norris 1994
Grade 3 4 or more low-power (40×) fields High grade CAP 2024; O'Connor and Norris 1994
  • Behavior by grade. Grade 1 tumors are low grade and curable with resection, whereas grades 2 and 3 are high grade (CAP 2024). In a pediatric intergroup trial, 44 children and adolescents with completely resected immature teratoma were managed with surgery alone, and the authors concluded that resection alone is effective treatment in this age group. Serum AFP was elevated in 34% of patients with pure immature teratoma and in 83% of those with microscopic foci of yolk sac tumor (Cushing et al. 1999).
  • Sampling. Solid teratomas and malignant germ cell tumors require careful gross examination and sampling, and grossly apparent implants are sampled with multiple sections (CAP 2024). Omental sampling is given in Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary.

Gliomatosis peritonei and growing teratoma syndrome

  • Gliomatosis peritonei. Gliomatosis peritonei consists of mature glial tissue in the peritoneum. In 21 patients aged 5–42 years, the primary tumors were immature teratoma (14), mixed germ cell tumor (6) and mature teratoma with carcinoid (1). Eleven patients also had metastatic mature or immature teratoma, and one developed glioma arising from gliomatosis. Gliomatosis expressed SOX2 and lacked OCT4 and NANOG, and the prognosis was favorable (Liang et al. 2015).
  • Implant assessment. Implants associated with immature teratoma are assessed for immature elements. Implants may consist entirely of mature glial tissue (CAP 2024).
  • Origin of gliomatosis. Microsatellite studies found glial implants heterozygous like normal tissue, whereas the associated teratomas were homozygous. These studies concluded that gliomatosis arises from non-teratomatous host cells (Ferguson et al. 2001; Kwan et al. 2004). A later multiregion exome study found that all disseminated components, including gliomatosis, shared the clonal loss-of-heterozygosity pattern of a primary ovarian tumor (Heskett et al. 2020).
  • Growing teratoma syndrome. Among 103 patients with pure or mixed immature teratoma, 12 (12%) developed growing teratoma syndrome at a median of 9 months. The peritoneum was the first site in 83%. Treatment is complete surgical resection, and late recurrences up to 14 years require prolonged follow-up (Zagamé et al. 2006). Residual mature teratoma can continue to grow and rarely undergoes malignant transformation (Renz et al. 2025).

Dysgerminoma and gonadoblastoma

  • Pathology. In 140 pure dysgerminomas (mean age 24.1 years), tumors were bilateral in 4%, with a mean diameter of 13 cm. A lymphocytic infiltrate was present in all, fibrovascular septa produced an alveolar pattern in 51%, and granulomatous infiltrates occurred in 46%. Variant patterns (cords, solid tubules, microspaces and follicle-like spaces) can mimic other tumors (Warnnissorn et al. 2021). KIT mutations were found only in unilateral tumors (Hoei-Hansen et al. 2007).
  • Outcome. In 158 dysgerminomas, 5-year and 10-year survival for pure tumors was 83% and 74%. Unilateral adnexectomy alone for stage IA pure dysgerminoma gave 95% 5-year survival, independent of tumor size (Gordon et al. 1981).
  • Management. Dysgerminoma is extremely sensitive to chemotherapy. Patients with stage IA disease may be observed after surgery, and disease beyond the ovary is treated with adjuvant chemotherapy (Renz et al. 2025).
  • Immunohistochemistry. OCT4 showed strong nuclear staining in >90% of cells in all 33 dysgerminomas and in the gonadoblastomas. Non-dysgerminomatous tumors were negative except 4 of 14 clear cell carcinomas, which showed focal staining (Cheng et al. 2004). OCT3/4 also stained 4 of 9 adult granulosa cell tumors (Chang et al. 2009). SALL4 stained >90% of tumor cells in all dysgerminomas (Cao et al. 2009). Dysgerminoma is NANOG positive, D2-40 positive and SOX2 negative (Chang et al. 2009). Dysgerminoma expresses CD117 (Renz et al. 2025).
  • Serum LDH. Serum lactate dehydrogenase was elevated at diagnosis in three patients with dysgerminoma, normalized after therapy and rose again at progression in one (Levato et al. 1995). LDH, AFP and hCG are part of follow-up of stage I germ cell malignancies (Renz et al. 2025).
  • Gonadoblastoma morphology. Classical gonadoblastoma consists of rounded islands of germ cells, sex cord elements and hyaline basement membrane material in a variably cellular stroma that may contain steroid cells. About 40% are bilateral. It arises almost entirely in dysgenetic gonads of patients with a Y chromosome or part of one, and TSPY1 is the putative gene. It is a non-invasive (in situ) precursor of germinoma and, indirectly, of other germ cell tumors (Roth and Cheng 2018; Roth and Cheng 2020).
  • Gonadoblastoma risk in disorders of sex development. Germ cell tumor risk guides the management of patients with disorders of sex development. The undifferentiated gonadal tissue pattern carries a high risk of gonadoblastoma, and TSPY and OCT3/4 are markers of early germ cell neoplasia (Cools et al. 2006).
  • Gonadoblastoma immunohistochemistry. Gonadoblastomas were positive for OCT4 (Cheng et al. 2004) and showed SALL4 staining in >90% of germ cells (Cao et al. 2009).

Yolk sac tumor

  • Historical behavior. In 71 endodermal sinus (yolk sac) tumors studied before modern combination chemotherapy, AFP was present in hyaline droplets, cytoplasm and intercellular spaces of all 15 tumors stained. Actuarial survival was 13% at 3 years, and 84% of stage I patients had subclinical metastasis (Kurman and Norris 1976a). Yolk sac tumor and choriocarcinoma are the most aggressive germ cell tumors, and they are highly curable with combination chemotherapy (Renz et al. 2025).
  • Patterns in 150 tumors. All were unilateral, and 70% measured ≥15 cm. The reticular (microcystic) pattern was conspicuous in 68% and present at least focally in all tumors, usually merging with cysts. Other patterns were polyvesicular (25%), labyrinthine (one-third), glandular (22%), solid (one-third) and festoon (6%). Schiller-Duval bodies (papillae with a central blood vessel) were present in one-third but numerous in only 5%. Hyaline bodies were present in most tumors. The solid pattern can resemble dysgerminoma but lacks its septa and lymphocytic infiltrate (Young et al. 2022).
  • Patterns and markers. Yolk sac tumors can differentiate into hepatic, intestinal and pulmonary tissues. AFP and glypican-3 are their characteristic immunohistochemical markers. SALL4, Lin28 and IMP-3 aid differential diagnosis, and CDX2, TTF-1 and HepPar1 help recognize unusual variants (Nogales et al. 2012).
  • Yolk sac tumor versus clear cell carcinoma. SALL4 stained >90% of cells in all 29 yolk sac tumors and only 3 of 45 clear cell carcinomas, focally (<15% of cells). AFP and glypican-3 stained 83% and 69% of yolk sac tumors and 35% and 28% of clear cell carcinomas (Cao et al. 2009). In another series, glypican-3 stained 97% of yolk sac tumors and no teratomas or embryonal carcinomas (Esheba et al. 2008).
  • Somatically derived yolk sac tumor. In 18 yolk sac tumors of the female genital tract in patients aged 40 years or older, 11 were associated with an epithelial neoplasm, most often high-grade serous carcinoma. Most showed glandular morphology closely mimicking adenocarcinoma, and some expressed epithelial markers (McNamee et al. 2016).

Embryonal carcinoma and non-gestational choriocarcinoma

  • Embryonal carcinoma, first description. Fifteen ovarian tumors resembling embryonal carcinoma of the adult testis were separated from endodermal sinus tumor. hCG was present in syncytiotrophoblast-like cells in all 10 tumors stained and AFP in mononuclear embryonal cells in 7. Sixty percent of patients had hormonal manifestations such as precocious puberty, irregular bleeding or hirsutism (Kurman and Norris 1976b).
  • Embryonal carcinoma in mixed tumors. In 55 tumors with an embryonal carcinoma component (median age 20.5 years), every case was part of a malignant mixed germ cell tumor, most often with yolk sac tumor (89%) and immature teratoma (62%). Glandular (45%) and solid (35%) patterns predominated. Many purported pure examples are likely undersampled mixed tumors or mimics such as dysgerminoma, SCCOHT or juvenile granulosa cell tumor (Zanfagnin et al. 2026).
  • Embryonal carcinoma immunophenotype. Embryonal carcinoma is SOX2, NANOG and OCT3/4 positive and D2-40 negative (Chang et al. 2009). SALL4 stained >90% of cells in all embryonal carcinomas (Cao et al. 2009). CD30 was expressed by 8 of 10 embryonal carcinomas and by the embryonal elements of all 4 mixed germ cell tumors, but by none of 11 other germ cell tumors or 92 non-hematopoietic tumors, in a series not restricted to the ovary (Pallesen and Hamilton-Dutoit 1988).
  • Non-gestational choriocarcinoma. Short tandem repeat genotyping of 22 choriocarcinomas identified 19 gestational tumors, which contained a paternal genome, and 3 non-gestational tumors, which lacked one: 2 ovarian and 1 pelvic. Ovarian and pelvic choriocarcinomas can be non-gestational and are not assumed to be metastases from an occult gestational tumor (Savage et al. 2017).

Mixed malignant germ cell tumor

  • Composition and prognosis. In 30 mixed germ cell tumors, dysgerminoma was the most common component (80%), followed by endodermal sinus tumor (70%), teratoma (53%), choriocarcinoma (20%) and embryonal carcinoma (16%). In stage I tumors, more than one-third endodermal sinus tumor, choriocarcinoma or grade 3 teratoma predicted a poor prognosis. All patients with tumors smaller than 10 cm survived. Serum hCG was elevated in 38% of non-pregnant patients and reflected choriocarcinoma or syncytiotrophoblastic giant cells (Kurman and Norris 1976c).
  • Reporting. The CAP protocol requires the component types and their percentages for mixed malignant germ cell tumors. Quantitation of tumor types within malignant germ cell tumors may be prognostically important (CAP 2024).

Immunohistochemistry and serum markers of ovarian germ cell tumors

Tumor OCT3/4 SALL4 NANOG SOX2 D2-40 Other markers Serum marker Source
Dysgerminoma Positive Positive Positive Negative Positive CD117 LDH Cheng et al. 2004; Cao et al. 2009; Chang et al. 2009; Renz et al. 2025; Levato et al. 1995
Embryonal carcinoma Positive Positive Positive Positive Negative CD30 hCG (tissue: syncytiotrophoblast-like cells in 10 of 10); AFP (tissue: mononuclear cells in 7 of 10) Chang et al. 2009; Cao et al. 2009; Pallesen and Hamilton-Dutoit 1988; Kurman and Norris 1976b
Yolk sac tumor Negative Positive Negative Negative Negative AFP; glypican-3 AFP Chang et al. 2009; Cao et al. 2009; Esheba et al. 2008; Kurman and Norris 1976a
Choriocarcinoma Negative Not reported Negative Negative Negative β-hCG; glypican-3 in syncytiotrophoblast hCG Chang et al. 2009; Esheba et al. 2008; Renz et al. 2025; Kurman and Norris 1976c
Immature teratoma Scattered epithelial cells only Variable (11 of 15) Negative Positive in neural tissue Negative None specific AFP in 34% of pure pediatric tumors Chang et al. 2009; Cao et al. 2009; Cushing et al. 1999
Gonadoblastoma Positive Positive Not reported Not reported Not reported None specific Not applicable Cheng et al. 2004; Cao et al. 2009

Differential diagnosis of ovarian germ cell tumors

Tumor Main mimic Distinguishing finding Source
Yolk sac tumor Clear cell carcinoma SALL4 diffusely positive; focal in only 3 of 45 clear cell carcinomas Cao et al. 2009
Somatically derived yolk sac tumor Adenocarcinoma Associated epithelial neoplasm in an older patient; glandular yolk sac morphology McNamee et al. 2016
Dysgerminoma Embryonal carcinoma D2-40 positive and SOX2 negative in dysgerminoma Chang et al. 2009
Immature teratoma Mature teratoma with differentiated neural tissue Embryonic neuroepithelium with mitoses and apoptosis Ulbright 2005
Gliomatosis peritonei Metastatic immature teratoma Mature glia only, SOX2 positive, OCT4 and NANOG negative Liang et al. 2015; CAP 2024
Primary insular carcinoid Metastatic carcinoid Unilateral, often with teratoma; metastatic carcinoid is nearly always bilateral Robboy et al. 1975
Non-gestational choriocarcinoma Gestational choriocarcinoma No paternal genome on genotyping Savage et al. 2017

Staging and CAP reporting of ovarian germ cell tumors

  • Staging. Ovarian germ cell tumors are staged with the same FIGO system as epithelial ovarian cancer (Renz et al. 2025).
  • Surgery. Conservative surgery is standard for all stages of germ cell tumors, and fertility-sparing surgery is the standard of care for young patients with early-stage disease (Renz et al. 2025).
  • Peritoneal fluid. Teratomas may shed benign-appearing cells into fluids, and these may be classified as atypia of undetermined significance (CAP 2024).

ovarian germ cell tumor immunohistochemistry lookup

Ovarian, Tubal and Peritoneal Cancer Staging and Reporting, Peritoneal Lesions and Metastases to the Ovary

Definition. Ovarian, fallopian tube and primary peritoneal cancers share one FIGO staging system, introduced in 2014 (Prat 2014). The FIGO Cancer Reports of 2021 and 2025 restate the 2014 system unchanged (Berek et al. 2021; Renz et al. 2025). The AJCC 8th edition pTNM categories correspond to it. The CAP protocol for primary tumors of the ovary, fallopian tube or peritoneum, version 1.5.0.0 (posted June 2024; required for accreditation from March 2025), uses AJCC-UICC 8 and the FIGO Cancer Report 2021 as its standards. It covers borderline tumors, carcinomas including carcinosarcoma, malignant germ cell and sex cord-stromal tumors and ovarian sarcomas, and it excludes peritoneal mesothelioma and lymphoma (CAP 2024).

Related page: Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response (primary site assignment of high-grade serous carcinoma, chemotherapy response score and serous borderline tumor implants) Related page: Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary (mucinous, endometrioid and clear cell grading and the primary versus metastatic mucinous algorithm) Related page: Ovarian Germ Cell Tumors: Teratomas, Dysgerminoma, Yolk Sac Tumor and Other Malignant Germ Cell Tumors (immature teratoma grading and gliomatosis peritonei) Related page: Non-Neoplastic Ovary and Fallopian Tube: Cysts, Endometriosis, Torsion, Salpingitis, Ectopic Pregnancy and Tubal Precursor Lesions (SEE-FIM, risk-reducing salpingo-oophorectomy and STIC) Related page: Pelvic washing cytology and ovarian cyst FNA and Peritoneal Washing Cytology (washings in FIGO 2014 IC3) Related page: Mesothelial vs Carcinoma Immunohistochemistry in Effusions and Diffuse Mesothelioma in Effusions (BAP1, MTAP and lineage panels) Related page: Metastatic Müllerian Carcinoma in Serous Effusions (Müllerian carcinoma in effusions) Related page: Appendiceal Neoplasms: Mucinous Neoplasms, Pseudomyxoma Peritonei, Goblet Cell Adenocarcinoma and Neuroendocrine Tumors (low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei) Related page: Endometrial Carcinoma Staging, CAP Reporting and Biomarker Testing (synchronous endometrial and ovarian carcinoma)

Grossing and sampling of adnexal and staging specimens

Specimen part CAP sampling recommendation Source
Ovarian or adnexal tumor One section per centimeter of greatest dimension, adjusted for heterogeneity and diagnostic difficulty CAP 2024
Serous borderline tumor (especially micropapillary/cribriform) and mucinous borderline tumor Two sections per centimeter, excluding smooth-walled cystic areas CAP 2024
Ovarian surface Area most closely approached by tumor; adhesions and rupture sites labeled CAP 2024
Risk-reducing salpingo-oophorectomy or known BRCA1/BRCA2 carrier Ovaries and tubes entirely, with SEE-FIM of the fimbriae CAP 2024
Fallopian tubes with high-grade serous carcinoma and no gross tubal lesion SEE-FIM of both fimbriated ends CAP 2024
Grossly normal omentum (borderline tumor, serous carcinoma, immature teratoma) 5–10 sections CAP 2024; Skala and Hagemann 2015
Omentum after neoadjuvant chemotherapy 4–6 sections of the most abnormal areas for the chemotherapy response score CAP 2024
Grossly negative lymph nodes Entirely submitted; largest metastatic deposit measured CAP 2024
Staging biopsies Entirely processed unless grossly positive CAP 2024

Intraoperative frozen section of adnexal masses

  • Purpose. Frozen section determines the extent of surgery: cystectomy for benign tumors, oophorectomy or limited staging for borderline tumors in younger patients who wish to preserve fertility, and full staging for carcinoma (Buza 2019).
  • Accuracy. In a Cochrane review of 38 studies with 11,181 participants, frozen section had 90.0% sensitivity and 99.5% specificity for invasive cancer. With borderline and invasive tumors together as positive, sensitivity was 96.5% and specificity 89.5% (Ratnavelu et al. 2016).
  • Borderline diagnoses. A frozen section diagnosis of benign or invasive cancer was unchanged on paraffin sections in 94% and 99% of cases. A frozen section diagnosis of borderline tumor became invasive cancer in 21% of cases (Ratnavelu et al. 2016).

Capsule rupture, surface involvement and specimen integrity

  • Prognosis of rupture. In 1545 stage I invasive epithelial ovarian carcinomas, degree of differentiation was the strongest prognostic factor. Rupture before surgery (hazard ratio 2.65) and rupture during surgery (hazard ratio 1.64) were independent adverse factors (Vergote et al. 2001).
  • Intraoperative rupture. In 161 comprehensively staged stage I cancers, intraoperative capsule rupture (hazard ratio 4.2) and positive washings (hazard ratio 6.4) independently predicted worse disease-free survival (Bakkum-Gamez et al. 2009).
  • Meta-analysis. The meta-analysis of rupture timing in 2,382 patients is given in Pelvic washing cytology and ovarian cyst FNA (Kim et al. 2013).
  • CAP reporting rule. Ovarian and tubal surface involvement and specimen integrity are reported for each ovary (capsule intact, capsule ruptured with preoperative, intraoperative or unknown timing, or fragmented). An ovary removed intact into a laparoscopic bag and opened in the bag without spillage into the peritoneal cavity is recorded as capsule intact, with an explanatory comment (CAP 2024).

FIGO 2014 staging of ovarian, fallopian tube and peritoneal cancer with AJCC 8th edition pTNM

FIGO 2014 stage Definition AJCC 8th edition Source
IA Tumor limited to one ovary (capsule intact) or fallopian tube; no surface tumor; no malignant cells in ascites or washings pT1a N0 M0 Prat 2015; CAP 2024
IB Tumor limited to both ovaries (capsules intact) or fallopian tubes; no surface tumor; no malignant cells in ascites or washings pT1b N0 M0 Prat 2015; CAP 2024
IC1 Surgical spill pT1c1 Prat 2015; CAP 2024
IC2 Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface pT1c2 Prat 2015; CAP 2024
IC3 Malignant cells in ascites or peritoneal washings pT1c3 Prat 2015; CAP 2024
IIA Extension or implants on the uterus, fallopian tubes or ovaries pT2a Prat 2015; CAP 2024
IIB Extension to other pelvic intraperitoneal tissues pT2b Prat 2015; CAP 2024
IIIA1(i) Positive retroperitoneal lymph nodes only; metastasis ≤10 mm pT1 or pT2, pN1a Prat 2015; CAP 2024
IIIA1(ii) Positive retroperitoneal lymph nodes only; metastasis >10 mm pT1 or pT2, pN1b Prat 2015; CAP 2024
IIIA2 Microscopic extrapelvic peritoneal involvement, with or without positive retroperitoneal nodes pT3a Prat 2015; CAP 2024
IIIB Macroscopic extrapelvic peritoneal metastasis ≤2 cm, with or without positive retroperitoneal nodes pT3b Prat 2015; CAP 2024
IIIC Macroscopic extrapelvic peritoneal metastasis >2 cm, with or without positive retroperitoneal nodes; includes extension to the liver or spleen capsule without parenchymal involvement pT3c Prat 2015; CAP 2024
IVA Pleural effusion with positive cytology pM1a Prat 2015; CAP 2024
IVB Parenchymal metastases and metastases to extra-abdominal organs, including inguinal nodes and nodes outside the abdominal cavity pM1b Prat 2015; CAP 2024
  • Primary site and histotype. The primary site (ovary, fallopian tube or peritoneum) is designated where possible, and the histologic type is recorded (Prat 2015). FIGO lists cases whose primary cannot be delineated as "undesignated" (Prat 2015; Renz et al. 2025), whereas the CAP protocol says "undesignated" should be avoided and uses "tubo-ovarian" for small biopsies, prior incomplete salpingo-oophorectomy or some treated cases (CAP 2024). Primary peritoneal cancer has no stage I and begins at stage II (Prat 2015; Renz et al. 2025).
  • Lymph node measurement. The IIIA1 subdivision refers to the size of the metastatic deposit in the node, and the node itself is not measured (CAP 2024). FIGO introduced the 10-mm cutoff without retrospective data supporting it (Prat 2015).
  • Liver and spleen. Extension of tumor from the omentum to the spleen or liver is IIIC, whereas isolated parenchymal splenic or liver metastasis is IVB (Prat 2015).

Changes from the FIGO 1988 system (pre-2014 rules)

Topic Pre-2014 FIGO rule FIGO 2014 rule Source
Scope Ovarian, fallopian tube and peritoneal cancer not incorporated in one system One system for ovary, fallopian tube and peritoneum, with the primary site designated Prat 2015; Renz et al. 2025
Stage IC Single stage IC for rupture, surface tumor or malignant ascites or washings IC1 surgical spill; IC2 rupture before surgery or surface tumor; IC3 malignant ascites or washings Prat 2015; Renz et al. 2025; Paik et al. 2015
Stage IIC IIA or IIB with surface tumor, ruptured capsule, ascites or positive washings Eliminated as redundant Prat 2015
Retroperitoneal nodes only Stage IIIC Stage IIIA1, divided into (i) ≤10 mm and (ii) >10 mm Onda et al. 1998; Renz et al. 2025
Microscopic extrapelvic peritoneum Stage IIIA Stage IIIA2, with or without positive retroperitoneal nodes Renz et al. 2025
Stage IIIB Macroscopic extrapelvic disease ≤2 cm Same threshold; wording now includes nodal status Renz et al. 2025; Rosendahl et al. 2016
Stage IV Single stage IV IVA pleural effusion with positive cytology; IVB parenchymal and extra-abdominal metastases, now including inguinal nodes Renz et al. 2025; Rosendahl et al. 2016; Paik et al. 2015
Number of substages 10 14 Rosendahl et al. 2016
  • Evidence for IIIA1. Fewer than 10% of ovarian carcinomas extend beyond the pelvis with exclusively retroperitoneal nodal involvement, and these patients have a better prognosis than those with abdominal peritoneal spread (Prat 2015). In one series, 5-year survival was 84% for patients upstaged to stage III by nodes alone and 26% for patients with intraperitoneal tumor beyond the pelvis (Onda et al. 1998).
  • Restaging data. Of 4036 Danish patients, 1532 were assigned new stages. IA and IC1 had similar 5-year survival (87%), and IB, IC2 and IC3 had 75–80%. Sixteen stage IIIC cases with nodal disease alone became IIIA1, and 63 became IIIB (Rosendahl et al. 2016).
  • IIIA1(i) and IIIA1(ii). Among 46 stage IIIA1 patients, 5-year overall survival was 83.1% for IIIA1(i) and 80.2% for IIIA1(ii) (p=0.44) (Matsuoka et al. 2022).
  • Stage distribution. Most high-grade serous carcinomas present at stage III, mostly IIIC, and 12–21% present at stage IV (Prat 2015).

AJCC 8th edition and CAP rules for pN, pM and special situations

CAP 1.5.0.0 reporting elements for ovarian, tubal and peritoneal tumors

Element Rule Linked detail Source
Histologic grade Required for endometrioid and mucinous carcinomas, immature teratomas and Sertoli-Leydig cell tumors Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary; Ovarian Germ Cell Tumors: Teratomas, Dysgerminoma, Yolk Sac Tumor and Other Malignant Germ Cell Tumors; Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors CAP 2024
Grading systems FIGO 3-tier (endometrioid; optional for mucinous); Silverberg; growth pattern (mucinous only); 2-tier and 3-tier (immature teratoma); WHO G1–G3 Units above CAP 2024
Serous carcinoma Low grade and high grade are separate histotypes Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response CAP 2024
Primary site of high-grade serous carcinoma Tubal, ovarian, tubo-ovarian or peritoneal by defined criteria; "undesignated" avoided Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response CAP 2024
Specimen integrity and surface involvement Recorded for each ovary and tube Not applicable CAP 2024
Implants Required only for advanced-stage serous and seromucinous borderline tumors Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response CAP 2024
Chemotherapy response score High-grade serous carcinoma after neoadjuvant therapy, assessed in omentum Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response CAP 2024
Mixed malignant germ cell tumor Types and percentages specified Ovarian Germ Cell Tumors: Teratomas, Dysgerminoma, Yolk Sac Tumor and Other Malignant Germ Cell Tumors CAP 2024
Separate synoptic reports Bilateral malignant tumors of two different types Not applicable CAP 2024
Mismatch repair immunohistochemistry Recommended in all adnexal endometrioid and clear cell carcinomas Mucinous, Endometrioid, Clear Cell, Seromucinous and Brenner Tumors of the Ovary CAP 2024
  • ICCR dataset. The second edition of the ICCR dataset for ovarian, tubal and primary peritoneal carcinoma replaces the 2015 first edition and reflects the WHO 5th edition (Gilks et al. 2022).

Nodal serous borderline tumor, endosalpingiosis and endocervicosis

  • Lymph node involvement by serous borderline tumor. Patterns and prognosis of nodal serous borderline tumor are given in Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response.
  • Nodal endosalpingiosis. Nodal endosalpingiosis was present in 58% of cases with nodal involvement and 35% without (McKenney et al. 2006).
  • Endosalpingiosis and cancer. Among 838 women with endosalpingiosis in a surgical cohort, concurrent endometriosis, uterine cancer and ovarian cancer were more frequent. Endosalpingiosis was associated with serous borderline (odds ratio 10.2), clear cell and invasive mucinous tumors (Esselen et al. 2016).
  • Endocervicosis. Endocervicosis of the urinary bladder forms a 2–5 cm mass of benign or mildly atypical endocervical-type glands in the bladder wall of women of reproductive age. Three of six cases were initially diagnosed as adenocarcinoma (Clement and Young 1992).

Mesothelial lesions of the female peritoneum

  • Reactive mesothelial hyperplasia. In 44 cases of florid peritoneal mesothelial hyperplasia, usually on the ovarian surface, endometriosis was the most common associated lesion. Small bland tubules, nests and cords in fibrous tissue were typical, and true or apparent lymphovascular invasion occurred. Calretinin positivity and Ber-EP4 negativity identified mesothelial cells (Oparka et al. 2011).
  • Multilocular peritoneal inclusion cyst. In 25 cases, all but 4 had prior surgery, endometriosis or pelvic inflammatory disease. Cysts were lined by flat to cuboidal mesothelial cells, sometimes with mural proliferation simulating mesothelioma. Twelve recurred locally, and the lesion is a non-neoplastic reactive mesothelial proliferation (Ross et al. 1989).
  • Adenomatoid tumor. Adenomatoid tumors of the genital tract carry somatic TRAF7 mutations (Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas). L1CAM was expressed in adenomatoid tumors and absent in normal mesothelium, peritoneal mesotheliomas and multilocular peritoneal inclusion cysts (Goode et al. 2018).
  • Well-differentiated papillary mesothelial tumor. The WHO 5th edition of thoracic tumors (2021) renamed well-differentiated papillary mesothelioma as well-differentiated papillary mesothelial tumor because of its indolent behavior (Sauter et al. 2022). In 26 women aged 23–75 years, lesions were 0.1–2 cm and usually incidental, and 22 of 25 with follow-up were free of disease (Malpica et al. 2012). All 10 peritoneal tumors sequenced carried mutually exclusive TRAF7 or CDC42 mutations, lacked BAP1, NF2 and CDKN2A alterations and retained BAP1 expression (Stevers et al. 2019).
  • Peritoneal mesothelioma, BAP1. BAP1 loss occurred in 1 of 395 serous carcinomas (0.3%) and in 6 of 9 abdominal mesotheliomas (67%) (Andrici et al. 2016). In another series, 16 of 25 peritoneal mesotheliomas lost BAP1, whereas all benign mesothelium and ovarian serous tumors retained it (Chapel et al. 2017).
  • Peritoneal mesothelioma, PAX8. PAX8 stained 99% of high-grade serous carcinomas, no pleural mesotheliomas and 2 of 23 peritoneal mesotheliomas (Laury et al. 2010). PAX8 staining of benign mesothelium and peritoneal mesothelioma is given in Mesothelial vs Carcinoma Immunohistochemistry in Effusions (Chapel et al. 2017).
  • Peritoneal mesothelioma, MTAP. MTAP loss is less frequent in peritoneal than in pleural mesothelioma (11 of 53 versus 35 of 60) (Davidson et al. 2024). In 39 peritoneal mesotheliomas, CDKN2A homozygous deletion was present in 27, and MTAP immunohistochemistry agreed poorly with FISH (κ=0.091), so MTAP is not a surrogate for CDKN2A FISH at this site (Quaranta et al. 2025). Retained MTAP therefore does not exclude mesothelioma. MTAP loss was absent from reactive peritoneal mesothelial proliferations in these series, and it may still serve as an independent adjunct marker of malignancy in a proven mesothelial proliferation (Quaranta et al. 2025; Quaranta et al. 2026). MTAP does not separate mesothelioma from serous tumors: loss occurred in 3 of 18 peritoneal mesotheliomas and 1 of 25 serous borderline tumors (Devins et al. 2023).
  • Peritoneal mesothelioma, claudin-4. Membranous claudin-4 stained 44 of 45 serous carcinomas (98%) and none of 40 peritoneal epithelioid mesotheliomas (Ordóñez 2013). It was positive in all 49 low-grade serous carcinomas and serous borderline tumors and negative in all 18 peritoneal mesotheliomas (Devins et al. 2023).
  • WT1 and other lineage markers. Calretinin, WT1, CK5/6 and D2-40 and the Müllerian markers PAX8 and SOX17 are each expressed by a subset of both mesothelial and Müllerian tumors (Churg et al. 2026). WT1 stained 72% of primary ovarian carcinomas in one series (Espinosa et al. 2015).
  • Peritoneal mesothelioma, ALK. ALK immunohistochemistry was positive in 11 of 88 peritoneal mesotheliomas. The 8 with focal weak staining lacked rearrangement, whereas the 3 with diffuse strong staining had ALK rearrangements (partners ATG16L1, STRN and TPM1). Patients with the rearrangement were women and younger (median 36 versus 62 years), had no asbestos fibers and lacked BAP1, SETD2 and NF2 alterations. All 205 pleural mesotheliomas were ALK negative (Hung et al. 2018).
Lesion Architecture Key immunohistochemistry Molecular finding Source
Reactive mesothelial hyperplasia Bland tubules, nests and cords in fibrous tissue Calretinin positive; Ber-EP4 negative Not applicable (non-neoplastic) Oparka et al. 2011
Multilocular peritoneal inclusion cyst Cysts lined by flat to cuboidal mesothelium L1CAM negative Not applicable (non-neoplastic) Ross et al. 1989; Goode et al. 2018
Adenomatoid tumor Not applicable L1CAM positive TRAF7 Goode et al. 2018
Well-differentiated papillary mesothelial tumor Papillae with bland mesothelial cells; rare mitoses BAP1 retained; L1CAM positive TRAF7 or CDC42 Malpica et al. 2012; Stevers et al. 2019
Peritoneal mesothelioma Not applicable BAP1 lost in 64–67%; PAX8 positive in up to 18%; claudin-4 negative CDKN2A deletion in 27 of 39; MTAP loss less frequent than in pleura; poor surrogate for CDKN2A FISH Andrici et al. 2016; Chapel et al. 2017; Quaranta et al. 2025; Davidson et al. 2024; Ordóñez 2013
Serous carcinoma Not applicable PAX8 positive in 99%; BAP1 retained in 99.7%; claudin-4 positive (98%) TP53 mutation in high-grade serous carcinoma (Ovarian and Tubal Serous Tumors: Serous Borderline Tumor, Low-Grade and High-Grade Serous Carcinoma, BRCA and HRD Testing and Chemotherapy Response) Laury et al. 2010; Andrici et al. 2016; Ordóñez 2013; CAP 2024

Desmoplastic small round cell tumor

  • Clinical features. In 109 cases, 90 patients were male and 19 female, aged 6–49 years (mean 22). Tumor involved the abdominal cavity in 103 (Gerald et al. 1998).
  • Immunophenotype. Tumor cells were usually positive for keratin (86%), epithelial membrane antigen (93%), vimentin (97%), desmin (90%) and neuron-specific enolase (81%), and for the EWS-WT1 chimeric protein (93%). Muscle-specific actin, myogenin and chromogranin were usually negative (Gerald et al. 1998).
  • Molecular finding. The t(11;22)(p13;q12) translocation fuses EWSR1 and WT1 (Ladanyi and Gerald 1994). A functional fusion was found in 25 of 26 cases tested (Gerald et al. 1998).

Reactive peritoneal lesions

  • Keratin granulomas. Peritoneal keratin granulomas accompany endometrioid carcinoma with squamous differentiation of the endometrium or ovary and atypical polypoid adenomyoma. In 22 cases they had no prognostic significance and are distinguished from viable tumor implants (Kim and Scully 1990).
  • Deciduosis. Pregnancy-related peritoneal deciduosis forms small subperitoneal nodules of large polygonal eosinophilic cells that express vimentin and progesterone receptor and lack keratin, calretinin and HMB-45 staining. It regresses after delivery (Bolat et al. 2012).
  • Sclerosing peritonitis. Sclerosing peritonitis accompanies luteinized thecoma, described in Ovarian Sex Cord-Stromal Tumors, Small Cell Carcinoma of Hypercalcemic Type and Wolffian and STK11 Adnexal Tumors (Staats et al. 2008).
  • Leiomyomatosis peritonealis disseminata. Its features are given in Uterine Mesenchymal Tumors: Smooth Muscle Tumors, Endometrial Stromal Tumors, Adenosarcoma and Other Sarcomas (Tavassoli and Norris 1982).
  • Splenosis. Splenosis is autotransplantation of splenic tissue after splenic trauma or splenectomy. Peritoneal and pelvic nodules can mimic peritoneal metastases at staging laparotomy or endometriosis. A history of splenic injury is the clue, and frozen section or a Tc-99m heat-damaged red cell scan confirms splenic tissue (Braun et al. 2021; Abdul Jawad et al. 2025).

Pseudomyxoma peritonei and ovarian mucinous tumors

All 30 women with pseudomyxoma peritonei and ovarian mucinous tumors had an associated appendiceal or intestinal mucinous tumor (Ronnett et al. 1995). Identical KRAS mutations were present in the appendiceal and ovarian tumors of all 16 cases studied, supporting a single, most likely appendiceal, origin (Szych et al. 1999). The PSOGI classification of pseudomyxoma peritonei is given in Appendiceal Neoplasms: Mucinous Neoplasms, Pseudomyxoma Peritonei, Goblet Cell Adenocarcinoma and Neuroendocrine Tumors (Carr et al. 2016). Extensive poorly cellular mucin dissecting the ovarian stroma (pseudomyxoma ovarii) suggests an appendiceal mucinous neoplasm (CAP 2024).

Metastases to the ovary and Krukenberg tumor

  • General principles. Metastatic tumors are often cystic in the ovary even when the primary tumor is not, and many show well-differentiated areas in the ovary that mimic benign or borderline tumors. Surface implants suggest metastasis (Young 2006). Tumor mainly on the ovarian surface or centered on the hilum is more likely metastatic (CAP 2024).
  • Krukenberg tumor. In 120 cases, the average age was 45 years, and 63% were documented as bilateral. Signet-ring cells by definition occupied at least 10% of the tumor. Two-thirds of the primaries were gastric, followed by appendix, colon, breast, small intestine, rectum, gallbladder and urinary bladder. Two-thirds of the primaries were detected with or after the ovarian tumor (Kiyokawa et al. 2006).
  • Colorectal carcinoma. In 86 cases, involvement was bilateral in 49, and 20 unilateral tumors measured ≥10 cm. Garland pattern and dirty necrosis were typical, and benign-appearing or borderline-like foci occurred in 23. CK20 stained all 29 tumors tested and CK7 was focal in 17% (Lewis et al. 2006).
  • Pancreaticobiliary carcinoma. In 35 cases, 89% were bilateral, 63% nodular and 40% surface involved. Borderline-like and cystadenomatous patterns occurred in 69%. DPC4 (SMAD4) expression was lost in 61% and gave the most useful immunohistochemical evidence of a pancreaticobiliary source (Meriden et al. 2011).
  • Endocervical adenocarcinoma. In 29 cases, ovarian metastases were unilateral in 65.5% and often simulated borderline tumors or well-differentiated carcinomas. Identical HPV types in paired cervical and ovarian tumors established metastasis, even from microinvasive or in situ cervical tumors (Ronnett et al. 2008).
  • Breast carcinoma. Seven of 9 breast metastases to the ovary were lobular. All metastases were GATA3 positive and PAX8 negative, and only 1 expressed WT1. Independent primary ovarian carcinomas were PAX8 positive in 88% and GATA3 negative in all (Espinosa et al. 2015).
Primary site Clues in the ovary Immunohistochemistry Source
Stomach (Krukenberg tumor) Bilateral; signet-ring cells ≥10%; cellular stroma; microcystic pattern Not specific Kiyokawa et al. 2006; Young 2006
Colon and rectum Garland pattern; dirty necrosis; may be large and unilateral CK20 positive; CK7 focal or negative Lewis et al. 2006
Appendix Pseudomyxoma ovarii; surface involvement; pseudomyxoma peritonei Primary ovarian mucinous tumors are SATB2 and CDX2 negative CAP 2024; Ronnett et al. 1995
Pancreas and biliary tract Bilateral, nodular, surface involvement; borderline-like areas DPC4 loss in 61% Meriden et al. 2011
Endocervix (HPV-associated) Borderline-like or villoglandular patterns; often unilateral Same HPV type as the cervical tumor Ronnett et al. 2008
Breast Lobular pattern; low nuclear grade GATA3 positive; PAX8 negative Espinosa et al. 2015

References

  1. Abdul Jawad K, Denny K, Osumah TS, et al. Splenosis Masquerading as Endometriosis: A Rare Pelvic Post-Trauma Presentation. Am J Case Rep. 2025;26:e946307. doi:10.12659/AJCR.946307. PMID 40055891
  2. Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011;35(4):484–494. doi:10.1097/PAS.0b013e31820a406c. PMID 21378549
  3. Aljassim F, Rigby CH, Drury JA, et al. Hydrosalpinx perturbs the tubal and endometrial immune environment. Reprod Fertil. 2026;7(2). doi:10.1530/RAF-25-0204. PMID 42284130 (PMC13317832)
  4. Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet. 2011;43(12):1262–1265. doi:10.1038/ng.994. PMID 22057236
  5. American College of Obstetricians and Gynecologists Committee on Clinical Consensus–Gynecology. ACOG Clinical Practice Update: Salpingectomy for the prevention of epithelial ovarian cancer. Obstet Gynecol. 2026;148(4):e275–e280. doi:10.1097/AOG.0000000000006400. PMID 42623672 (cited as ACOG 2026)
  6. American College of Obstetricians and Gynecologists. Adnexal torsion in adolescents: ACOG Committee Opinion No. 783. Obstet Gynecol. 2019;134(2):e56–e63. doi:10.1097/AOG.0000000000003373. PMID 31348225 (cited as ACOG 2019)
  7. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Gynecology. ACOG Practice Bulletin No. 193: Tubal ectopic pregnancy. Obstet Gynecol. 2018;131(3):e91–e103. doi:10.1097/AOG.0000000000002560. PMID 29470343 (cited as ACOG 2018)
  8. Andrici J, Jung J, Sheen A, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol. 2016;51:9–15. doi:10.1016/j.humpath.2015.12.012. PMID 27067777
  9. Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med. 2017;376(19):1835–1848. doi:10.1056/NEJMoa1614814. PMID 28489996 (PMC5555376)
  10. Assem H, Rambau PF, Lee S, et al. High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases. Am J Surg Pathol. 2018;42(4):534–544. doi:10.1097/PAS.0000000000001016. PMID 29309296
  11. Atileh LIA, Dahbour D, Hammo H, et al. Laparoscopic Removal of a 40-cm Paratubal Cyst in a Morbidly Obese Patient. Gynecol Minim Invasive Ther. 2020;9(1):39–41. doi:10.4103/GMIT.GMIT_110_18. PMID 32090013 (PMC7008651)
  12. Bagué S, Rodríguez IM, Prat J. Sarcoma-like mural nodules in mucinous cystic tumors of the ovary revisited: a clinicopathologic analysis of 10 additional cases. Am J Surg Pathol. 2002;26(11):1467–1476. doi:10.1097/00000478-200211000-00009. PMID 12409723
  13. Bakkum-Gamez JN, Richardson DL, Seamon LG, et al. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009;113(1):11–17. doi:10.1097/AOG.0b013e3181917a0c. PMID 19104354
  14. Banet N, Kurman RJ. Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis. Int J Gynecol Pathol. 2015;34(1):3–8. doi:10.1097/PGP.0000000000000120. PMID 25473746
  15. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol. 2000;24(11):1465–1479. doi:10.1097/00000478-200011000-00002. PMID 11075848
  16. Bennett JA, Pesci A, Morales-Oyarvide V, et al. Incidence of Mismatch Repair Protein Deficiency and Associated Clinicopathologic Features in a Cohort of 104 Ovarian Endometrioid Carcinomas. Am J Surg Pathol. 2019;43(2):235–243. doi:10.1097/PAS.0000000000001165. PMID 30256257
  17. Bennett JA, Ritterhouse LL, Furtado LV, et al. Female adnexal tumors of probable Wolffian origin: morphological, immunohistochemical, and molecular analysis of 15 cases. Mod Pathol. 2020;33(4):734–747. doi:10.1038/s41379-019-0375-9. PMID 31591497 (cited as Bennett et al. 2020)
  18. Bennett JA, Young RH, Howitt BE, et al. A Distinctive Adnexal (Usually Paratubal) Neoplasm Often Associated With Peutz-Jeghers Syndrome and Characterized by STK11 Alterations (STK11 Adnexal Tumor): A Report of 22 Cases. Am J Surg Pathol. 2021;45(8):1061–1074. doi:10.1097/PAS.0000000000001677. PMID 33534223 (cited as Bennett et al. 2021)
  19. Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1:61–85. doi:10.1002/ijgo.13878. PMID 34669199
  20. Bessière L, Todeschini AL, Auguste A, et al. A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1 in Juvenile Granulosa Cell Tumors. EBioMedicine. 2015;2(5):421–431. doi:10.1016/j.ebiom.2015.03.002. PMID 26137586
  21. Bogaerts JMA, Steenbeek MP, van Bommel MHD, et al. Recommendations for diagnosing STIC: a systematic review and meta-analysis. Virchows Arch. 2022;480(4):725–737. doi:10.1007/s00428-021-03244-w. PMID 34850262 (PMC9023413)
  22. Bogaerts JMA, van Bommel MHD, Hermens RPMG, et al. Consensus based recommendations for the diagnosis of serous tubal intraepithelial carcinoma: an international Delphi study. Histopathology. 2023;83(1):67–79. doi:10.1111/his.14902. PMID 36939551
  23. Böhm S, Faruqi A, Said I, et al. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. J Clin Oncol. 2015;33(22):2457–2463. doi:10.1200/JCO.2014.60.5212. PMID 26124480
  24. Bolat F, Canpolat T, Tarim E. Pregnancy-related peritoneal ectopic decidua (deciduosis): morphological and clinical evaluation. Turk Patoloji Derg. 2012;28(1):56–60. doi:10.5146/tjpath.2012.01098. PMID 22207433
  25. Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–2310. doi:10.1001/jama.2011.743. PMID 21642682
  26. Boudaouara O, Sellami A, Roger P. Ovarian stromal hyperthecosis: An underestimated virilizing disorder in postmenopausal women. Ann Endocrinol (Paris). 2025;86(5):101800. doi:10.1016/j.ando.2025.101800. PMID 40513985
  27. Braun T, De Gregorio A, Baumann L, et al. Coincidence of Intra-Abdominal Splenosis in a Patient with Advanced Ovarian Cancer: Case Report and Review of the Literature. Surg J (N Y). 2021;7(2):e116–e120. doi:10.1055/s-0041-1731426. PMID 34179460
  28. Bryk S, Färkkilä A, Bützow R, et al. Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2016;143(3):571–577. doi:10.1016/j.ygyno.2016.10.002. PMID 27729108
  29. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996;20(11):1319–1330. doi:10.1097/00000478-199611000-00003. PMID 8898836
  30. Busca A, Nofech-Mozes S, Olkhov-Mitsel E, et al. Histological grading of ovarian mucinous carcinoma - an outcome-based analysis of traditional and novel systems. Histopathology. 2020;77(1):26–34. doi:10.1111/his.14039. PMID 31782197
  31. Buza N. Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls. Arch Pathol Lab Med. 2019;143(1):47–64. doi:10.5858/arpa.2018-0289-RA. PMID 30785337
  32. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25(25):3985–3990. doi:10.1200/JCO.2007.12.2622. PMID 17761984
  33. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615. doi:10.1038/nature10166. PMID 21720365 (PMC3163504)
  34. Cao D, Guo S, Allan RW, et al. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol. 2009;33(6):894–904. doi:10.1097/PAS.0b013e318198177d. PMID 19295406 (cited as Cao et al. 2009)
  35. Cao J, Meng Z, Li C. Sonographic and Clinicopathological Characterization of Struma Ovarii: A Retrospective Analysis for Enhanced Preoperative Diagnosis. Curr Med Imaging. 2026;22:e15734056393689. doi:10.2174/0115734056393689250929185251. PMID 41088975 (cited as Cao et al. 2026)
  36. Cao Y, Wu W, Wang W, et al. Three cases of ovarian actinomycosis with literature review. Int J Clin Exp Pathol. 2023;16(7):158–163. PMID 37559683 (PMC10408434)
  37. Carr NJ, Cecil TD, Mohamed F, et al. A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: The Results of the Peritoneal Surface Oncology Group International (PSOGI) Modified Delphi Process. Am J Surg Pathol. 2016;40(1):14–26. doi:10.1097/PAS.0000000000000535. PMID 26492181
  38. Chae HS, Rheu CH. Precocious pseudopuberty due to an autonomous ovarian follicular cyst: case report with a review of literatures. BMC Res Notes. 2013;6:319. doi:10.1186/1756-0500-6-319. PMID 23937919 (PMC3766658)
  39. Chang MC, Vargas SO, Hornick JL, et al. Embryonic stem cell transcription factors and D2-40 (podoplanin) as diagnostic immunohistochemical markers in ovarian germ cell tumors. Int J Gynecol Pathol. 2009;28(4):347–355. doi:10.1097/PGP.0b013e318195da86. PMID 19483629
  40. Chapel DB, Husain AN, Krausz T, et al. PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma. Am J Surg Pathol. 2017;41(12):1675–1682. doi:10.1097/PAS.0000000000000935. PMID 28877056
  41. Cheasley D, Wakefield MJ, Ryland GL, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019;10(1):3935. doi:10.1038/s41467-019-11862-x. PMID 31477716 (PMC6718426)
  42. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28(10):1341–1346. doi:10.1097/01.pas.0000135528.03942.1f. PMID 15371950
  43. Churg A, Malpica A, Hung YP. Mesothelial Proliferations Involving the Gynecologic Tract. Adv Anat Pathol. 2026. doi:10.1097/PAP.0000000000000560. PMID 43000614
  44. Clarke BA, Witkowski L, Ton Nu TN, et al. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology. 2016;69(5):727–738. doi:10.1111/his.12988. PMID 27100627
  45. Clement PB, Young RH. Endocervicosis of the urinary bladder. A report of six cases of a benign müllerian lesion that may mimic adenocarcinoma. Am J Surg Pathol. 1992;16(6):533–542. doi:10.1097/00000478-199206000-00001. PMID 1318002
  46. Clement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol. 2007;14(4):241–260. doi:10.1097/PAP.0b013e3180ca7d7b. PMID 17592255
  47. Clement PB. Tumor-like lesions of the ovary associated with pregnancy. Int J Gynecol Pathol. 1993;12(2):108–115. doi:10.1097/00004347-199304000-00004. PMID 8463033
  48. Coatham M, Li X, Karnezis AN, et al. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. Mod Pathol. 2016;29(12):1586–1593. doi:10.1038/modpathol.2016.156. PMID 27562491
  49. Cohen PA, Powell A, Böhm S, et al. Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448. Gynecol Oncol. 2021;161(1):328–329. doi:10.1016/j.ygyno.2021.01.032. PMID 33551198 (cited as Cohen et al. 2021)
  50. Cohen PA, Powell A, Böhm S, et al. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019;154(2):441–448. doi:10.1016/j.ygyno.2019.04.679. PMID 31118141
  51. College of American Pathologists. Protocol for the Examination of Specimens from Patients with Primary Tumors of the Ovary, Fallopian Tube, or Peritoneum. Version 1.5.0.0. Posted June 2024. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (cited as CAP Ovary 1.5.0.0)
  52. College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of Gynecologic Origin. Version 1.3.0.0. Posted September 2025. https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates (cited as CAP Gynecologic Biomarker 1.3.0.0)
  53. Comerci JT, Licciardi F, Bergh PA, et al. Mature cystic teratoma: a clinicopathologic evaluation of 517 cases and review of the literature. Obstet Gynecol. 1994;84(1):22–28. PMID 8008317
  54. Cools M, Drop SL, Wolffenbuttel KP, et al. Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev. 2006;27(5):468–484. doi:10.1210/er.2006-0005. PMID 16735607
  55. Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group. Am J Obstet Gynecol. 1999;181(2):353–358. doi:10.1016/s0002-9378(99)70561-2. PMID 10454682
  56. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–1098. doi:10.1016/S1474-4422(08)70224-2. PMID 18851928
  57. Davidson B, Holth A, Hummel C, et al. Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma. Appl Immunohistochem Mol Morphol. 2024;32(6):280–284. doi:10.1097/PAI.0000000000001206. PMID 38812360
  58. de Kock L, Terzic T, McCluggage WG, et al. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors. Am J Surg Pathol. 2017;41(9):1178–1187. doi:10.1097/PAS.0000000000000895. PMID 28654427
  59. Dehghani A, Sharma AE, Siegmund SE, et al. STK11 (LKB1) immunohistochemistry is a sensitive and specific marker for STK11 adnexal tumours. Histopathology. 2024;85(5):769–782. doi:10.1111/his.15303. PMID 39169716
  60. Devins KM, Zukerberg L, Watkins JC, et al. BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma. Int J Gynecol Pathol. 2023;42(2):159–166. doi:10.1097/PGP.0000000000000877. PMID 35512220
  61. Esheba GE, Longacre TA, Atkins KA, et al. Expression of the urothelial differentiation markers GATA3 and placental S100 (S100P) in female genital tract transitional cell proliferations. Am J Surg Pathol. 2009;33(3):347–353. doi:10.1097/PAS.0b013e3181908e24. PMID 19092634
  62. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32(4):600–607. doi:10.1097/PAS.0b013e31815a565a. PMID 18277882
  63. Espinosa I, Gallardo A, D'Angelo E, et al. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases. Int J Gynecol Pathol. 2015;34(3):257–265. doi:10.1097/PGP.0000000000000155. PMID 25844549
  64. Esselen KM, Terry KL, Samuel A, et al. Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery? Gynecol Oncol. 2016;142(2):255–260. doi:10.1016/j.ygyno.2016.05.036. PMID 27261327
  65. Evans DG, Ladusans EJ, Rimmer S, et al. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30(6):460–464. doi:10.1136/jmg.30.6.460. PMID 8326488
  66. Ferguson AW, Katabuchi H, Ronnett BM, et al. Glial implants in gliomatosis peritonei arise from normal tissue, not from the associated teratoma. Am J Pathol. 2001;159(1):51–55. doi:10.1016/S0002-9440(10)61672-0. PMID 11438453
  67. Folkins AK, Jarboe EA, Saleemuddin A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol. 2008;109(2):168–173. doi:10.1016/j.ygyno.2008.01.012. PMID 18342932 (PMC2746001)
  68. Fukunaga M, Nomura K, Ishikawa E, et al. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology. 1997;30(3):249–255. doi:10.1046/j.1365-2559.1997.d01-592.x. PMID 9088954
  69. Garg K, Karnezis AN, Rabban JT. Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation. Pathology. 2018;50(2):238–256. doi:10.1016/j.pathol.2017.10.009. PMID 29373116
  70. Genestie C, Auguste A, Al Battal M, et al. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers. Virchows Arch. 2021;478(5):885–891. doi:10.1007/s00428-020-02939-w. PMID 33009577
  71. Gerald WL, Ladanyi M, de Alava E, et al. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): desmoplastic small round-cell tumor and its variants. J Clin Oncol. 1998;16(9):3028–3036. doi:10.1200/JCO.1998.16.9.3028. PMID 9738572
  72. Gershenson DM, Miller A, Brady WE, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022;399(10324):541–553. doi:10.1016/S0140-6736(21)02175-9. PMID 35123694 (PMC8819271)
  73. Gilks CB, Selinger CI, Davidson B, et al. Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). Int J Gynecol Pathol. 2022;41(Suppl 1):S119–S142. doi:10.1097/PGP.0000000000000908. PMID 36305537
  74. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019;381(25):2391–2402. doi:10.1056/NEJMoa1910962. PMID 31562799
  75. Goode B, Joseph NM, Stevers M, et al. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod Pathol. 2018;31(4):660–673. doi:10.1038/modpathol.2017.153. PMID 29148537
  76. Gordon A, Lipton D, Woodruff JD. Dysgerminoma: a review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol. 1981;58(4):497–504. PMID 7279343
  77. Grisham RN, Slomovitz B, Podder V, et al. Low-grade serous ovarian cancer: 2026 expert consensus report. Gynecol Oncol. 2026;214:144–163. doi:10.1016/j.ygyno.2026.10.011. PMID 42913278 (cited as Grisham et al. 2026b)
  78. Grisham RN, Van Nieuwenhuysen E, Santin AD, et al. Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201. Gynecol Oncol. 2026;213:59–67. doi:10.1016/j.ygyno.2026.09.003. PMID 42748602 (cited as Grisham et al. 2026a)
  79. Guleria P, Kumar L, Kumar S, et al. A clinicopathological study of granulosa cell tumors of the ovary: Can morphology predict prognosis? Indian J Pathol Microbiol. 2020;63(1):53–59. doi:10.4103/IJPM.IJPM_403_19. PMID 32031123
  80. Hackethal A, Brueggmann D, Bohlmann MK, et al. Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet Oncol. 2008;9(12):1173–1180. doi:10.1016/S1470-2045(08)70306-1. PMID 19038764
  81. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85(6):841–851. doi:10.1016/s0092-8674(00)81268-4. PMID 8681379
  82. Hayes MC, Scully RE. Ovarian steroid cell tumors (not otherwise specified). A clinicopathological analysis of 63 cases. Am J Surg Pathol. 1987;11(11):835–845. doi:10.1097/00000478-198711000-00002. PMID 2823622
  83. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 2012;366(3):234–242. doi:10.1056/NEJMoa1102903. PMID 22187960
  84. Heskett MB, Sanborn JZ, Boniface C, et al. Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components. Mod Pathol. 2020;33(6):1193–1206. doi:10.1038/s41379-019-0446-y. PMID 31911616
  85. Hoei-Hansen CE, Kraggerud SM, Abeler VM, et al. Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007;6:12. doi:10.1186/1476-4598-6-12. PMID 17274819
  86. Hollis RL, Thomson JP, Stanley B, et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat Commun. 2020;11(1):4995. doi:10.1038/s41467-020-18819-5. PMID 33020491 (PMC7536188)
  87. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis". Obstet Gynecol Surv. 1982;37(2):59–77. doi:10.1097/00006254-198202000-00001. PMID 7033852
  88. Hung YP, Dong F, Watkins JC, et al. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. JAMA Oncol. 2018;4(2):235–238. doi:10.1001/jamaoncol.2017.2918. PMID 28910456
  89. Iannone V, Martinelli C, Maiorano P, et al. Laparoscopic treatment of a rare primary peritoneal serous borderline tumor: Case report and narrative review of the literature. Gynecol Oncol Rep. 2025;59:101742. doi:10.1016/j.gore.2025.101742. PMID 40276631 (PMC12018051)
  90. Irving JA, Alkushi A, Young RH, et al. Cellular fibromas of the ovary: a study of 75 cases including 40 mitotically active tumors emphasizing their distinction from fibrosarcoma. Am J Surg Pathol. 2006;30(8):929–938. doi:10.1097/00000478-200608000-00001. PMID 16861962 (cited as Irving et al. 2006)
  91. Irving JA, Lee CH, Yip S, et al. Microcystic Stromal Tumor: A Distinctive Ovarian Sex Cord-Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin Nuclear Expression and CTNNB1 Mutations. Am J Surg Pathol. 2015;39(10):1420–1426. doi:10.1097/PAS.0000000000000482. PMID 26200099 (cited as Irving et al. 2015)
  92. Irving JA, Young RH. Microcystic stromal tumor of the ovary: report of 16 cases of a hitherto uncharacterized distinctive ovarian neoplasm. Am J Surg Pathol. 2009;33(3):367–375. doi:10.1097/PAS.0b013e31818479c3. PMID 18971779
  93. Jarboe E, Folkins A, Nucci MR, et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol. 2008;27(1):1–9. doi:10.1097/pgp.0b013e31814b191f. PMID 18156967
  94. Jenkins CS, Williams SR, Schmidt GE. Salpingitis isthmica nodosa: a review of the literature, discussion of clinical significance, and consideration of patient management. Fertil Steril. 1993;60(4):599–607. doi:10.1016/s0015-0282(16)56207-4. PMID 8405510
  95. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272(5268):1668–1671. doi:10.1126/science.272.5268.1668. PMID 8658145
  96. Karnezis AN, Wang Y, Keul J, et al. DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. Am J Surg Pathol. 2019;43(5):628–638. doi:10.1097/PAS.0000000000001232. PMID 30986800 (cited as Karnezis et al. 2019)
  97. Karnezis AN, Wang Y, Ramos P, et al. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2016;238(3):389–400. doi:10.1002/path.4633. PMID 26356327 (cited as Karnezis et al. 2016)
  98. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol. 2006;19(1):83–89. doi:10.1038/modpathol.3800492. PMID 16258507
  99. Kim HS, Ahn JH, Chung HH, et al. Impact of intraoperative rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: a meta-analysis. Eur J Surg Oncol. 2013;39(3):279–289. doi:10.1016/j.ejso.2012.12.003. PMID 23273873
  100. Kim KR, Scully RE. Peritoneal keratin granulomas with carcinomas of endometrium and ovary and atypical polypoid adenomyoma of endometrium. A clinicopathological analysis of 22 cases. Am J Surg Pathol. 1990;14(10):925–932. doi:10.1097/00000478-199010000-00005. PMID 1698340
  101. Kim SH, Da Cruz Paula A, Basili T, et al. Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nat Commun. 2020;11(1):44. doi:10.1038/s41467-019-13806-x. PMID 31896750
  102. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–169. doi:10.1097/01.pas.0000213335.40358.47. PMID 17255760
  103. Kiyokawa T, Young RH, Scully RE. Krukenberg tumors of the ovary: a clinicopathologic analysis of 120 cases with emphasis on their variable pathologic manifestations. Am J Surg Pathol. 2006;30(3):277–299. doi:10.1097/01.pas.0000190787.85024.cb. PMID 16538048
  104. Köbel M, Kang EY. The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel). 2022;14(2). doi:10.3390/cancers14020416. PMID 35053578 (PMC8774015)
  105. Köbel M, Kang EY. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting. Int J Gynecol Pathol. 2021;40(1):32–40. doi:10.1097/PGP.0000000000000725. PMID 33290354
  106. Köbel M, Piskorz AM, Lee S, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2(4):247–258. doi:10.1002/cjp2.53. PMID 27840695 (PMC5091634)
  107. Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020;38(11):1222–1245. doi:10.1200/JCO.19.02960. PMID 31986064 (PMC8842911)
  108. Kopczynski J, Kowalik A, Chłopek M, et al. Oncogenic Activation of the Wnt/β-Catenin Signaling Pathway in Signet Ring Stromal Cell Tumor of the Ovary. Appl Immunohistochem Mol Morphol. 2016;24(5):e28–e33. doi:10.1097/PAI.0000000000000271. PMID 26509912
  109. Kostopoulou E, Daponte A, Kallitsaris A, et al. Xanthogranulomatous salpingitis: report of three cases and comparison with a case of pseudoxanthomatous salpingitis. Clin Exp Obstet Gynecol. 2008;35(4):291–294. PMID 19205448
  110. Krämer P, Talhouk A, Brett MA, et al. Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. Clin Cancer Res. 2020;26(20):5400–5410. doi:10.1158/1078-0432.CCR-20-1268. PMID 32737030
  111. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–2416. doi:10.1001/jama.2017.7112. PMID 28632866
  112. Kuhn E, Ayhan A, Shih IeM, et al. Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer. 2013;49(18):3839–3849. doi:10.1016/j.ejca.2013.08.011. PMID 24012099
  113. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226(3):421–426. doi:10.1002/path.3023. PMID 21990067 (PMC4782784)
  114. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597–1601. doi:10.2353/ajpath.2009.081000. PMID 19349352 (PMC2671248)
  115. Kurman RJ, Norris HJ. Embryonal carcinoma of the ovary: a clinicopathologic entity distinct from endodermal sinus tumor resembling embryonal carcinoma of the adult testis. Cancer. 1976;38(6):2420–2433. doi:10.1002/1097-0142(197612)38:6<2420::aid-cncr2820380630>3.0.co;2-2. PMID 63319 (cited as Kurman and Norris 1976b)
  116. Kurman RJ, Norris HJ. Endodermal sinus tumor of the ovary: a clinical and pathologic analysis of 71 cases. Cancer. 1976;38(6):2404–2419. doi:10.1002/1097-0142(197612)38:6<2404::aid-cncr2820380629>3.0.co;2-3. PMID 63318 (cited as Kurman and Norris 1976a)
  117. Kurman RJ, Norris HJ. Malignant mixed germ cell tumors of the ovary. A clinical and pathologic analysis of 30 cases. Obstet Gynecol. 1976;48(5):579–589. PMID 185553 (cited as Kurman and Norris 1976c)
  118. Kurman RJ, Shih IeM. Seromucinous Tumors of the Ovary. What's in a Name?. Int J Gynecol Pathol. 2016;35(1):78–81. doi:10.1097/PGP.0000000000000266. PMID 26598986 (PMC5512580)
  119. Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016;186(4):733–747. doi:10.1016/j.ajpath.2015.11.011. PMID 27012190 (PMC5808151)
  120. Kwan MY, Kalle W, Lau GT, et al. Is gliomatosis peritonei derived from the associated ovarian teratoma? Hum Pathol. 2004;35(6):685–688. doi:10.1016/j.humpath.2004.01.025. PMID 15188134
  121. Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093. doi:10.1038/s41467-017-00962-1. PMID 29061967 (PMC5653668)
  122. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994;54(11):2837–2840. PMID 8187063
  123. Lager CJ, Koenig RJ, Lieberman RW, et al. Rare Clinical Entity: Metastatic malignant struma ovarii diagnosed during pregnancy - Lessons for management. Clin Diabetes Endocrinol. 2018;4:13. doi:10.1186/s40842-018-0064-5. PMID 29946481
  124. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34(5):627–635. doi:10.1097/PAS.0b013e3181da7687. PMID 20414098
  125. Lawson BC, Euscher ED, Bassett RL, et al. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?. Am J Surg Pathol. 2020;44(2):206–213. doi:10.1097/PAS.0000000000001391. PMID 31651523 (PMC6954274)
  126. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol. 2000;24(11):1447–1464. doi:10.1097/00000478-200011000-00001. PMID 11075847
  127. Lee S, Piskorz AM, Le Page C, et al. Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience. Int J Gynecol Pathol. 2016;35(3):209–221. doi:10.1097/PGP.0000000000000251. PMID 26598982
  128. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26–35. doi:10.1002/path.2091. PMID 17117391
  129. Leskela S, Romero I, Rosa-Rosa JM, et al. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification. Am J Surg Pathol. 2020;44(7):982–990. doi:10.1097/PAS.0000000000001478. PMID 32384322
  130. Levato F, Martinello R, Campobasso C, et al. LDH and LDH isoenzymes in ovarian dysgerminoma. Eur J Gynaecol Oncol. 1995;16(3):212–215. PMID 7664770
  131. Lewis MR, Deavers MT, Silva EG, et al. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol. 2006;30(2):177–184. doi:10.1097/01.pas.0000176436.26821.8a. PMID 16434891
  132. Liang L, Zhang Y, Malpica A, et al. Gliomatosis peritonei: a clinicopathologic and immunohistochemical study of 21 cases. Mod Pathol. 2015;28(12):1613–1620. doi:10.1038/modpathol.2015.116. PMID 26564007
  133. Linder D, McCaw BK, Hecht F. Parthenogenic origin of benign ovarian teratomas. N Engl J Med. 1975;292(2):63–66. doi:10.1056/NEJM197501092920202. PMID 162806
  134. Lomme M, Kostadinov S, Zhang C. Large solitary luteinized follicle cyst of pregnancy and puerperium: report of two cases. Diagn Pathol. 2011;6:3. doi:10.1186/1746-1596-6-3. PMID 21219622 (PMC3022785)
  135. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005;29(6):707–723. doi:10.1097/01.pas.0000164030.82810.db. PMID 15897738
  136. Lozoya Araque T, Monfort Ortiz IR, Martín González JE, et al. Ovarian Stromal Hyperplasia: A Rare Cause of Postmenopausal Hyperandrogenism. J Menopausal Med. 2020;26(1):39–43. doi:10.6118/jmm.19012. PMID 32307950 (PMC7160587)
  137. Malakzai HA, Abdul-Ghafar J, Ibrahimkhil AS, et al. A rare ovarian hilus cell tumour accompanying bilateral serous cystadenomas: report of a case. J Ovarian Res. 2021;14(1):81. doi:10.1186/s13048-021-00833-w. PMID 34154625 (PMC8218513)
  138. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496–504. doi:10.1097/00000478-200404000-00009. PMID 15087669
  139. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31(8):1168–1174. doi:10.1097/PAS.0b013e31803199b0. PMID 17667538
  140. Malpica A, Sant'Ambrogio S, Deavers MT, et al. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases. Am J Surg Pathol. 2012;36(1):117–127. doi:10.1097/PAS.0b013e3182354a79. PMID 22024662
  141. Matsuoka A, Tate S, Nishikimi K, et al. Validity of the 2014 FIGO Stage IIIA1 Subclassification for Ovarian, Fallopian Tube, and Peritoneal Cancers. In Vivo. 2022;36(5):2453–2460. doi:10.21873/invivo.12980. PMID 36099140
  142. McCluggage WG, Irving JA, Chong AS, et al. Ovarian Microcystic Stromal Tumors Are Characterized by Alterations in the Beta-Catenin-APC Pathway and May be an Extracolonic Manifestation of Familial Adenomatous Polyposis. Am J Surg Pathol. 2018;42(1):137–139. doi:10.1097/PAS.0000000000000981. PMID 29076875
  143. McCluggage WG, Rivera B, Chong AS, et al. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs. Am J Surg Pathol. 2023;47(4):490–496. doi:10.1097/PAS.0000000000002010. PMID 36583307
  144. McCluggage WG, Singh N, Gilks CB. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80(5):762–778. doi:10.1111/his.14609. PMID 34996131
  145. McCluggage WG. New histopathological and molecular findings in gynecological cancers. Int J Gynaecol Obstet. 2025;171 Suppl 1:109–119. doi:10.1002/ijgo.70283. PMID 40739655 (cited as McCluggage 2025)
  146. McConechy MK, Färkkilä A, Horlings HM, et al. Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. J Natl Cancer Inst. 2016;108(11):djw134. doi:10.1093/jnci/djw134. PMID 27297428
  147. McKenney JK, Balzer BL, Longacre TA. Lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors): pathology, prognosis, and proposed classification. Am J Surg Pathol. 2006;30(5):614–624. doi:10.1097/01.pas.0000194743.33540.e6. PMID 16699316
  148. McKenney JK, Balzer BL, Longacre TA. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. Am J Surg Pathol. 2006;30(10):1209–1221. doi:10.1097/01.pas.0000213299.11649.fa. PMID 17001150
  149. McNamee T, Damato S, McCluggage WG. Yolk sac tumours of the female genital tract in older adults derive commonly from somatic epithelial neoplasms: somatically derived yolk sac tumours. Histopathology. 2016;69(5):739–751. doi:10.1111/his.13021. PMID 27334714
  150. Meagher NS, Wang L, Rambau PF, et al. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. 2019;32(12):1834–1846. doi:10.1038/s41379-019-0302-0. PMID 31239549 (PMC8207534)
  151. Medeiros F, Bell DA. Pseudoneoplastic lesions of the female genital tract. Arch Pathol Lab Med. 2010;134(3):393–403. doi:10.5858/134.3.393. PMID 20196667
  152. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30(2):230–236. doi:10.1097/01.pas.0000180854.28831.77. PMID 16434898
  153. Medvediev MV, Malvasi A, Gustapane S, et al. Hemorrhagic corpus luteum: Clinical management update. Turk J Obstet Gynecol. 2020;17(4):300–309. doi:10.4274/tjod.galenos.2020.40359. PMID 33343977 (PMC7731611)
  154. Meriden Z, Yemelyanova AV, Vang R, et al. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol. 2011;35(2):276–288. doi:10.1097/PAS.0b013e31820508d0. PMID 21263249
  155. Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020;31(12):1606–1622. doi:10.1016/j.annonc.2020.08.2102. PMID 33004253
  156. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018;379(26):2495–2505. doi:10.1056/NEJMoa1810858. PMID 30345884
  157. Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023;389(23):2162–2174. doi:10.1056/NEJMoa2309169. PMID 38055253
  158. Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol. 2002;26(11):1477–1483. doi:10.1097/00000478-200211000-00010. PMID 12409724
  159. Muyldermans K, Moerman P, Amant F, et al. Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur J Cancer. 2013;49(7):1600–1608. doi:10.1016/j.ejca.2012.12.004. PMID 23321546
  160. Nogales FF, Preda O, Nicolae A. Yolk sac tumours revisited. A review of their many faces and names. Histopathology. 2012;60(7):1023–1033. doi:10.1111/j.1365-2559.2011.03889.x. PMID 22008025
  161. Norquist BM, Harrell MI, Brady MF, et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016;2(4):482–490. doi:10.1001/jamaoncol.2015.5495. PMID 26720728 (PMC4845939)
  162. Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer. 1976;37(5):2359–2372. doi:10.1002/1097-0142(197605)37:5<2359::aid-cncr2820370528>3.0.co;2-q. PMID 1260722
  163. O'Connor DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol. 1994;13(4):283–289. doi:10.1097/00004347-199410000-00001. PMID 7814189
  164. Oliva E, Alvarez T, Young RH. Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol. 2005;29(2):143–156. doi:10.1097/01.pas.0000149692.21205.9c. PMID 15644771
  165. Onda T, Yoshikawa H, Yasugi T, et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients. Cancer. 1998;83(8):1555–1560. PMID 9781949
  166. Oparka R, McCluggage WG, Herrington CS. Peritoneal mesothelial hyperplasia associated with gynaecological disease: a potential diagnostic pitfall that is commonly associated with endometriosis. J Clin Pathol. 2011;64(4):313–318. doi:10.1136/jcp.2010.086074. PMID 21421699
  167. Oranratanaphan S, Khemapech N. Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution. Asian Pac J Cancer Prev. 2013;14(8):4693–4697. doi:10.7314/apjcp.2013.14.8.4693. PMID 24083728
  168. Ordóñez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 2013;26(4):553–562. doi:10.1038/modpathol.2012.200. PMID 23196794
  169. Paik ES, Lee YY, Lee EJ, et al. Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification. Obstet Gynecol Sci. 2015;58(2):124–134. doi:10.5468/ogs.2015.58.2.124. PMID 25798426
  170. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133(3):446–450. PMID 2849300
  171. Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet. 2011;43(12):1256–1261. doi:10.1038/ng.1004. PMID 22057234
  172. Paraskevas M, Scully RE. Hilus cell tumor of the ovary. A clinicopathological analysis of 12 Reinke crystal-positive and nine crystal-negative cases. Int J Gynecol Pathol. 1989;8(4):299–310. PMID 2553628
  173. Parker RL, Dadmanesh F, Young RH, et al. Polypoid endometriosis: a clinicopathologic analysis of 24 cases and a review of the literature. Am J Surg Pathol. 2004;28(3):285–297. doi:10.1097/00000478-200403000-00001. PMID 15104291
  174. Patrono MG, Iniesta MD, Malpica A, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review. Gynecol Oncol. 2015;139(3):568–572. doi:10.1016/j.ygyno.2015.09.018. PMID 26407480
  175. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–394. doi:10.1016/S1470-2045(11)70404-1. PMID 22361336 (PMC3664011)
  176. Peres LC, Cushing-Haugen KL, Köbel M, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst. 2019;111(1):60–68. doi:10.1093/jnci/djy071. PMID 29718305 (PMC6335112)
  177. Pilsworth JA, Cochrane DR, Neilson SJ, et al. Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. J Pathol Clin Res. 2021;7(3):243–252. doi:10.1002/cjp2.198. PMID 33428330 (cited as Pilsworth et al. 2021)
  178. Pilsworth JA, Cochrane DR, Xia Z, et al. TERT promoter mutation in adult granulosa cell tumor of the ovary. Mod Pathol. 2018;31(7):1107–1115. doi:10.1038/s41379-018-0007-9. PMID 29449679 (cited as Pilsworth et al. 2018)
  179. Poulos C, Cheng L, Zhang S, et al. Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. Mod Pathol. 2006;19(6):766–771. doi:10.1038/modpathol.3800596. PMID 16547466
  180. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23(1):127–132. doi:10.1200/JCO.2005.04.109. PMID 15625367
  181. Prat J; FIGO Committee on Gynecologic Oncology. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87–89. doi:10.3802/jgo.2015.26.2.87. PMID 25872889 (cited as Prat 2015)
  182. Prat J; FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. doi:10.1016/j.ijgo.2013.10.001. PMID 24219974 (cited as Prat 2014)
  183. Quaranta A, Mancini D, Caporusso C, et al. Low frequency of MTAP co-deletion with CDKN2A in peritoneal mesothelioma suggests an independent diagnostic role for MTAP. Histopathology. 2026. doi:10.1111/his.70276. PMID 42766860 (cited as Quaranta et al. 2026)
  184. Quaranta A, Marzullo A, Fortarezza F, et al. Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma. Histopathology. 2025;87(4):526–535. doi:10.1111/his.15502. PMID 40566743 (cited as Quaranta et al. 2025)
  185. Rabban JT, Garg K, Crawford B, et al. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014;38(6):729–742. doi:10.1097/PAS.0000000000000199. PMID 24820399
  186. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–1107. doi:10.1038/ng.955. PMID 21964575
  187. Rambau PF, McIntyre JB, Taylor J, et al. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. Am J Surg Pathol. 2017;41(5):685–695. doi:10.1097/PAS.0000000000000812. PMID 28125452
  188. Ramos P, Karnezis AN, Craig DW, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014;46(5):427–429. doi:10.1038/ng.2928. PMID 24658001
  189. Ramzy I. Signet-ring stromal tumor of ovary. Histochemical, light, and electron microscopic study. Cancer. 1976;38(1):166–172. doi:10.1002/1097-0142(197607)38:1<166::aid-cncr2820380126>3.0.co;2-r. PMID 181127
  190. Ratnavelu ND, Brown AP, Mallett S, et al. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev. 2016;3(3):CD010360. doi:10.1002/14651858.CD010360.pub2. PMID 26930463
  191. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019;381(25):2416–2428. doi:10.1056/NEJMoa1911361. PMID 31851799
  192. Renz M, Friedlander M, Berek JS. Cancer of the ovary, fallopian tube, and peritoneum: 2025 update. Int J Gynaecol Obstet. 2025;171 Suppl 1:6–35. doi:10.1002/ijgo.70282. PMID 40908761 (PMC12411830)
  193. Robboy SJ, Norris HJ, Scully RE. Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases. Cancer. 1975;36(2):404–418. doi:10.1002/1097-0142(197508)36:2<404::aid-cncr2820360216>3.0.co;2-0. PMID 1157010 (cited as Robboy et al. 1975)
  194. Robboy SJ, Scully RE. Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer. 1980;46(9):2019–2034. doi:10.1002/1097-0142(19801101)46:9<2019::aid-cncr2820460921>3.0.co;2-w. PMID 7427909
  195. Robboy SJ, Shaco-Levy R, Peng RY, et al. Malignant struma ovarii: an analysis of 88 cases, including 27 with extraovarian spread. Int J Gynecol Pathol. 2009;28(5):405–422. doi:10.1097/PGP.0b013e3181a27777. PMID 19696610 (cited as Robboy et al. 2009)
  196. Rodríguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26(2):139–152. doi:10.1097/00000478-200202000-00001. PMID 11812936
  197. Roma AA, Masand RP. Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. Hum Pathol. 2014;45(12):2417–2422. doi:10.1016/j.humpath.2014.08.003. PMID 25281026
  198. Romey M, Rodepeter F, Hattesohl A, et al. Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance. Mod Pathol. 2024;37(4):100445. doi:10.1016/j.modpat.2024.100445. PMID 38341130
  199. Ronnett BM, Kurman RJ, Zahn CM, et al. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. Hum Pathol. 1995;26(5):509–524. doi:10.1016/0046-8177(95)90247-3. PMID 7750935 (cited as Ronnett et al. 1995)
  200. Ronnett BM, Yemelyanova AV, Vang R, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008;32(12):1835–1853. doi:10.1097/PAS.0b013e3181758831. PMID 18813124 (cited as Ronnett et al. 2008)
  201. Rosendahl M, Høgdall CK, Mosgaard BJ. Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. Int J Gynecol Cancer. 2016;26(4):680–687. doi:10.1097/IGC.0000000000000675. PMID 26937751
  202. Ross MJ, Welch WR, Scully RE. Multilocular peritoneal inclusion cysts (so-called cystic mesotheliomas). Cancer. 1989;64(6):1336–1346. doi:10.1002/1097-0142(19890915)64:6<1336::aid-cncr2820640628>3.0.co;2-x. PMID 2766227
  203. Roth LM, Cheng L. Classical gonadoblastoma: its relationship to the 'dissecting' variant and undifferentiated gonadal tissue. Histopathology. 2018;72(4):545–555. doi:10.1111/his.13387. PMID 28881049
  204. Roth LM, Cheng L. Gonadoblastoma: origin and outcome. Hum Pathol. 2020;100:47–53. doi:10.1016/j.humpath.2019.11.005. PMID 31805291
  205. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. doi:10.1016/j.fertnstert.2003.10.004. PMID 14711538
  206. Saini T, Gupta P, Gupta N, et al. Cytomorphologic diagnosis of adult granulosa cell tumors at the metastatic sites with an emphasis on the cytologic mimics. Am J Transl Res. 2023;15(9):5633–5641. PMID 37854236
  207. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. J Thorac Oncol. 2022;17(5):608–622. doi:10.1016/j.jtho.2021.12.014. PMID 35026477
  208. Savage J, Adams E, Veras E, et al. Choriocarcinoma in Women: Analysis of a Case Series With Genotyping. Am J Surg Pathol. 2017;41(12):1593–1606. doi:10.1097/PAS.0000000000000937. PMID 28877059
  209. Schultz KAP, Nelson AT, Mallinger PHR, et al. DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies. Clin Cancer Res. 2024;30(24):5681–5692. doi:10.1158/1078-0432.CCR-24-1532. PMID 39400264
  210. Seidman JD, Khedmati F. Exploring the histogenesis of ovarian mucinous and transitional cell (Brenner) neoplasms and their relationship with Walthard cell nests: a study of 120 tumors. Arch Pathol Lab Med. 2008;132(11):1753–1760. doi:10.5858/132.11.1753. PMID 18976011
  211. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27(7):985–993. doi:10.1097/00000478-200307000-00014. PMID 12826891
  212. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31(5):539–557. doi:10.1053/hp.2000.8048. PMID 10836293
  213. Seidman JD, Oberer S, Bitterman P, et al. Pathogenesis of pseudoxanthomatous salpingiosis. Mod Pathol. 1993;6(1):53–55. PMID 8426857
  214. Shaco-Levy R, Bean SM, Bentley RC, et al. Natural history of biologically malignant struma ovarii: analysis of 27 cases with extraovarian spread. Int J Gynecol Pathol. 2010;29(3):212–227. doi:10.1097/PGP.0b013e3181bfb133. PMID 20407319
  215. Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360(26):2719–2729. doi:10.1056/NEJMoa0902542. PMID 19516027
  216. Shen Y, Liang Y, Cheng X, et al. Ovarian fibroma/fibrothecoma with elevated serum CA125 level: A cohort of 66 cases. Medicine (Baltimore). 2018;97(34):e11926. doi:10.1097/MD.0000000000011926. PMID 30142807
  217. Shimizu Y, Kamoi S, Amada S, et al. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer. 1998;82(5):893–901. doi:10.1002/(sici)1097-0142(19980301)82:5<893::aid-cncr14>3.0.co;2-w. PMID 9486579
  218. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000;19(1):7–15. doi:10.1097/00004347-200001000-00003. PMID 10638449
  219. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484–486. doi:10.1093/jnci/95.6.484. PMID 12644542
  220. Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29(2):218–224. doi:10.1097/01.pas.0000146025.91953.8d. PMID 15644779
  221. Singh N, Gilks CB, Hirschowitz L, et al. Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecol Oncol. 2016;141(2):195–198. doi:10.1016/j.ygyno.2015.10.022. PMID 26827965
  222. Singh N, Gilks CB, Wilkinson N, et al. Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. Histopathology. 2015;67(3):331–337. doi:10.1111/his.12651. PMID 25640750
  223. Singh N, Gilks CB, Wilkinson N, et al. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology. 2014;65(2):149–154. doi:10.1111/his.12419. PMID 24660659
  224. Skala SL, Hagemann IS. Optimal sampling of grossly normal omentum in staging of gynecologic malignancies. Int J Gynecol Pathol. 2015;34(3):281–287. doi:10.1097/PGP.0000000000000148. PMID 25760907
  225. Skibsted L, Sperling L, Hansen U, et al. Salpingitis isthmica nodosa in female infertility and tubal diseases. Hum Reprod. 1991;6(6):828–831. doi:10.1093/oxfordjournals.humrep.a137436. PMID 1757522
  226. Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006;107(5):1075–1085. doi:10.1097/01.AOG.0000216004.22588.ce. PMID 16648414
  227. Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25(4):625–636. doi:10.1038/modpathol.2011.183. PMID 22193042
  228. Staats PN, McCluggage WG, Clement PB, et al. Luteinized thecomas (thecomatosis) of the type typically associated with sclerosing peritonitis: a clinical, histopathologic, and immunohistochemical analysis of 27 cases. Am J Surg Pathol. 2008;32(9):1273–1290. doi:10.1097/PAS.0b013e3181666a5f. PMID 18636018
  229. Steenbeek MP, van Bommel MHD, Bulten J, et al. Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. J Clin Oncol. 2022;40(17):1879–1891. doi:10.1200/JCO.21.02016. PMID 35302882 (PMC9851686)
  230. Stevers M, Rabban JT, Garg K, et al. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Mod Pathol. 2019;32(1):88–99. doi:10.1038/s41379-018-0127-2. PMID 30171198
  231. Stewart I, Twidale E. Ovarian luteoma masses in pregnancy: an uncommon cause of virilisation. BMJ Case Rep. 2024;17(9). doi:10.1136/bcr-2024-261239. PMID 39266026 (PMC11404140)
  232. Stock RJ. Histopathology of fallopian tubes with recurrent tubal pregnancy. Obstet Gynecol. 1990;75(1):9–14. PMID 2296430
  233. Stock RJ. Large intraligamentous cysts. Technique of surgical removal and correlation of surgical observations and histologic findings pertaining to origin. J Reprod Med. 1987;32(5):347–352. PMID 3598983
  234. Sumathi VP, McCluggage WG. CD10 is useful in demonstrating endometrial stroma at ectopic sites and in confirming a diagnosis of endometriosis. J Clin Pathol. 2002;55(5):391–392. doi:10.1136/jcp.55.5.391. PMID 11986349 (PMC1769659)
  235. Sun HD, Lin H, Jao MS, et al. A long-term follow-up study of 176 cases with adult-type ovarian granulosa cell tumors. Gynecol Oncol. 2012;124(2):244–249. doi:10.1016/j.ygyno.2011.10.015. PMID 22019525
  236. Szych C, Staebler A, Connolly DC, et al. Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. Am J Pathol. 1999;154(6):1849–1855. doi:10.1016/S0002-9440(10)65442-9. PMID 10362811
  237. Tavassoli FA, Norris HJ. Peritoneal leiomyomatosis (leiomyomatosis peritonealis disseminata): a clinicopathologic study of 20 cases with ultrastructural observations. Int J Gynecol Pathol. 1982;1(1):59–74. PMID 7184891
  238. Tchrakian N, Oliva E, Chong AS, et al. Ovarian Signet-ring Stromal Tumor: A Morphologic, Immunohistochemical, and Molecular Study of 7 Cases With Discussion of the Differential Diagnosis. Am J Surg Pathol. 2022;46(12):1599–1610. doi:10.1097/PAS.0000000000001954. PMID 36040033
  239. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655–1679. doi:10.1093/humrep/dead156. PMID 37580037 (PMC10477934)
  240. Tischkowitz M, Huang S, Banerjee S, et al. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines. Clin Cancer Res. 2020;26(15):3908–3917. doi:10.1158/1078-0432.CCR-19-3797. PMID 32156746
  241. Tzelios C, Neuhausser WM, Ryley D, et al. Female Genital Tuberculosis. Open Forum Infect Dis. 2022;9(11):ofac543. doi:10.1093/ofid/ofac543. PMID 36447614 (PMC9697622)
  242. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005;18 Suppl 2:S61–S79. doi:10.1038/modpathol.3800310. PMID 15761467
  243. US Food and Drug Administration. FDA approves mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. March 22, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant-epithelial-ovarian (cited as FDA 2024)
  244. US Food and Drug Administration. FDA grants accelerated approval to mirvetuximab soravtansine-gynx for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. November 14, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mirvetuximab-soravtansine-gynx-fra-positive-platinum-resistant (cited as FDA 2022)
  245. van Meurs HS, Bleeker MC, van der Velden J, et al. The incidence of endometrial hyperplasia and cancer in 1031 patients with a granulosa cell tumor of the ovary: long-term follow-up in a population-based cohort study. Int J Gynecol Cancer. 2013;23(8):1417–1422. doi:10.1097/IGC.0b013e3182a57fb4. PMID 24257556
  246. Vang R, Gown AM, Zhao C, et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol. 2007;31(6):854–869. doi:10.1097/PAS.0b013e31802efb45. PMID 17527072
  247. Vang R, Levine DA, Soslow RA, et al. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2016;35(1):48–55. doi:10.1097/PGP.0000000000000207. PMID 26166714 (PMC4696053)
  248. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267–282. doi:10.1097/PAP.0b013e3181b4fffa. PMID 19700937 (PMC2745605)
  249. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31(3):243–253. doi:10.1097/PGP.0b013e31823b8831. PMID 22498942 (PMC3366037)
  250. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176–182. doi:10.1016/S0140-6736(00)03590-X. PMID 11213094
  251. Vergote I, González-Martín A, Ray-Coquard I, et al. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022;33(3):276–287. doi:10.1016/j.annonc.2021.11.013. PMID 34861371
  252. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol. 2011;35(12):1766–1775. doi:10.1097/PAS.0b013e31822f58bc. PMID 21989347 (PMC4612640)
  253. Wang Y, Karnezis AN, Magrill J, et al. DICER1 hot-spot mutations in ovarian gynandroblastoma. Histopathology. 2018;73(2):306–313. doi:10.1111/his.13630. PMID 29660837
  254. Warnnissorn M, Watkins JC, Young RH. Dysgerminoma of the Ovary: An Analysis of 140 Cases Emphasizing Unusual Microscopic Findings and Resultant Diagnostic Problems. Am J Surg Pathol. 2021;45(8):1009–1027. doi:10.1097/PAS.0000000000001687. PMID 33577182
  255. Watkins JC, Lebok P, Young RH. Hyperreactio Luteinalis (Multiple Luteinized Follicle Cysts): A Report of 10 Cases. Int J Gynecol Pathol. 2021;40(5):427–434. doi:10.1097/PGP.0000000000000746. PMID 33323862
  256. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–1543. doi:10.1056/NEJMoa1008433. PMID 20942669 (PMC2976679)
  257. Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet. 2014;46(5):438–443. doi:10.1038/ng.2931. PMID 24658002
  258. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. doi:10.15585/mmwr.rr7004a1. PMID 34292926 (PMC8344968)
  259. Yamashita Y, Nagasaka T, Naiki-Ito A, et al. Napsin A is a specific marker for ovarian clear cell adenocarcinoma. Mod Pathol. 2015;28(1):111–117. doi:10.1038/modpathol.2014.61. PMID 24721826
  260. Yang X, Leslie G, Doroszuk A, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020;38(7):674–685. doi:10.1200/JCO.19.01907. PMID 31841383 (PMC7049229) (cited as Yang et al. 2020b)
  261. Yang X, Song H, Leslie G, et al. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020;112(12):1242–1250. doi:10.1093/jnci/djaa030. PMID 32107557 (PMC7735771) (cited as Yang et al. 2020a)
  262. Yemelyanova AV, Vang R, Judson K, et al. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol. 2008;32(1):128–138. doi:10.1097/PAS.0b013e3180690d2d. PMID 18162780
  263. Young RH, Dickersin GR, Scully RE. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol. 1984;8(8):575–596. doi:10.1097/00000478-198408000-00002. PMID 6465418 (cited as Young et al. 1984)
  264. Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalcemic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18(11):1102–1116. doi:10.1097/00000478-199411000-00004. PMID 7943531 (cited as Young et al. 1994)
  265. Young RH, Scully RE. Fibromatosis and massive edema of the ovary, possibly related entities: a report of 14 cases of fibromatosis and 11 cases of massive edema. Int J Gynecol Pathol. 1984;3(2):153–178. doi:10.1097/00004347-198402000-00005. PMID 6490313
  266. Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol. 1985;9(8):543–569. doi:10.1097/00000478-198508000-00001. PMID 3911780
  267. Young RH, Welch WR, Dickersin GR, et al. Ovarian sex cord tumor with annular tubules: review of 74 cases including 27 with Peutz-Jeghers syndrome and four with adenoma malignum of the cervix. Cancer. 1982;50(7):1384–1402. doi:10.1002/1097-0142(19821001)50:7<1384::aid-cncr2820500726>3.0.co;2-5. PMID 7104978 (cited as Young et al. 1982)
  268. Young RH, Wong A, Stall JN. Yolk Sac Tumor of the Ovary: A Report of 150 Cases and Review of the Literature. Am J Surg Pathol. 2022;46(3):309–325. doi:10.1097/PAS.0000000000001793. PMID 34469331 (cited as Young et al. 2022)
  269. Young RH. From krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the krukenberg tumor. Adv Anat Pathol. 2006;13(5):205–227. doi:10.1097/01.pap.0000213038.85704.e4. PMID 16998315
  270. Zagamé L, Pautier P, Duvillard P, et al. Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol. 2006;108(3 Pt 1):509–514. doi:10.1097/01.AOG.0000231686.94924.41. PMID 16946208
  271. Zanfagnin V, Oliva E, Young RH. Embryonal Carcinoma Involving the Ovary: A Morphologic Study of 55 Tumors Almost Never Pure, But Common Within Malignant Mixed Germ Cell Tumors. Arch Pathol Lab Med. 2026;150(8):595–602. doi:10.5858/arpa.2025-0482-OA. PMID 41887253
  272. Zeppernick F, Ardighieri L, Hannibal CG, et al. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol. 2014;38(12):1603–1611. doi:10.1097/PAS.0000000000000313. PMID 25188864 (PMC4314953)
  273. Zhang J, Hua R, Ma L, et al. Ovarian juvenile granulosa cell tumors with Ollier's disease in children with IDH1 gene somatic mutation. Front Endocrinol (Lausanne). 2023;14:1093273. doi:10.3389/fendo.2023.1093273. PMID 37324278
  274. Zhang Y, Chen J, Lu W, et al. Clinical characteristics of persistent ectopic pregnancy after salpingostomy and influence on ongoing pregnancy. J Obstet Gynaecol Res. 2017;43(3):564–570. doi:10.1111/jog.13251. PMID 28127836 (PMC5347973)
  275. Zhao C, Barner R, Vinh TN, et al. SF-1 is a diagnostically useful immunohistochemical marker and comparable to other sex cord-stromal tumor markers for the differential diagnosis of ovarian sertoli cell tumor. Int J Gynecol Pathol. 2008;27(4):507–514. doi:10.1097/PGP.0b013e31817c1b0a. PMID 18753972 (cited as Zhao et al. 2008)
  276. Zhao C, Vinh TN, McManus K, et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol. 2009;33(3):354–366. doi:10.1097/PAS.0b013e318188373d. PMID 19033865 (cited as Zhao et al. 2009)
  277. Zhao X, Yuan C, Wang X, et al. Clinical manifestation and pathological changes of serous papillary adenofibroma: A case series. Mol Clin Oncol. 2025;23(5):98. doi:10.3892/mco.2025.2893. PMID 41019454 (PMC12464471)

Image credits

  • Endometriosis in the wall of the fallopian tube. Image: Ed Uthman, Wikimedia Commons, CC BY 2.0.
  • Serous borderline tumor of the ovary. Image: Mikael Häggström, M.D., Wikimedia Commons, CC0.
  • Benign Brenner tumor of the ovary. Image: Mikael Häggström, M.D., Wikimedia Commons, CC0.